The Cellular Effects of Nicotine and Tobacco Particulate Matter on Monoamine Transporters by Danielson, Kirsty Maree
 
 
 
The Cellular Effects of Nicotine and 
Tobacco Particulate Matter on 
Monoamine Transporters 
 
by 
 
Kirsty Maree Danielson 
 
 
 
 
 
A thesis 
submitted to the Victoria University of Wellington 
in fulfilment of the requirements for the degree of 
Doctor of Philosophy 
 
Victoria University of Wellington 
2013 
ii 
 
Abstract 
 
Cigarette smoking causes nearly 6 million deaths worldwide every year (WHO, 2011).  
Current smoking cessation therapies available to the public are only marginally effective 
(Jorenby, 2006; Balfour et al., 2000), partly due to our incomplete understanding of the 
molecular biology of smoking addiction.  The majority of studies examining the molecular 
biology of smoking addiction have focused on nicotine alone.  However, there is a growing 
body of evidence that non-nicotinic components of cigarette smoke contribute to smoking 
addiction.  Nicotine has previously been shown to modulate the function of the monoamine 
transporters, but studies in the literature are often contradictory and this effect is not 
completely understood (see Danielson et al., 2011 for review).  Furthermore, very few 
studies have examined the effects of non-nicotinic components of tobacco smoke on the 
monoamine transporters.   
 
This thesis has examined the effects of nicotine and a tobacco extract (TPM) on the 
dopamine, serotonin, and norepinephrine transporters (DAT, NET, and SERT).  Changes in 
monoamine transporter function, protein expression, and mRNA expression were measured 
ex vivo in discrete regions of the rat brain following chronic and acute in vivo nicotine and 
TPM treatment, and in vitro nicotine and TPM treatment.  We found that nicotine and TPM 
affect monoamine transporter function, in a time- and dose-dependent manner, and that 
intact whole brain circuitry is required for these effects to be seen.  In particular, nicotine 
(0.35 mg/kg) and TPM (containing 0.35 mg/kg nicotine) significantly decreased DAT 
function in the NAc at 30 min.  This effect did not result in a corresponding decrease in 
DAT protein expression and was mediated by nicotinic receptors containing β2 subunits.  
Furthermore, TPM caused some changes in monoamine transporter function and mRNA 
expression that were not observed with nicotine alone.  In functional studies this effect was 
particularly seen in the striatum of rats treated with nicotine (0.35 mg/kg) or TPM 
(containing 0.35 mg/kg nicotine).  
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Overall these data demonstrate that nicotine affects monoamine transporter function in a 
nicotinic receptor-dependent manner, and that nicotine and TPM have different effects on 
monoamine transporter function and expression.  This is the first study to examine the 
effects of TPM on monoamine transporter function, and supports previous evidence of a 
contribution of non-nicotinic components of cigarette smoke to neuroadaptations related to 
smoking.  Findings from this study contribute to knowledge on the molecular biology of 
smoking addiction, which could in future lead to the development of more effective smoking 
cessation therapies.   
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Chapter 1:  Introduction 
 
1.1 Tobacco Addiction and the Global Health Burden 
Cigarette smoke causes nearly 6 million deaths per year worldwide (WHO, 2011), and 
5000 deaths per year in New Zealand alone (New Zealand Ministry of Health, 2005).  It is 
now common knowledge that smoking contributes to a plethora of diseases including 
lung cancer, cardiovascular disease and emphysema (see Fagerstrom, 2002 for review).  
There are currently more than 1 billion smokers worldwide, half of whom will die of 
smoking related illnesses (WHO, 2011).  Cigarette smoking is highly addictive and 
anecdotally reported as being one of the most difficult drugs to quit.  Effective smoking 
cessation therapies are essential to limit the global health burden that is produced by 
cigarette smoking.  However, our current understanding of smoking addiction at the 
biological level is poor, and this is reflected in the limited success of current smoking 
cessation aids.  Therefore, research needs to address both the biological mechanisms 
underlying smoking addiction, and possible pharmacotherapeutic aids to assist in quit 
attempts. 
 
1.1.1 Cigarette Smoking is Addictive 
Cigarette smoke contains over 4000 components, of which, the tobacco alkaloid nicotine 
is the major neurologically active compound (see Balfour 2002, for review).  Numerous 
studies have demonstrated that nicotine is an addictive compound; it acts as a reinforcer 
in self-administration studies in rats (Corrigall and Coen, 1989) and non-human primates 
(Le Foll et al., 2007), reduces intra-cranial self-stimulation reward thresholds (Bozarth et 
al. 1998), and acts on the reward circuitry of the brain in a manner similar to other 
psychostimulant drugs (Balfour et al., 2002).  Nicotine dependence can be described by 
three separate stages that are each characterised by different molecular events, 
neuroadaptations, and subjective experiences (see De Biasi and Dani, 2011 for review).  
The initiation of drug taking comprises a mixture of rewarding and aversive effects and 
involves the excess release of dopamine (DA) in the mesolimbic system to mediate 
rewarding and reinforcing effects (Singer et al., 2004; Dichiara and Imperato, 1988; 
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Nisell et al., 1996).  Chronic nicotine exposure then results in a dependant stage where 
vast neurochemical changes occur including nicotinic acetylcholine receptor (nAChR) 
up-regulation (Brennan et al., 2010) and alterations in monoamine neurotransmitter 
signalling (Shearman et al., 2008), as well endogenous opioid (Xue et al., 2008), 
glutamate and γ-amminobutyric acid (GABA) systems (Yu et al., 2010).  Finally, the 
withdrawal stage occurs upon cessation of nicotine exposure (De Biasi and Dani 2011).  
This stage is typically characterised by feelings of irritability, dysphoria and anxiety.  At 
the molecular level the withwrawal stage involves neurochemical changes including 
decreases in synaptic DA in the nucleus accumbens (NAc) and increased DA release in 
the prefrontal cortex (PFC) (De Biasi and Dani 2011). 
 
The mesolimbic reward pathway of the brain consists of dopaminergic cell bodies in the 
ventral tegmental area (VTA) that project to the NAc and PFC (Figure 1.3).  All drugs of 
abuse affect this pathway either directly or indirectly to cause DA release in these 
regions, particularly in the NAc (Volkow et al., 2007).  This produces reward and 
reinforcement, and is heavily implicated in the initiation of drug abuse.  Nicotine and 
cigarette smoke also produce this increase in DA release in the NAc (Brody et al., 2010).  
Inhaled cigarette smoke is taken into the lungs and absorbed through the alveoli into the 
blood stream.  From here, nicotine rapidly reaches the brain and exerts its effects within 
10 seconds of inhalation (Benowitz, 1995).  In the brain, nicotine binds to the nAChRs 
throughout the central nervous system and induces DA release in the VTA (Singer et al., 
2004), NAc (Dichiara and Imperato, 1988), PFC (Nisell et al., 1996) and striatum 
(Scholze et al., 2007).  Additionally, nicotine induces the release of the monoamines 
serotonin (5-hydroxytryptamine; 5-HT) in the dorsal raphe nuclei (DRN) (Ma et al., 
2005) and striatum (Yu and Wecker, 1994); and norepinephrine (NE) in the PFC (Rossi et 
al., 2005), hippocampus, and striatum (Scholze et al., 2007).  Following release into the 
synapse, the monoamine neurotransmitters bind to post-synaptic receptors and cause 
further downstream signalling.  The activity of the neurotransmitters is primarily 
terminated by re-uptake via the monoamine transporters, after which they are either re-
packaged into vesicles or degraded by monoamine oxidases (MAO) (Figure 1.1) (see 
Bortolato et al., 2008 for review).   
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Figure 1.1:  Monoamine neurotransmission at the synapse.  Nicotine binds to 
acetylcholine receptor (nAChRs) on the presynaptic neuron and induces the vesicular 
release of monoamines in the synapse.  Once released, the monoamines bind to receptors 
on the postsynaptic neurons and cause further downstream signalling.  The monoamines 
also bind to auto-receptors on the presynaptic neuron that regulate their release.  
Clearance of the monoamines from the synapse occurs via degradation by monoamine 
oxidase (MAO) and catechol-o-methyl transferase (COMT), or through re-uptake by the 
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monoamine transporters in the peri-synaptic space.  Following re-uptake, the monoamines 
are either re-packaged into vesicles or degraded by MAO. 
 
1.1.2 Current Smoking Cessation Therapies 
Current smoking cessation therapies centre on nicotine replacement therapies (NRT), and 
include nicotine patches, inhalers, nasal sprays and gums.  It has been reported that the 
delivery method for NRT makes no significant difference to the success of quit attempts, 
with smoking abstinence rates of 20% (gum), 21% (patch), 24% (spray) and 24% 
(inhaler) over 12 weeks (Hajek et al., 1999).  The rationale behind using NRT for 
smoking cessation is that replacing the addictive component of cigarette smoke, nicotine, 
should reduce the unpleasant withdrawal effects of quitting and increase the likelihood of 
abstinence from cigarette smoking (Di Matteo et al., 2007).  However, studies have 
shown that NRTs offer only approximately a 10% success rate after one year (see Balfour 
et al., 2000a for review).   
 
More recently the non-nicotine smoking cessation aids varenicline (Coe et al., 2005) and 
bupropion (Hurt et al., 1997) have been developed.  Varenicline is a synthetic drug that is 
a partial nicotinic agonist and binds specifically to α4β2 receptors (Coe et al., 2005).  
Bupropion is an atypical anti-depressant that has shown efficacy as a smoking cessation 
aid (see Dwoskin et al., 2006 for review).  However, the mechanism of bupropion’s anti-
smoking properties is currently unclear. It is known to be a non-selective inhibitor of the 
dopamine transporter (DAT) and the norepinephrine transporter (NET) and a partial 
antagonist of nAChRs, suggesting that modulation of monoamine transporter function 
may modulate smoking addiction (Paterson et al., 2007).  These non-nicotinic 
pharmacotherapies show an improved 1 year success rate of 23% for varenicline and 
14.6% for bupropion (Jorenby et al., 2006) compared with 10% for NRT (Balfour et al., 
2000a). 
 
In addition to bupropion and varenicline, cytisine is a non-nicotinic smoking cessation 
therapy that has been used in Eastern Europe for forty years (Etter 2006).  It is a partial 
nAChR agonist that specifically binds to α4β2 receptors.  Past studies examining cytisine 
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are methodologically flawed; however, they report some efficacy as a smoking cessation 
aid, with reported quit rates of 13.8-70% with up to 12 months follow up (Etter 2006).  
Recently West et al. (2011) performed the first randomized, double-blind, placebo-
controlled trial of cytisine and found it to be significantly more efficacious than placebo 
at aiding smoking cessation.  The sustained 12 month abstinence rate for subjects on a 
four week course of cytisine was 8.4% vs. 2.4% for placebo, and the authors suggested 
that extending the treatment course could produce better abstinence rates. Although some 
non-nicotinic pharmacotherapies are showing significant improvements over NRT, 
success rates are still disappointingly low.  In light of this there is a definite need for an 
improved understanding of the smoking addiction process to aid the development of new 
alternatives to current cessation therapies. 
 
1.2 The biochemical actions of tobacco smoke in the brain 
1.2.1 Nicotine and the nAChRs 
The nAChRs are ligand-gated ion channels that are endogenously activated by 
acetylcholine (ACh), and are found in both the central nervous system CNS and periphery 
(Deutch et al., 1987; reviewed in Brennan et al., 2010).  Neuronal nAChRs are 
pentameric structures composed of α2-α10 and β2-β4 subunits (Figure 1.2) (Anand et al. 
1991).  Typically they consist of a mixture of both α and β subunits, the exception being 
the homomultimeric α7 receptors.  nAChRs are expressed throughout the brain, including 
the VTA and NAc, and are located in both the peri-synaptic and extra-synaptic areas 
(Brennan et al. 2010).  They are found on a diverse range of neurons including 
dopaminergic (Janhunen and Ahtee, 2007), serotonergic, norephinephric (Bitner and 
Nikkel 2002), GABAergic (Yang et al., 2011), and glutamatergic (Jones and Wonnacott, 
2004) neurons, and thus have a complex role in modulating responses to both endogenous 
and exogenous stimuli.  They have been shown to functionally, and in some cases 
physically, interact with several other receptors including muscarinic, glutamate, and 
D2/D3 DA receptors (Marchi and Grilli 2010).  Numerous nAChR subtypes have been 
implicated in smoking reinforcement and addiction including α4β2, α6β2, α4α6β2, 
α6β2β3, α4α5β2 and α7 (Brennan et al., 2010).  The α4β2 and α7 subtypes are the two 
most abundant in the brain, and the most commonly implicated in nicotine reinforcement 
and reward (Salminen et al. 2004; Salminen et al. 2007; Scholze et al. 2007).  Binding of 
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nicotine to the α subunit of nAChRs causes a conformational change in the receptor and 
opening of the cation channel.  This causes influx of Na
+
 or Ca
2+
 ions into the neuron and 
can result in the release of neurotransmitters such as DA, serotonin (5-
hydroxytryptamine; 5-HT) and NE (reviewed in Brennan et al. 2010).  Continuous 
activation of the nAChRs leads to a desensitised state that has a higher affinity for agonist 
than receptors in standby.  Typically this will lead to down-regulation of the nAChRs; 
however, chronic nicotine causes an up-regulation of receptors.  The mechanism for this 
up-regulation is not fully understood, but it is believed that the receptors have an 
increased affinity for nicotine rather than an increased number of receptors being present.  
In this up-regulated state the receptors have different standby, activation and desensitised 
states and may have slower desensitisation rates (Brennan et al., 2010).  Interestingly, 
Ambrose et al. (2007) found that tobacco particulate matter (TPM) increased nAChR 
expression in a cell culture model to a significantly greater extent than nicotine alone 
(Ambrose et al., 2007).     
 
Figure 1.2:  Pentameric structure of nAChRs and subunit composition of α4β2 and 
α7 receptors.  (A)  nAChRs are arranged in a pentameric structure forming a pore in the 
centre for Na
+ 
and Ca
2+
 influx.  (B)  Arrangement of subunits for the heteromeric α4β2 
receptor and homomultimeric α7 receptor.   
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1.2.2 The effects of nicotine on monoaminergic systems 
The monoamines DA, 5-HT and NE are integral to numerous systems in the brain and 
have all been shown to be involved in drug abuse and addiction. Nicotine affects synaptic 
monoamine concentrations across a number of brain regions.  Nicotine-induced release of 
monoamines has been shown to be both Ca
2+ 
dependent and elicited by nAChR activation 
(Rao et al., 2003).  Dopamine in particular is classically associated with natural reward 
systems and addiction (Kelley and Berridge 2002).  The mesolimbic dopaminergic reward 
pathway is considered the brain’s major mechanism for incurring reinforcement and 
reward, and as mentioned above, nicotine stimulates this pathway.  In addition to DA 
release in the NAc and PFC, nicotine stimulates the nigro-striatal pathway to induce DA 
release in the dorsal striatum, which has been implicated in the locomotor effects of 
nicotine, and habit learning.  Increased DA overflow in the dorsal striatum of individual 
human subjects has also been associated with the hedonic effects of smoking (Barrett et 
al., 2004).  Upon release into the synapse, DA interacts with pre- and post-synaptic 
receptors.  The pre-synaptic D2/D3 DA auto-receptors provide a negative-feedback 
system for DA release and have been shown to functionally interact with nAChRs 
(Marchi and Grilli 2010).  It is hypothesized that stimulation of the nAChRs facilitates 
function of the auto-receptors to prevent further DA release, and that the D2/D3 receptors 
may directly inhibit β2 nicotinic receptors in rat NAc through a physical interaction.  
Interestingly, D2/D3 receptors have also been shown to interact with DAT (Bolan et al., 
2007).     
 
Serotonergic systems are involved in the regulation of a wide range of systems in the 
brain including mood, anxiety, cognition, emotion, memory, and learning (Murphy et al. 
2004).  Research on smoking addiction has primarily focused on DA systems; however, 
5-HT has also been shown to be involved in stimulant and reward effects of nicotine, and 
nicotine withdrawal (Seth et al., 2002).  The response of serotonergic systems to nicotine 
is complex and not completely understood.  Nicotine has been shown to increase [
3
H] 5-
HT release from striatal synaptosomes (Reuben and Clarke, 2000), but has also
 
been 
shown to reduce striatal 5-HT in nicotine self-administering rats (Boules et al., 2010).  
Nicotinic receptors and 5-HT3 serotonin receptors have been shown to co-localize on rat 
striatal nerve terminals (Nayak et al., 2000), and may cross-regulate one another 
(Dougherty and Nichols, 2009).  In addition, serotonergic systems also interact with DA 
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neurotransmission to affect reward in an indirect manner, including the inhibition of DA 
neurons in the VTA by 5-HT raphe projections (Di Matteo et al., 2002).       
 
Norepinephrine is involved in mood, alertness and arousal, as well as heart rate 
regulation, glucose metabolism and fight or flight responses (Weinshenker and Schroeder 
2007).  Although not traditionally a focus of research on substance abuse disorders, 
norepinephrine has more recently been implicated in the neurobiology of drug addiction, 
and NE neurotransmission has recently been targeted for the development of 
psychostimulant addiction treatments (Sofuoglu and Sewell 2009).  Nicotine has been 
shown to cause the release of NE in a wide range of brain regions including the 
hippocampus, frontal cortex, striatum, cerebellum and midbrain (Anderson et al., 2000).  
There is currently limited information in the literature on the effects of nicotine on 
norepinephric systems in the brain.  Norepinephrine is heavily implicated in clinical 
depression in humans (Goddard et al., 2010), and it has been hypothesised that subjects 
with clinical depression may self-medicate with smoking (Balfour et al., 2000c).  In 
addition, the smoking cessation agent bupropion acts in part by blocking NET (Dwoskin 
et al., 2006).  This suggests that NE is involved in the biochemical basis of smoking 
addiction.      
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Figure 1.3:  Selected neuronal pathways for monoamine neurotransmission in the rat brain.  Dopaminergic pathways (red) relevant to 
addiction include: the mesolimbic reward pathway which consists of cell bodies in the ventral tegmental area (VTA) that project to the nucleus 
accumbens (NAc) and prefrontal cortex (PFC); and the nigrostriatal pathway, consisting of cell bodies in the substantia nigra (SN) that project 
to the dorsal striatum.  Norepinephric cell bodies in the locus coeruleus (LC) also project to the PFC (blue); and serotonergic cell bodies in the 
dorsal raphe nuclei (DRN) project to the dorsal striatum (green).     
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1.2.3 The contribution of non-nicotinic tobacco components to smoking addiction 
Nicotine alone is a relatively weak reinforcer in self-administration studies in animals 
(Stolerman and Jarvis, 1995), contradictory to the apparently high addictive nature of 
tobacco smoking in humans (Kandel et al., 1997).  Nicotine in the form of NRTs has been 
reported to have a low abuse liability (West et al., 2000), as well as a limited efficacy in 
aiding smoking cessation (Balfour et al., 2000a).  There are over 4000 components 
present in cigarette smoke, some of which have been shown to be neurologically active 
and may contribute to smoking addiction.  For example, acetaldehyde is a major 
component of cigarette smoke which has been shown to increase firing rates of VTA 
neurons (Foddai et al., 2004), and to increase acquisition of nicotine self-administration in 
adolescent, but not adult, rats (Belluzzi et al., 2005).  Furthermore, Touiki et al. (2007) 
showed that a tobacco extract produced stronger inhibition of dorsal raphe serotonergic 
neurons when compared to a matched dose of nicotine (Touiki et al., 2007).  In humans, 
de-nicotinised tobacco smoke has been shown to decrease craving for cigarettes over 
nicotine inhalers, and to delay onset of smoking a preferred brand cigarette (Barrett, 
2010).  Furthermore, smokers given the choice between de-nicotinised tobacco smoke 
and intravenous (i.v.) nicotine will preferentially self-administer the de-nicotinised 
tobacco smoke (Rose et al., 2010).  The choice of tobacco smoke over nicotine could be 
due to several factors including sensory cues, pharmacologically active compounds in 
tobacco smoke, or a mixture of the two.  An overwhelming majority of the research into 
tobacco addiction has focused on nicotine alone, and further research into the contribution 
of non-nicotinic components of tobacco smoke on addiction is warranted. 
 
One of the most thoroughly researched non-nicotinic compounds to date is the MAO 
inhibitors, which are believed to contribute to smoking addiction by preventing the 
degradation of monoamines, thus increasing the reward signal generated by nicotine (see 
Lewis et al., 2007 for review).  Human smokers have been shown to have decreased 
MAO activity in the brain, and recently several studies that have found that MAO 
inhibition increases nicotine self-administration in the rat (Guillem et al., 2005; Guillem 
et al., 2006; Villegier et al., 2007).  This has been shown with both acute (Villegier et al., 
2007) and chronic (Guillem et al., 2005) MAO inhibition, and may be mediated through 
MAO A inhibition rather than MAO B inhibition (Guillem et al., 2006).  Another 
compound of interest is nornicotine, a metabolite of nicotine that is also present in 
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tobacco and cigarette smoke (Crooks et al., 1997; Stedman, 1968).  Nornicotine evokes 
DA release from rat NAc slices (Green et al., 2001), and is self-administered by rats 
(Bardo et al., 1999), suggesting that it has rewarding properties.  In addition to 
nornicotine the minor alkaloids cotinine, myosmine, anatabine, and anabasine are also 
found in cigarette smoke and together make up 2-3% of the total alkaloid content in 
tobacco (Clemens et al., 2009).  The addition of the five minor tobacco alkaloids to 
nicotine has been shown to increase nicotine-induced locomotor activity, locomotor 
sensitization, and self-administration over nicotine alone in rats (Clemens et al., 2009).  
Anatabine, cotinine and myosmine were also shown to individually increase locomotor 
activity in rats (Clemens et al., 2009).  This suggests that the minor tobacco alkaloids 
have addictive properties and may augment nicotine addiction.  Overall, there is strong 
suggestion that components of tobacco smoke other than nicotine contribute to smoking 
addiction.  Additional research to understand these effects is required and care should be 
taken when extrapolating conclusions about smoking behaviour based on nicotine 
research alone. 
 
1.3 The monoamine transporters 
The monoamine transporters are a highly conserved group of Na
+
/Cl
- 
symporters 
containing 620, 617 and 630 amino acid residues for DAT, NET and the serotonin 
transporter (SERT) respectively (see Torres et al., 2003 for review).  The human DAT, 
NET and SERT proteins are encoded by the SLC6A3, SLC6A2 and SLC6A4 genes 
respectively.  They range in size from 37-65 kb and contain 13-15 exons (Table 1.1).  
Polymorphisms in these genes have been associated with a wide range of disorders 
including attention deficit hyperactivity disorder (ADHD), bipolar disorder and substance 
abuse (see Gainetdinov and Caron, 2003 for review).   
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Table 1.1:  Location, size and number of exons for the human DAT, SERT and NET 
genes. 
 Location Size Number of exons 
SLC6A3 (DAT) 5p15.3 65 kb 15 
SLC6A4 (SERT) 17q11.2 37.8 kb 13 
SLC6A2 (NET) 16q12.2 45 kb 14 
 
The monoamine transporter proteins contain twelve highly conserved trans-membrane 
domains (TMDs), with more variable N- and C- terminals located on the cytoplasmic side 
of the cell.  Binding and transport of the monoamines is facilitated by the binding of Na
+
 
and Cl
-
 to the transporter (Howell and Kimmel 2008).  Upon binding of the monoamine 
neurotransmitter and the two ions, the transporter undergoes a conformational change and 
internalizes the ions and the neurotransmitter.  DAT co-transports two Na
+
 and one Cl
-
 
ion with each DA molecule, while SERT and NET co-transport one Na
+
 and one Cl
-
 ion 
each (Howell and Kimmel 2008).  Additionally, SERT transports K
+ 
in an anti-port 
fashion to return to its original state (Murphy et al. 2004).  The monoamine transporters 
employ the Na
+
 gradient generated by Na
+
/K
+
 ATPase to facilitate this transport (Howell 
and Kimmel 2008). 
 
Uptake by the transporters is mostly monoamine specific; however, DAT and NET have 
the ability to take up either DA or NE (Gainetdinov and Caron 2003).  This has 
particularly been observed in areas of the brain with high norephinephric innervations, 
such as the PFC, where NET may be responsible for a significant portion of DA uptake 
(Dichiara et al. 1992).  Additionally, NET may provide a compensatory mechanism in 
DA uptake when DAT is impaired.  Carboni et al. (2006) showed that when DAT activity 
is attenuated by a specific blocker, synaptic DA levels are increased by a further 100% in 
the presence of a NET blocker in the NAc shell of rats (Carboni et al. 2006). 
 
1.3.1 Location of the monoamine transporters in the CNS 
In the central nervous system the monoamine transporters DAT, SERT and NET are 
located in the perisynapse, and are found almost exclusively on the neurons containing 
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the corresponding monoamine neurotransmitter (Torres et al., 2003).  DAT is typically 
found in cells co-expressing tyrosine hydroxylase.  Dopaminergic cell bodies are located 
primarily in the VTA and substantia nigra (SN) (Ciliax et al., 1999) and it is in these 
regions that the highest expression of DAT mRNA is found.  DAT protein is also 
expressed in these areas as well as in terminal regions of the neurons including the 
striatum, NAc, olfactory tubercle, layers of the cingulate cortex and the PFC.  Some DAT 
cell bodies have also been visualized in the hypothalamus; however, expression of DAT 
mRNA and protein is not as high in this region as the VTA and SN (see Howell and 
Kimmel, 2008 for review). 
 
Serotonin transporters are found extensively throughout the brain; with serotonergic cell 
bodies located in the raphe nuclei in the brainstem (see Murphy et al., 2004 for review).  
The highest levels of SERT mRNA as well as protein are found in these regions, 
particularly in the DRN.  Serotonin transporter protein levels are also high in the cerebral 
cortex, hippocampus, ventral striatum and hypothalamus.  Intermediate levels of SERT 
are found in the midbrain, thalamus and dorsal striatum and low levels are in the cortex 
with virtually none in the cerebellum.  Norepinephrine transporters are found less 
extensively in the brain, with the highest amounts present in the locus coeruleus (LC), and 
raphe nuclei (see Hoffman et al., 1998 for review).  Norepinephrine transporters are 
located in cells that are both tyrosine hydroxylase and dopamine β-hydroxylase positive.  
Norepinephric cell bodies are also found in the LC, as is the majority of NET mRNA.  
Moderate levels of NET are found in the hypothalamus and midline thalamic nuclei, with 
lower expression in the cortex, hippocampus and striatum.   
 
1.3.2 Regulation of the monoamine transporters 
Monoamine transporter activity is regulated on several different levels including the 
velocity of monoamine uptake, and trafficking of the transporters to or from the cell 
surface (sees Kristensen et al., 2011 for review).  The transporters are functional at the 
cell surface, where they are most likely associated with membrane lipid rafts, and are 
constitutively internalised to create a steady-state distribution split between the cell 
surface and intracellular domain.  Following internalization, transporters may be either 
degraded, or form part of the intracellular pool available for rapid recycling back to the 
cell membrane (Melikian 2004).  It has been shown that N-linked glycosylation and 
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oligomerisation of the transporters is essential for their trafficking to the cell surface, 
where they most likely function as homomultimeric complexes (see Melikian, 2004 for 
review).  In addition, export from the endoplasmic reticulum to the cell surface is also 
regulated by the C terminus of the transporters (Kristensen et al., 2011).  Putative N-
linked glycosylation sites on the monoamine transporters have been located in the large 
extracellular loop between TMDs three and four (Figure 1.4).  There are three proposed 
sites in human DAT and NET and two in human SERT (Blakely et al., 1994; Li et al., 
2004a).  De-glycosylation generally results in internalisation of the transporters and thus a 
decrease in monoamine uptake.  It does not, however, appear to affect transporter 
function or ligand binding to the transporters (Kristensen et al., 2011).   
 
DAT, NET and SERT contain several putative intracellular phosphorylation sites that are 
involved in their regulation (Figure 1.4).  Phosphorylation of these sites is involved in 
trafficking of the transporters to and from the cell surface, and kinases may also regulate 
transporter catalytic activity through phosphorylation (Apparsundaram et al., 2001; Zhu et 
al., 2004).  Protein kinase C (PKC) is the best characterised kinase known to 
phosphorylate the monoamine transporters.  It has been shown to increase 
phosphorylation levels of DAT, NET, and SERT, and to down-regulate their activity, 
most likely through transporter internalization (Kirstensen et al., 2011).  There is, 
however, some suggestion that phosphorylation by PKC may initially inactivate 
transporter function through a trafficking-independent mechanism; and PKC-mediated 
DAT internalisation may require concurrent ubiquitination.   
 
In addition to PKC there are several other kinases that are known to phosphorylate and 
regulate the monoamine transporters.  It has been demonstrated that DAT is 
phosphorylated on the N-terminus by numerous kinases including; mitogen activated 
protein kinases (MAPK), protein kinase A (PKA) and Ca
2+
/calmodulin-dependent protein 
kinase (CamK) α (Kristensen et al., 2011).  How this phosphorylation affects the function 
and cellular distribution of DAT in each case is not entirely clear.  PKA has been shown 
to up-regulate DAT (Batchelor and Schenk, 1998), and inhibition of MAPK kinase has 
been shown to decrease DAT phosphorylation and activity (Moron et al., 2003).  SERT 
has been shown to be phosphorylated by protein kinase G (PKG) and PKA.  PKG 
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phosphorylation increases SERT function; however, it is not known whether this is due to 
redistribution of SERT to the cell surface or an increase in the catalytic activity of the 
transporter (Kristensen et al., 2011).  In addition, inhibition of p38 MAPK decreases 
SERT phosphorylation and cell surface expression (Zhu et al., 2004).  NET 
phosphorylation has been less extensively studied.  It has been reported that CaMKII 
phosphorylates a segment of the N-terminus of NET; and CaMKII stimulation increases 
NET activity (Kristensen et al., 2011).  Dephosphorylation of the monoamine transporters 
is an equally important mechanism for transporter regulation.  It has been proposed that 
the monoamine transporters remain in a relatively dephosphorylated state the majority of 
the time due to tonic phosphatase activity.  Both protein phosphatase I and protein 
phosphatase 2A act at DAT, NET and SERT, and the catalytic subunit of protein 
phosphatase 2A has been found to co-immunoprecipitate with all of the monoamine 
transporters (Kristensen et al., 2011).   
 
Substrates of the monoamine transporters may also regulate trafficking between the cell 
surface and interior.  Amphetamine and DA have both been shown to induce endocytosis 
of DAT (Saunders et al., 2000; Chi and Reith, 2003), while cocaine and methylphenidate 
increase DAT cell surface expression (Daws et al., 2002; Little et al., 2002).  
Furthermore, amphetamine stimulates internalisation of NET in a CaMKII- and 
syntaxin1A-dependent manner (Dipace et al., 2007).  Serotonin is believed to have a 
biphasic effect on SERT cell surface expression (Kristensen et al., 2011).  Lower 5-HT 
concentrations appear to stabilize SERT expression at the cell surface, and higher 
concentrations reduce cell surface expression.  The cellular mechanisms for this 
regulation of the monoamine transporters have not been fully elucidated.  One theory is 
that the transporter conformation may determine likelihood of internalisation, so that an 
inward-facing DAT protein is more likely to be endocytosed than an outward-facing 
protein (Kristensen et al., 2011).  In addition to substrate regulation, the monoamine 
transporters may be regulated by co-localised receptors.  One example of this is the 
interaction between the D2 DA receptor and DAT.  Activation of the D2 DA receptor has 
been shown to increase DAT function in a trafficking dependent manner (Bolan et al., 
2007).  There is currently no information in the literature on interactions between SERT 
or NET and their respective monoamine receptors; however, it would be of interest to 
establish whether there is a similar relationship as that observed with D2 and DAT.  
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Figure 1.4:  Monoamine transporter structure with putative glycosylation and phosphorylation sites for DAT, NET and SERT.  Asn, asparagine; PKC, 
protein kinase C; PKA, protein kinase A; PKG, protein kinase G; CamKII, Ca
2+
/calmodulin kinase II; CKII, casein kinase II; Cdk5, cyclin-dependant kinase 5; 
ERK 1/2, extracellular signal regulated kinase 1/2; JNK, c-Jun NH2-terminal kinase; MAPK, mitogen activated protein kinase.  Compiled from Kristensen et al. 
(2011).   
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1.4 Cigarette Smoking and the Monoamine Transporters:  human 
studies 
1.4.1 Genetic Variation in Monoamine Transporters and Human Smoking Behaviour 
Numerous twin studies have indicated that smoking addiction has a heritable component 
(see Li et al., 2004b and Arinami et al., 2000 for review).  The contribution of inheritance 
in smoking dependence is debatable and has been estimated to be between 0.04 and 0.86.  
In recent years a substantial number of candidate gene polymorphisms have been 
proposed to contribute to smoking addiction.  The dopamine transporter gene contains a 
polymorphic 40 bp variable nucleotide tandem repeat (VNTR) sequence at the 3’ 
untranslated region that has been implicated in smoking initiation and dependence (Kang 
et al., 1999).  Each DAT allele contains between three and eleven repeats of this VNTR, 
with the nine and ten repeat (9r, 10r) alleles being the most common. Individuals 
homozygous for the 10r allele show significantly higher DAT availability than 
individuals with the 9r allele (Laucht et al. 2008).  Studies have indicated that individuals 
with the 9r allele are less likely to be smokers or to start smoking before the age of 16 
(Lerman et al., 1999).  Adolescent individuals homozygous for the 10r allele are more 
likely to begin smoking daily at a younger age, and show significantly less intention to 
quit smoking when compared to other allele carriers (Laucht et al., 2008).  Furthermore, 
individuals homozygous for the 10r allele who began smoking daily before the age of 14 
were found to be heavier smokers at age 19 (Schmid et al., 2009). 
 
Another DAT polymorphism that has been implicated in smoking behaviour is the G > A 
transversion at position rs27072 in the 3’ untranslated region (Ling et al., 2004).  This 
transversion produces what is commonly referred to as the DAT A allele.  Ling et al. 
(2004) found a significant association between the DAT A allele and smoking onset in 
under 18 year olds but not severe nicotine dependence (Ling et al., 2004).  Sieminska et 
al. (2009) found that the DAT A allele carriers remained abstinent longer during quit 
attempts, and that 9r allele carriers had a decreased risk of smoking initiation under the 
age of 20 (Sieminska et al., 2009).  Furthermore, it was found that individuals who 
carried the DAT A and 9r alleles in combination had a decreased risk of smoking 
regularly under the age of 20, compared to individuals who carried neither of these alleles 
(Sieminska et al., 2009).  
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The SERT gene contains two VNTR polymorphisms (Li et al., 2004b).  One of these is 
located in the second intron and has no apparent relevance to smoking dependence.  The 
second, known as the 5-HT transporter long promoter region (5HTTLPR) is located 
upstream of the coding region in the transcriptional control region.  The long, or L-type, 
allele contains a 44 bp insertion that the short, or S-type, allele does not.  The S-type 
allele displays decreased transcriptional activity compared to the L-type allele (Heils et 
al., 1996). Gerra et al. (2005) have found that the S-type allele is associated with early 
onset of smoking in teenagers (Gerra et al., 2005). They also found that in Caucasian high 
school students the homozygous S-type allele was more common amongst smokers than 
non-smokers, as well as being more predominant in heavy smokers.  In contrast, Ishikawa 
et al. (1999) found that in Japanese males the L allele is significantly more predominant 
in smokers than non-smokers, and that individuals with the S/S genotype are more likely 
to be non-smokers or to be successful in quit attempts (Ishikawa et al., 1999).  This 
inconsistency highlights the importance of considering factors such as age, gender and 
ethnic background when examining the genetics of smoking addiction.   
 
Present understanding of the genetic contribution to smoking addiction is incomplete and 
needs to be further developed.  As stated, however, there is evidence that genetic 
polymorphisms play a role in the development of tobacco addiction, and there are likely 
to be multiple genes that contribute to this.  Acquiring knowledge of an individual’s 
genetic vulnerability to smoking addiction may help direct prevention and cessation 
therapy resources to where they will be more effective. In future, pharmacotherapies may 
be developed based upon an individual’s genetic makeup. 
 
1.4.2 Smoking and monoamine transporter expression 
To date, there have been few studies investigating the effects of cigarette smoke on the 
function of monoamine transporters in human smokers.  [
99m
Tc] TRODAT-1 specifically 
binds to DAT, and has been used in several single-photon emission computed 
tomography imaging studies in human smokers (Krause et al., 2002; Newberg et al., 
2007; Yang et al., 2008).  A significant decrease in [
99m
Tc] TRODAT-1 binding is seen in 
19 
 
the striatum of human smokers compared to non-smokers.  This decrease in DAT in 
human smokers is consistent with the DA hypothesis of drug addiction, whereby 
decreased DAT availability results in increased synaptic DA and increased reward (see 
Pierce and Kumaresan, 2006 for review).   
 
The observed decrease in binding to DAT in human smokers has not been seen with NET.  
Klimek et al. (2001) analysed [
3
H]nisoxetine binding to NET in the LC of human post 
mortem brains.  They found that there was no significant difference in binding between 
smokers and non-smokers, suggesting that smoking has no effect on NET density in the 
LC (Klimek et al. 2001).  This is consistent with the findings of Andreasen et al. (2009), 
who found no change in [
3
H]nisoxetine binding in hippocampal and cortical membrane 
preparations from mice treated with chronic nicotine (40-50 mg/kg/day oral >2 months) 
(Andreasen et al., 2009).  These findings suggest that the effects of nicotine and cigarette 
smoke may differ for the different transporters.  There are so little data to date on the 
effects of nicotine or cigarette smoke on SERT and NET so that it is difficult to draw 
many conclusions.  Further study on these transporters should begin to make their role in 
smoking addiction clearer. 
  
 
1.4.3 Monoamine Transporters as a Pharmacotherapeutic Target for Smoking 
Cessation 
Polymorphisms in the monoamine transporter genes have been associated with several 
psychiatric conditions including ADHD (Franke et al., 2008; Joung et al., 2009), 
depression (Clarke et al., 2010) and schizophrenia (Cordeiro et al., 2010).  These 
conditions are associated with the dysfunction of monoamine systems and monoamine re-
uptake inhibitors are commonly prescribed for the treatment of mental illnesses, 
particularly for depression (Butler and Meegan, 2008; Christman et al., 2004).  
Interestingly, smoking rates are higher amongst patients with these psychiatric disorders 
than the general population.  Lasser et al. (2000) reported that in the United States the 
current smoking rate for individuals with reported mental illness was 41% compared to 
22.5% in the general population (Lasser et al., 2000).  The prevalence of smoking in 
20 
 
schizophrenic patients has been shown to be between 45-88%, and 40-60% in individuals 
with clinically significant symptoms of depression (Kalman et al., 2005).  Furthermore, 
subjects with ADHD are approximately twice as likely to become dependent on tobacco 
compared to the general population (Gray and Upadhyaya, 2009).   
 
Methylphenidate (Ritalin) and d-amphetamine are commonly prescribed 
pharmacotherapies for ADHD that act on the monoamine transporters to increase 
monoaminergic neurotransmission (Heal et al., 2009).  Studies have shown that both 
methylphenidate and d-amphetamine dose-dependently increase smoking in healthy adult 
smokers when administered acutely (Rush et al., 2005; Vansickel et al., 2007; Cousins et 
al., 2001).  Methylphenidate also increases smoking behaviour in sustained-release form 
(Vansickel et al., 2009).  Acute methylphenidate has also been shown to increase the rate 
of nicotine self-administration in adult male rats (Wooters et al., 2008), and d-
amphetamine increased the choice of smoking over money in healthy human smokers 
(Tidey et al., 2000).  In contrast atomoxetine, a specific NET inhibitor, was shown to 
have no effect on smoking behaviour (Vansickel et al., 2007).  These findings at first 
appear contradictory to the actions of bupropion, a proven smoking cessation aid that 
works at least in part by blocking DAT and NET function.  However, bupropion has been 
shown to increase smoking behaviour when administered acutely, and only works as a 
cessation aid with chronic administration (Cousins et al., 2001).  This suggests that 
alteration of monoamine transporter function, in particular DAT, may lead to changes in 
smoking behaviour and susceptibility to addiction.   
 
Bupropion is currently the only approved smoking cessation aid that affects the function 
of monoamine transporters.  However, several anti-depressants have been tested for their 
anti-smoking properties (Miller et al., 2002; Prochazka et al., 1998; Rauhut et al., 2002).  
Depression is a common withdrawal symptom in people attempting to quit smoking, and 
it has even been suggested that people may smoke to self-medicate due to depression 
(Lerman et al., 1998).  It is therefore logical that antidepressants would be a good basis 
for smoking cessation treatments.  Antidepressants that have been investigated to date 
include the tricyclic antidepressants reboxetine and nortirptyline, and the selective 
serotonin reuptake inhibitor fluoxetine (see Hughes et al., 2007 for review). 
21 
 
 
Reboxetine is a selective NET inhibitor that has been found to inhibit nAChR function 
(Miller et al., 2002).  It has recently been shown to attenuate nicotine self administration 
in rats at rates similar to mecamylamine; however, it also attenuates food-maintained 
responding (Paterson et al., 2008; Rauhut et al., 2002).  Nortriptyline inhibits NET 
function and SERT to a lesser extent.  In a randomised trial conducted by Prochazka et al. 
(1998) nortriptyline was shown to increase short term cessation rates with small 
reductions in withdrawal (Prochazka et al., 1998).  It was shown to double the odds of 
patients quitting smoking (Polosa and Benowitz, 2011), and did not differ from bupropion 
in 1 year abstinence rates (Hall et al., 2002).  Fluoxetine is the most commonly 
investigated selective serotonin reuptake inhibitor for smoking cessation.  It has been 
shown to have some anti-smoking effects in patients with a history of severe depression; 
however it does not seem to produce any significant benefits in non-depressed patients 
(Blondal et al., 1999).   
 
1.5 The Effects of Nicotine and Cigarette Smoke on Monaomine 
Transporter Function:  preclinical studies 
1.5.1 Nicotine, Cigarette Smoke, and the Dopamine Transporter 
Nicotine has been shown to increase DAT function in the PFC (Middleton et al., 2004; 
Zhu et al., 2009), striatum (Middleton et al., 2004) and NAc (Hart and Ksir, 1996).  Using 
in vivo voltammetry techniques, acute systemic nicotine treatment has been shown to 
decrease DA peak amplitudes in the NAc, striatum and PFC of the rat, indicating an 
increase in DA clearance (see Table 1.2 for a summary of the effects of nicotine and 
cigarette smoke on DAT) (Hart and Ksir, 1996; Middleton et al., 2004).  A single dose of 
0.4 mg/kg subcutaneous (s.c.) nicotine produced a maximal decrease in signal amplitude 
of 50% of the baseline value in the NAc at 60 min post-injection (Hart and Ksir, 1996).  
The decrease in peak amplitude was dose-dependent with s.c. administration of nicotine 
at doses between 0.03 and 0.3 mg/kg (free base) in both the striatum and PFC; however, 
the striatum and PFC displayed differences in dose-response to nicotine (Middleton et al., 
2004).  In the PFC a U-shaped dose-response curve was observed with maximal decrease 
in signal amplitude at 0.14 mg/kg nicotine at 30 min post-injection.  In the striatum a 
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maximal response was observed with 0.3 mg/kg (s.c.) nicotine at 45 min post-injection in 
a monophasic dose-response (Middleton et al., 2004).  This work suggests that nicotine 
increases DAT function in the striatum, NAc and PFC in a region-specific manner.   
 
Further support for increases in DAT function following nicotine treatment have been 
demonstrated by radioactive DA uptake studies in striatal and prefrontocortical 
synaptosome preparations (Middleton et al., 2007a; Zhu et al., 2009).  Middleton et al. 
(2007a) obtained striatal synaptosomes from rats 5, 10, 40 and 60 min following a single 
exposure to nicotine (0.32 mg/kg s.c.) and found a 25% increase in maximal velocity of 
uptake (Vmax) of [
3
H]DA at 10 and 40 min only.  However, no overall change in DAT 
protein levels or cell surface expression was revealed using [
3
H]GBR 12935 binding and 
synaptosomal biotinylation methods, indicating that the observed changes may be 
trafficking-independent (Middleton et al., 2007a).   
 
Contrary to the findings of Middleton et al. (2007a), Zhu et al. (2009) found no 
significant change in [
3
H]DA uptake in striatal synaptosomes obtained from rats 15 min 
to 24 hr following acute nicotine exposure at 0.3 or 0.8 mg/kg nicotine (s.c.) (Zhu et al., 
2009).  However, there was a trend towards an increase in Vmax of approximately 20% 
that approached significance.  A significant increase in Vmax of [
3
H]DA uptake in PFC 
synaptosomes from rats treated with 0.8, but not 0.3 mg/kg nicotine (s.c.) was observed at 
15 min (55% increase in Vmax) and 30 min (87% increase in Vmax) following nicotine 
exposure.  In transporter binding assays the DAT specific radioligand [
3
H]WIN 35,428 
showed no change in overall DAT binding in PFC synaptosomes.  However, biotinylation 
studies and Western blot analysis of synaptosomes showed a 32% increase in DAT cell 
surface expression 30 min following 0.8 mg/kg nicotine.  This increase was not as great 
in magnitude as the 87% increase in Vmax, suggesting that increased DAT activity may 
not be entirely trafficking dependent (Zhu et al., 2009). Further research into the 
mechanism by which nicotine modulates DAT trafficking and cell surface expression is 
warranted, including clarification of the role of trafficking in DAT up-regulation. 
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There has been some research to suggest that nicotine causes a decrease, rather than an 
increase in DA uptake.  Earlier studies by Izenwasser et al. (1991) and Yamashita et al. 
(1995) reported decreases in [
3
H]DA uptake in minced striatal tissue and PC12 cells 
(endogenously expressing DAT) following nicotine treatment (1 µM; 10 µM-10 mM) 
(Izenwasser et al., 1991; Yamashita et al., 1995).  This discrepancy is most likely due to 
differences between in vitro and in vivo treatment.  Interestingly, Zhu et al. (2009) found 
that PFC synaptosomes from in vivo treated rats showed an 87% increase in Vmax of 
[
3
H]DA uptake, whereas in vitro treatment (1 nM-10 µM nicotine) of synaptosomes 
resulted in no change in uptake (Zhu et al., 2009).  This is consistent with the findings of 
Izenwasser et al. (1991) and Drew and Werling (2003), that in vitro nicotine treatment (1 
µM; 1-50 µM) did not alter DA uptake in striatal and prefrontocortical synaptosomes 
respectively (Drew and Werling, 2003; Izenwasser et al., 1991).  This indicates that 
whole brain circuitry affects the modulation of transporter activity by nicotine, and is 
required for more biologically relevant experiments.   
 
The majority of research on the effects of nicotine on monoamine transporters has been 
conducted using acute nicotine treatment; however, human smokers expose themselves to 
nicotine and cigarette smoke chronically.  The few studies that have examined chronic 
nicotine treatment have reported conflicting results.  Drew and Werling (2003) measured 
DA uptake by PFC synaptosomes prepared from chronically treated animals (2 mg/kg 
(s.c.) 2x daily for 10 days) and interestingly found no difference in DA uptake between 
nicotine and saline treated animals (Drew and Werling, 2003).  This is consistent with the 
findings of Izenwasser and Cox (1992) and Carr et al. (1989) who found no change in 
[
3
H]DA uptake in chopped striatal or accumbal tissue from rats treated with 6 mg/kg/day 
nicotine for 7 days via osmotic minipumps (Izenwasser and Cox, 1992); or in striatal or 
NAc synaptosomes from chronically treated rats (3 mg/kg/day nicotine via s.c. osmotic 
minipump).  However, Rahman et al. (2004) found a significant increase in DA uptake in 
the NAc of nicotine self-administering rats (i.v. for 25 days) 12-24 hours after final self-
administration session, using no-net-flux microdialysis and in vivo extraction fraction 
techniques (Rahman et al., 2004).  Interestingly, they found no difference between self-
administering animals and the yoked nicotine group that received passive infusions of 
nicotine paired to the self-administering animals.  Both the self-administering group and 
yoked nicotine group showed an increase in DAT function over the yoked saline group 
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with extraction fractions of 86%, 91% and 77% respectively.  Hadjiconstantinou et al. 
(2011) investigated the effects of withdrawal from chronic nicotine on DAT function in 
mice using radioactive uptake in striatal synaptosomes.  Animals were treated with 2 
mg/kg nicotine (s.c.) 4 times daily for 14 days and sacrificed 4-72 hrs after final drug 
treatment. A 27-38% increase in DAT function was found 12-24 hrs into withdrawal, 
with no change at 4 or 8 hrs, and function returned to normal by 48 hrs.  It should be 
noted that both Rahman et al. (2004) and Hadjiconstantinou et al. (2011) used chronic 
models that consisted of longer treatments (14-25 days), compared to only 7-10 days used 
by other researchers.  The discrepancy in results may be due to differences in response to 
nicotine between sub-chronic and chronic dosing.  In addition, the length of time in 
nicotine withdrawal may also make a significant difference to DAT function.  Overall, 
these findings suggest that there could be differences in the modulation of DAT by acute 
and chronic nicotine treatments whereby acute nicotine administration results in an 
increase in DAT function, while chronic or sub-chronic treatment results in no change in 
function.     
 
In addition to having a direct effect on DA uptake by DAT, nicotine has also been shown 
to modulate DAT activity by enhancing amphetamine-induced efflux of DA in PFC and 
striatal, but not NAc, slices prepared from rats (Drew et al., 2000; Drew and Werling, 
2003; Jutkiewicz et al., 2008).  This effect was seen in response to acute in vitro (5 µM 
nicotine) treatment and following nicotine challenge (5 µM) to slices from chronically 
treated animals (2 mg/kg (s.c.) 2x daily for 10 days) in PFC synaptosomes (Drew et al., 
2000; Drew and Werling, 2003).  In striatal slices, this effect was seen following both in 
vivo nicotine (0.32 mg/kg) treatment and in vitro treatment (10 µM nicotine) (Jutkiewicz 
et al., 2008).  It is interesting to note that nicotine enhanced amphetamine-induced efflux 
in vivo and in vitro (Jutkiewicz et al., 2008) and with both chronic and acute treatments 
(Drew et al., 2000; Drew and Werling, 2003).  This contrasts to the discrepancies in the 
literature of the direct effect of nicotine on DA uptake by DAT with different treatments 
(Hart and Ksir, 1996; Middleton et al., 2004; Izenwasser et al., 1991; Yamashita et al., 
1995; Drew and Werling, 2003).  This could suggest that nicotine may act via different 
pathways and mechanisms for the direct effect of DA uptake by DAT compared to 
amphetamine induced efflux through DAT.  Furthermore, this work indicates that there 
could be differences in response to stimulant pharmacotherapies including 
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methylphenidate and d-amphetamine between smokers and non-smokers.  
Methylphenidate and d-amphetamine have been shown to increase smoking behaviour in 
humans (Rush et al., 2005; Vansickel et al., 2007; Cousins et al., 2001) and are 
commonly prescribed to patients with ADHD, who have a high prevalence of smoking 
(Gray and Upadhyaya, 2009).  In light of this, further research into the effects of co-
administered nicotine and amphetamine or other stimulants on the monoamine 
transporters would be beneficial in developing tailored smoking cessation aids for 
individuals on stimulant medications. 
 
To date, few studies have investigated the effects of cigarette smoke or non-nicotinic 
compounds found in cigarette smoke on the monoamine transporters.  Miller et al. (2007) 
used [
3
H]GBR12935 binding to determine the changes in DAT protein levels in the 
midbrain of guinea pigs exposed to cigarette smoke (Miller et al., 2007).  The animals 
were exposed to cigarette smoke from three cigarettes for approximately one hour twice 
daily for seven weeks prior to sacrifice.  A 52% increase in [
3
H]GBR 12935 binding was 
found in crude membrane preparations compared to control animals.  This finding 
contrasts to previous work by Middleton et al. (2007a) that showed no change in overall 
DAT protein levels in rat synaptosomes following nicotine treatment (Middleton et al., 
2007a); however, the findings of Middleton et al. (2007a) were from rats that were 
exposed to nicotine acutely.  This suggests that there may be differences in nicotinic 
modulation of DAT between species, at different time points, or that non-nicotinic 
compounds in cigarette smoke may also modulate DAT expression.  Research into the 
effects of non-nicotinic components of cigarette smoke is severely lacking and is required 
to confirm this.   
 
One non-nicotinic compound that has been studied is nornicotine, a metabolite of nicotine 
that is present in cigarette smoke.  It has been shown to be neurologically active and 
induces the release of DA in slice preparations (Dwoskin et al., 2001).  Recently 
Middleton et al. (2007b) showed that nornicotine (0.35-12 mg/kg (s.c.)) decreased DAT 
function using in vivo voltammetry in the striatum of rats, in contrast to nicotine which 
has been shown to increase DAT activity (Middleton et al., 2007b).  The authors 
suggested that this discrepancy could be due to nornicotine activating a different subset of 
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nAChRs to those activated by nicotine.  This finding highlights the importance of 
considering the effects of non-nicotinic compounds present in cigarette smoke when 
investigating smoking addiction. 
 
The decreased binding of TRODAT to DAT in the striatum of human smokers found by 
Krause et al. (2002), Newberg et al. (2007) and Yang et al. (2008) is inconsistent with 
animal studies described above, where there was either an increase or no change in 
overall DAT binding (Middleton et al., 2007a; Miller et al., 2007).  There are several 
possible explanations for these differences.  Firstly, there are vast differences between 
human smoking behaviour and nicotine dosing regiments for animals including; inhaled 
cigarette smoke compared to injections, the number of nicotine treatments per day 
compared to what a human smoker will smoke, and the self-administering behaviour of 
human smokers compared to the forced injections often received by animals.  It should 
also be noted that in chronic models of nicotine administration animals often receive 
either a consistent infusion of nicotine via minipump, or a single large injection of 
nicotine in a day.  This does not accurately reflect the peaks and falls in plasma nicotine 
concentration seen in human smokers over the period of a day. In addition to this, human 
smokers expose themselves to cigarette smoke chronically; whereas, many animal studies 
focus solely on single nicotine administrations.  Current research suggests that chronic 
nicotine may have no effect on DA uptake by DAT.  In consideration of the changes seen 
in human smokers, it could be speculated that an initial increase in DA uptake by DAT is 
counteracted by a decrease in DAT expression with chronic administration.  Finally, 
while most animal studies investigate nicotine alone, there are over 4000 compounds in 
cigarette smoke, some of which are neurologically active and are likely to contribute to 
cigarette smoking addiction (Fowles and Dybing, 2003).   
 
1.5.2 The effects of nicotine on SERT 
Despite numerous investigations linking the serotonergic system to tobacco addiction, 
few studies have examined the effects of nicotine on SERT (see Fletcher et al., 2008 for 
review).  Awtry and Werling (2003) found significant increases in [
3
H]5-HT uptake in rat 
synaptosomal preparations of the hippocampus and PFC following nicotine treatment 
(Awtry and Werling, 2003).  Single 0.7 mg/kg (s.c.) nicotine injections given 15-75 min 
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prior to sacrifice gave significant increases in SERT Vmax at 15, 30 and 45 min for the 
PFC, and at 60 min only for the hippocampus.  Chronic nicotine delivery (0.7 mg/kg 
twice daily for 10 days) resulted in significant increases in [
3
H]5-HT uptake in the PFC 
(>200%) and the hippocampus (150%).  These increases were accompanied by a 36% 
increase in [
3
H]paroxetine binding in the PFC and a 64% increase in the hippocampus, 
indicating that the increase in [
3
H]5-HT uptake is at least in part due to an increase in 
SERT density.  In addition to this, 4 µM in vitro additions of nicotine to PFC 
synaptosomes resulted in a 75% increase in [
3
H]5-HT uptake (Awtry and Werling, 2003).   
In summary, the effects of nicotine on SERT differ from those on DAT, in that an 
increase in 5-HT uptake is observed with both acute and chronic, and in vivo and in vitro 
nicotine treatment.  However, as was observed with DAT, nicotine induced changes in 
SERT function appears to be brain region specific.  Future research to confirm these 
findings as well as establishing the mechanism responsible for the increase in 5-HT 
uptake is necessary to better characterise the effects of nicotine on SERT.   
 
1.5.3 The effects of nicotine on NET 
There has been only one published study on the effects of nicotine on NE uptake to date. 
Recently, Itoh et al. (2010) found a dose- and time-dependant increase in [
3
H]NE uptake 
in cultured bovine adrenal medullary cells (endogenously expressing NET) in response to 
nicotine (0.1-10 µM) (Itoh et al., 2010).  This effect was seen over a 5 day period with the 
greatest increase in uptake observed between 2-3 days.  Subsequently, cells incubated 
with different concentrations of nicotine for 2 days showed a monophasic dose response 
to nicotine, with the greatest increase in uptake (161% of control) observed with 10 µM 
nicotine.  Furthermore, a significant increase in Vmax, with no change in Km, was observed 
in cells incubated with 10 µM nicotine for 2 days.  The DNA-dependant RNA polymerase 
inhibitor actinomycin D, and the ribosomal protein synthesis inhibitor cylcoheximide, 
were used to determine whether the observed change in NET function was due to 
transcriptional or translational regulation of NET.  Both actinomycin D and 
cycloheximide produced a small inhibition of basal NE uptake, reducing uptake to 78% 
and 77% respectively; however, only cylcoheximide attenuated the nicotine induced 
increase in NE uptake.  Furthermore, the proteosome inhibitor MG132 had no significant 
effect on NET function (Itoh et al., 2010).  This would suggest that modulation of NET 
by nicotine may be partially due to an increase in protein synthesis, independent of an 
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increase in gene transcription.  However, due to the nonspecific nature of these 
compounds results should be interpreted with extreme caution as a number of other 
systems may have been affected that could have nonspecific downstream effects on NET.     
 
To the best of the authors knowledge there have been no studies on the effects of nicotine 
or cigarette smoke on NE uptake in laboratory animals.  Zhu et al. (2009) did examine 
DA uptake by NET in PFC synaptosomes 30 min after 0.8 mg/kg nicotine (s.c.).  They 
found no change in the Vmax or Km of DA uptake using a radioactive uptake assay.  It is 
surprising that there have not been studies on the effects of nicotine or cigarette smoke on 
NET considering that the smoking cessation therapy bupropion works in part by blocking 
this transporter.  Nicotine has been shown to increase NE levels in the PFC, hippocampus 
and striatum (Rossi et al., 2005; Scholze et al., 2007) and there is increasing evidence that 
NE is involved in the pathology of drug addiction (see Weinshenker and Schroeder, 2007 
for review).  The contribution of NE to forming a pathological addictive state is partly 
mediated through its effects on DA release; however, there is also evidence for an 
independent NE pathway involved in drug addiction, particularly for ethanol and opiates 
(Weinshenker and Schroeder, 2007).  In addition, it has been suggested that NE 
contributes to the withdrawal state of a number of drugs of abuse, including nicotine 
(Sofuoglu and Sewell 2008).  Therefore, it would be highly beneficial for future research 
to ascertain how nicotine and cigarette smoke affect the function of NET.  
 
1.6 Mechanisms of Nicotinic Alteration of Monoamine Transporter 
Function 
1.6.1 nAChRs 
Nicotine does not directly interact with DAT (Izenwasser et al., 1991).  Instead, it has 
been consistently demonstrated that monoamine transporter activity is modulated by 
nAChRs (Awtry et al., 2006; Izenwasser et al., 1991; Middleton et al., 2004; Middleton et 
al., 2007b; Yamashita et al., 1995; Zhu et al., 2009).  Modulation of DAT activity has 
been shown to be nicotinic receptor specific as atropine, a muscarinic antagonist, has no 
effect on nicotine induced changes in DAT function (Yamashita et al., 1995).  
Mecamylamine and hexamethonium are nAChR antagonists that are nonspecific for 
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nAChR subtypes.  Mecamylamine has been shown to attenuate nicotine effects on DAT 
in the PFC, NAc and striatum (Drew et al., 2000; Hart and Ksir, 1996; Middleton et al., 
2004; Yamashita et al., 1995; Zhu et al., 2009), and SERT in the PFC (Awtry et al., 
2006).  Both mecamylamine and hexamethonium have been shown to attenuate the 
effects of nicotine on NET in bovine adrenal medullary cells (Itoh et al., 2010). 
Interestingly, Zhu et al. (2009) found that mecamylamine not only attenuates the increase 
in Vmax produced by nicotine, but it also attenuates the nicotine induced increase in DAT 
cell surface expression in the PFC (Zhu et al., 2009).  Mecamylamine also blocked the 
nornicotine induced decrease in DA uptake observed by Middleton (2007b).  This 
research suggests that nAChR antagonism modulates DAT, NET and SERT function, by 
blocking the effects of nicotine on the transporters.  However, the mechanism by with this 
occurs remains to be determined and additional research using specific nAChR 
antagonists is also needed to determine which nAChR subtypes are responsible for the 
observed effects.   
 
Several studies have investigated the involvement of specific nAChR subtypes and they 
have been shown to vary in their ability to modulate monoamine transporter function.  
Dihydro-beta-erythroidine (DHβE) is a β2 nAChR antagonist that has been shown to 
attenuate the nicotine induced increases in DAT function, and amphetamine stimulated 
DA efflux in PFC synaptosomes (Drew et al., 2000; Zhu et al., 2009).  DHβE also 
attenuates the nicotine induced increase in SERT uptake in PFC synaptosomes (Awtry et 
al., 2006).  These results suggest that α4β2 nAChRs are important in nicotinic modulation 
of monoamine transporter function.  There is some evidence for the involvement of α7 
receptors in nicotinic modulation of monoamine transporter function.  Zhu et al. (2009) 
found that the α7 antagonist methyllycaconitine blocked the nicotine induced increase in 
DAT function (Zhu et al., 2009).  In contrast Drew et al. (2000) found that the α7 
antagonist α-bungarotoxin did not have any effect on nicotine induced increases in 
amphetamine stimulated DA efflux (Drew et al., 2000).  Similarly, Itoh et al. (2010) 
reported no change in nicotine induced increases in NET function following α-
bungarotoxin treatment (Itoh et al., 2010).  This may be due to the different systems 
modulating DA uptake by DAT and DA efflux via DAT.  Different nAChR subtypes may 
also be responsible for the modulation of the different monoamine transporters.  More 
work is necessary before any definitive conclusions can be drawn.   
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1.6.2 Secondary Messenger Systems 
There has been some work conducted on secondary messenger involvement in nicotinic 
modulation of monoamine transporters.  Drew and Werling (2001) and Drew et al. (2003) 
found that the PKC inhibitor chelerythrine blocked the nicotinic enhancement of 
amphetamine induced DA release (Drew and Werling, 2001; Drew and Werling, 2003).  
Furthermore, it was found that CamKII inhibitors did not attenuate nicotine effects (Drew 
and Werling, 2001).  Awtry et al. (2006) found that PKA stimulation increased 5-HT 
uptake; whereas, the PKA blocker Rp-cAMP caused a decrease in uptake.  In addition, 
Rp-cAMP was shown to block 5-HT uptake following nicotine treatment, indicating that 
modulation of SERT by nAChRs is PKA-dependent (Awtry et al., 2006).  Itoh et al. 
(2010) found no effect on nicotine induced increases in NET function with H-89 (a 
cAMP-dependent protein kinase inhibitor), U0126 (mitogen activated protein kinase 
kinase inhibitor), calphositn C (PKC inhibitor), or the Rho kinase inhibitors Fasudil and 
Y27632 (Itoh et al., 2010).  It was found; however, that nicotinic effects on NET were 
completely abolished by removing extracellular calcium.  The CaMKII inhibitor KN-93 
significantly inhibited increases in NET function; however, the inactive analogue KN-92 
produced a similar effect.  It was then found that both analogues suppressed the nicotine 
induced 
45
Ca
2+ 
influx, suggesting that it was the lack of calcium and not CaMKII 
inhibition responsible for this observation.  In summary, the effects of nicotine on NET 
appear to require calcium influx into the cell, but no specific signalling pathways have 
been shown to be required.  It is not currently known how calcium influx affects NET to 
produce the nicotine induced increase in uptake, and further research on this is necessary 
for clarification.   
 
It should be noted that activation of signalling pathways such as PKA and PKC may not 
be due to a direct effect of nAChR stimulation.  Binding of nicotine to the nAChRs 
induces the release of DA into the synapse, which in turn activates DA receptors 
including the D2 auto-receptor, which has been shown to modulate DAT function (Bolan 
et al., 2007).  Therefore, care should be taken when extrapolating conclusions from 
research on signalling pathways, as the effects of blocking or stimulating these pathways 
on a whole system can have multiple and indirect effects.     
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Table 1.2: The effects of chronic nicotine and cigarette smoke on DAT function.  
 Animal Treatment Effect Mechanism Author 
PFC Rat 2 mg/kg nicotine s.c. 2x daily, 10 
days; 1-50 µM nicotine in vitro 
no change in uptake  Drew and Werling 
2003 
 Rat 2 mg/kg nicotine s.c. 2x daily, 10 
days followed by 5 µM nicotine in 
vitro  
inc. amphetamine-induced DA 
efflux (no difference between 
chronic nicotine and chronic saline 
pre-treatment) 
Attenuated by DHβE & the 
PKC inhibitor chelerythrine 
Drew and Werling 
2003 
NAc Rat self-administration i.v. for 25 days inc. uptake  Rahman et al. 2003 
 Rat 
 
 
Rat 
6 mg/kg/day nicotine for 7 days via 
osmotic minipump 
3 mg/kg/day for 14 days via 
osmotic minipump 
no change in uptake 
 
 
no change in uptake 
 Izenwasser and Cox 
1992 
 
Carr et al. 1989 
Striatum Rat 
 
6 mg/kg/day nicotine for 7 days via 
osmotic minipump  
no change in uptake 
 
 
 Izenwasser and Cox 
1992 
 
 Guinea 
pig 
Cigarette smoke ~1 hr 2x daily, 7 
weeks 
52% inc. DAT binding 
 
 Miller et al. 2007 
 
 Human 
 
 
Mouse 
 
 
Cigarette smokers 
 
 
2 mg/kg nicotine s.c. 4x daily, 14 
days, sacrificed 4-72 hrs after final 
treatment. 
dec. in [
99m
Tc] TRODAT-1 binding   
 
 
27-38% increase in function 12-24 
hrs into withdrawal, no change at 4 
or 8 hrs, function normal by 48 hrs.   
 Krause et al. 2002; 
Newberg et al. 
2007; Yang et al. 
2008 
Hadjiconstantinou 
et al. 2011 
 Rat 3 mg/kg/day for 14 days via 
osmotic minipump 
No change in uptake.  Carr et al. (1989) 
inc., increase; dec., decrease; s.c., subcutaneous; i.v.; intravenous; DHβE, Dihydro-beta-erythroidine; PKC, protein kinase C
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Table 1.3:  The effects of acute nicotine on DAT function. 
 Animal Treatment Effect Mechanism Author 
PFC 
 
Rat 0.1-0.8 mg/kg nicotine s.c. inc. uptake, max at 0.4 mg/kg  Attenuated by mecamylamine Middleton et al. 2004 
 Rat 0.8 mg/kg nicotine s.c. 55% inc. uptake (Vmax) at 15 min, 87% inc. 
uptake (Vmax) at 30 min  
Attenuated by mecamylamine, MLA & 
DHβE.  32% inc. DAT cell surface 
expression at 30 min. 
Zhu et al. 2009 
 Rat 5 µM nicotine in vitro inc. amphetamine-induced DA efflux Attenuated by DHβE & mecamylamine 
but not α-bungarotoxin 
Drew et al. 2000                
NAc 
 
Rat 0.4 mg/kg nicotine s.c. inc. uptake Attenuated by mecamylamine Hart and Ksir 1996 
 
 Rat 5 µM nicotine in vitro no change in amphetamine-induced efflux  Drew et al. 2000 
 
 Rat 0.1 mg/kg s.c. no change in synaptosomes  Carr et al. 1989  
Striatum 
 
Rat 
 
0.1-0.8 mg/kg nicotine s.c. inc. uptake, max at 0.8 mg/kg s.c. Attenuated by 1.5 mg/kg  
mecamylamine 
Middleton et al. 2004 
 Rat 0.32 mg/kg nicotine s.c. 25% inc. uptake (Vmax) at 10 & 40 min no change in DAT density or cell 
surface expression 
Middleton et al. 
2007a 
 
 Rat  0.8 mg/kg nicotine s.c.; 1 nM-
10 µM nicotine in vitro 
no change in uptake 
 
 Zhu et al. 2009 
 
 Rat 
 
1 µM nicotine in vitro no  change in synaptosomes  Izenwasser et al. 
1991 
 Rat 1 µM nicotine in vitro dec. uptake in chopped tissue Attenuated by chlorisondamine and 
mecamylamine 
Izenwasser et al. 
1991 
 
 Rat 5 µM nicotine in vitro 
 
no change in amphetamine-induced efflux  Drew et al. 2000 
 
 Rat 10 µM nicotine in vitro; 0.32 
mg/kg s.c. nicotine 
 
increase in amphetamine-induce efflux  Jutkiewicz et al. 2008 
 
Cell 
models 
PC12 cells 10 µM-10 mM nicotine dec. uptake Attenuated by hexamethonium & 
mecamylamine 
Yamashita et al. 1995 
inc., increase; Vmax, maximal velocity of uptake; MLA, methyllycaconitine; DHβE, Dihydro-beta-erythroidine; PKC, protein kinase C; dec., decrease.
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1.6.3 Nicotinic Regulation of Monoamine Transporter Gene Expression 
In addition to being regulated at the level of functional activity and protein expression, 
the monoamine transporters may be modulated through altered gene expression.  Animal 
studies by Awtry and Werling (2003) and Miller et al. (2007) have shown increases in 
SERT and DAT protein expression in response to nicotine and cigarette smoke 
respectively (Awtry and Werling, 2003; Miller et al., 2007).  In contrast, human studies 
have shown decreases in DAT protein in the brain of smokers compared to non-smokers 
(Krause et al., 2002; Newberg et al., 2007; Yang et al., 2008).  A possible mechanism 
responsible for these observed changes in protein expression is through altered gene 
expression.  There have been several recent studies that examined the effects of nicotine 
and cigarette smoke on monoamine transporter gene expression (Li et al., 2004c; Semba 
and Wakuta, 2008; Itoh et al., 2010).   
 
Semba and Wakuta (2008) measured SERT mRNA production in the DRN of rats using 
in situ hybridization following both chronic (6 mg/kg/day (s.c.) via minipump, 12 days) 
and acute (0.5 mg/kg intraperitoneal (i.p.) 2 hours before sacrifice) nicotine treatment 
(Semba and Wakuta, 2008).  A significant decrease in SERT mRNA expression was 
found in rats treated chronically, up to two days into withdrawal.  Furthermore, co-
administration of the non-nicotinic smoking cessation aid Bupropion significantly 
antagonised the increase in SERT mRNA expression to levels comparable to controls.  
No change was found in acutely treated animals (Semba and Wakuta, 2008).  This 
decrease in SERT mRNA expression does not correlate to the increase in SERT protein 
observed by Awtry and Werling (2003); however, the dosing regimens differ (Awtry and 
Werling, 2003).  Although the time period is comparable, Semba and Wakuta (2008) used 
a significantly larger dose of nicotine for treating animals in a continuous manner via 
minipump, which could lead to differences in response to nicotine.  Future research 
should address the differences between protein and mRNA expression profiles of SERT 
by directly comparing samples from animals that have received the same dosing regimens 
before any conclusions can be drawn. 
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A study in rats by Li et al. (2004) showed that chronic nicotine and cigarette smoke 
exposure caused an increase in DAT mRNA expression in the VTA and SN (Li et al., 
2004c).  Animals were given either 3 mg oral nicotine daily, or passively inhaled cigarette 
smoke in tightly sealed boxes for 10, 30 or 60 min, three times a day, for four weeks.  
DAT mRNA expression was measured using in situ hybridization and RNAse protection 
assay.  Interestingly, exposure to cigarette smoke for 30 min daily resulted in a 152.5% 
increase in DAT mRNA expression compared to control, where nicotine alone resulted in 
a 126.4% increase (Li et al., 2004c).  Hadjicontantinou et al. (2011) also found an 
increase in DAT mRNA expression using in situ hybridization in the SN and VTA of 
mice in response to chronic nicotine.  This effect was seen in response to 14 days 
treatment of 2 mg/kg nicotine 4 times daily, and produced 20-41% increases in expression 
12-48 hrs following final nicotine treatment.  In contrast to this, Ferrari et al. (2001) 
found no change in DAT mRNA levels in the VTA or SN using in situ hybridization 24 
hours after rats received a single 0.4 mg/kg (i.p.) nicotine injection (Ferrari et al., 2002).  
This inconsistency may be due to differences in the effects of acute and chronic dosing on 
mRNA expression.  Furthermore the route of nicotine administration and doses are vastly 
different.  Lastly, it should be noted that the increase in DAT mRNA expression shown in 
the study by Li et al. (2004c) is small, and that without an accompanying increase in 
protein expression the molecular relevance of it is questionable.   
 
Ohyama et al. (2010) recently reported that nicotine enhanced transcription of the DAT 
gene in SK-N-SH cells transiently transfected with human DAT (Ohyama et al., 2010).  
The 5’ flanking region of the DAT gene which contains the promotor was analysed using 
luciferase reporter assays.  It was found that 5 µM nicotine treatment for 24 hours 
enhanced promoter activity, and that this enhancement was abolished by the deletion of 
intron 1.  A concentration dependent increase in activity was also observed at 0.1-100 µM 
nicotine that was blocked by the nicotinic antagonist hexamethonium, suggesting that the 
effect is dependent on nAChR activation.  The authors propose a novel nicotinic 
responsive element in the human DAT genes somewhere between -3478 to -1036 that is 
responsible for these changes.  This enhanced promoter activity suggests that nicotine 
increases the gene expression of DAT, which would be consistent with the findings of Li 
et al. (2004), that nicotine and cigarette smoke increase DAT mRNA expression (Li et al., 
2004). 
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Itoh et al. (2010) measured NET mRNA expression in bovine adrenal medullary cells 
using RT-PCR following 2 days treatment with 10 µM nicotine (Itoh et al., 2010).  They 
found a slight but non-significant increase in NET mRNA expression which appears 
consistent with their finding that the DNA-dependent RNA polymerase inhibitor 
cyclohexin had no effect on nicotine induced increases in NE uptake (Itoh et al., 2010).  
This is, however, the only study that has looked at NET gene expression in response to 
nicotine to date and further work is necessary to validate this finding.  It would be 
particularly beneficial to investigate nicotine’s effect on NET mRNA expression in 
specific brain regions of laboratory animals to ascertain the effects of nicotine in an intact 
whole system. 
 
1.7 Aims and Objectives 
The overall aim of this study is to examine the effects of nicotine and TPM on DAT, 
NET, and SERT in discrete regions of the rat brain.  No previous study has compared the 
effects of nicotine on the monoamine transporters to a tobacco extract.  By investigating 
the effects of TPM as well as nicotine we may obtain a greater understanding of the 
contribution of non-nicotinic components of tobacco smoke to smoking-related 
neuroadaptations.  In future this could lead to the development of more efficacious 
smoking cessation pharmacotherapies.   
The specific objectives of this study were (1) to examine the effects of nicotine and TPM 
on monoamine transporter function, protein expression, and mRNA expression in chronic 
and acute treatment models; (2) to determine whether any changes in monoamine 
transporter function were nAChR-dependent, and whether nAChRs containing α7 or β2 
subunits were involved where changes were observed; (3) to directly compare the effects 
of nicotine and TPM to establish whether or not they have differential effects on the 
monoamine transporters.  
Based on the previously published literature, we expect that nicotine and TPM will cause 
changes in monoamine transporter function.  It is well established that elevated levels of 
mesolimbic DA is involved in the development of drug addiction, particularly in the NAc 
(Singer et al., 2004; Dichiara and Imperatio, 1988; Nisell et al., 1996).  For this reason, a 
36 
 
decrease in DA uptake in these brain regions in response to nicotine would be expected to 
contribute to an addiction state.  Conversely, there are reports of nicotine increasing 
monoamine transporter function (Zhu et al., 2009; Itoh et al., 2010; Awtry and Werling, 
2003), which may provide a feedback mechanism in response to excess monoamine 
release.  Regardless of the direction of change in monoamine transporter function, we 
expect that changes in response to nicotine alone will be nAChR dependent.  
Furthermore, we predict differences between TPM treatment and nicotine alone, based on 
recently reported differences in the pharmacological profile of tobacco extracts compared 
to nicotine.    
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Chapter 2:  Materials and Methods 
 
2.1 Animals 
Male Sprague-Dawley rats weighing between 240 and 340 g were used for all 
experiments.  Animals were housed in the Victoria University of Wellington animal 
housing facility in groups of 3-4 per cage and maintained on a 12 hr light/dark cycle with 
free access to food and water.  Subsequent to treatment with nicotine or TPM animals 
were euthanized by CO2 asphyxiation followed by rapid decapitation.  All experiments 
were conducted with approval from the Victoria University of Wellington Animal Ethics 
Committee. 
 
2.2 Nicotine and Tobacco Particulate Matter 
2.2.1 Tobacco Particulate Matter Collection 
Tobacco Particulate Matter (TPM) for this study was provided by the Institute of 
Environmental Science and Research Ltd (ESR) (Wellington).  The extract contains 
combustion products from tobacco smoke representative of what a human smoker would 
typically inhale.  The TPM was produced following the methods outlined by Ambrose et 
al. (2007).  Briefly, Holiday Special Filter cigarettes (a leading New Zealand brand of 
cigarettes) were sent to Labstat International Inc. (Kitchener, Canada) where they were 
combusted using a smoking machine, and combustion products were collected on 
Cambridge filter pads.  These filter pads were stored at -20°C until required and products 
were extracted in absolute ethanol.  The extract was analysed for nicotine content using a 
mass spectrometer and nitrogen phosphorous detector. Typically, the nicotine 
concentration was between 1-1.5 mg/mL.  Two separate batches of TPM were used in this 
study and experiments were batch controlled.  All chronic and 1 hr time point 
experiments utilised one batch of TPM, while 15 and 30 min experiments were performed 
with the second batch.    
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2.2.2 Nicotine and TPM Administration 
Animals were administered nicotine, TPM or vehicle in acute or chronic regimens via i.p. 
injection.  (-)-Nicotine hydrogen tartrate salt (Sigma) was used for nicotine treatments 
and stated doses represent the free base weight.  Stock solutions of TPM in 100% ethanol 
were diluted with 1x phosphate buffered saline (PBS, 137 mM NaCl, 2.7 mM KCl, 8.1 
mM Na2HPO4, 1.5 mM KH2PO4, pH 7.4) (Appendix I) so that the endogenous nicotine 
content of the TPM would match the nicotine only injection solutions.  All injection 
solutions contained 8% ethanol to match the ethanol content of the TPM extract.  Vehicle 
consisted of 8% ethanol in 1x PBS.  Both chronic and acute regimens were used in this 
study.  For chronic treatments, 4 daily injections were chosen to better mimic the peaks 
and falls in plasma nicotine that are observed in human smokers, rather than a single large 
dose of nicotine.  Chronic regimens consisted of 4x injections daily with 2 hrs between 
each treatment over a period of 10 days.  Ten days was chosen as the treatment period 
because it has previously been used in chronic nicotine administration studies examining 
monoamine transporter activity (Drew and Werling, 2003; Awtry and Werling, 2003).  
The total daily dose was either 0.35 or 3 mg/kg nicotine, or TPM containing 0.35 mg/kg 
nicotine.  Animals were killed 14-16 hrs following final injection, so that the greatest time 
between first and last killed animal in each chronically treated group was 2 hrs.  This time 
point also fell just before the animal would have received its first daily injection.  The 
above doses represent a low (0.35 mg/kg nicotine) and high (3 mg/kg nicotine) dose and 
were chosen for several reasons: they fall roughly within the range of what a rat will self-
administer (Corrigall and Coen, 1989; Boules et al., 2010), they are comparable to doses 
used in previous studies (Middleton et al., 2004; Middleton et al., 2007a; Hart and Ksir, 
1996; Drew and Werling, 2003; Rahman et al., 2003), and they should produce plasma 
nicotine levels comparable to nicotine plasma levels in human smokers (Matta et al., 
2007). 
   
Acute treatments consisted of a single i.p. injection of 0.35 mg/kg nicotine or dose 
matched TPM.  Animals were euthanized 15 min, 30 min or 1 hr following injection.  The 
effects of nicotine on monoamine transporter function appear to be heavily time-
dependent; therefore, a range of times was chosen based on previously reported times 
where alterations in monoamine transporter function was observed (Zhu et al., 2009; Hart 
and Ksir, 1996; Awtry and Werling, 2003).  The 3 mg/kg nicotine treatment was not used 
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in acute treatments due to adverse effects observed in the animals in preliminary 
experiments.  When nicotinic antagonists were used (with acute treatments only), animals 
received a single injection (i.p.) of 1.5 mg/kg mecamylamine HCl (salt weight; Tocris), 8 
mg/kg DHβE hydrobromide (salt weight), or 10 mg/kg methyllacotinine citrate (MLA) 
(salt weight, Tocris).  These doses were chosen based on published work by Zhu et al. 
(2009).  Nicotinic antagonists were administered 20 min prior to nicotine, TPM or control 
treatment, and the vehicle was 1x PBS (pH7.4). 
 
2.3 Tissue Dissection 
Following removal of the brain, discrete brain regions were dissected using an acrylic 
stereotaxic brain matrixes block (Alto, AgnTho’sAB, Sweden), based on coordinates 
from Paxinos and Watson (2005) (see Table 2.1).  A single side of the PFC and dorsal 
striatum was used for each experiment, whereas both sides of the NAc, SN, VTA, DRN 
and LC were pooled for experiments.  This is an accepted and widely used method of 
tissue dissection (Heffner et al., 1980; Corcoran et al., 2011); however, the midbrain 
regions used in this study are small and not very clearly defined in the rat.  While every 
effort was made to be precise in all tissue dissections, due to the small size of some of the 
brain regions examined it cannot be claimed that samples taken contained solely the 
specified regions.  In particular, the SN and VTA are very small and situated closely 
together in the brain.  Therefore, samples labelled as SN and VTA are perhaps best 
described to contain predominantly, but not always exclusively, the region stated.  All 
tissue samples were weighed to check dissection consistency (see Table 2.1).  Following 
dissection, samples were either immediately homogenized in TRIzol
®
 LS Reagent 
(Invitrogen) for RNA extraction and frozen at -80°C, or frozen dry in microcentrifuge 
tubes at -80°C for use in RDEV and Western blotting experiments. 
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Table 2.1:  Reference coordinates and mean tissue weights for brain dissections. 
Brain Region Interaural Coordinates 
Tissue weight in mg  
(mean ± SEM) 
PFC +12 to +14 12.3 ± 0.2 
Dorsal Striatum +9 to +11 15.1 ± 0.5 
NAc +9 to +11 11.3 ± 0.2 
SN +3 to +4 7.6 ± 0.3 
VTA +2 to +3 7.5 ± 0.3 
DRN +1 to +2 7.4 ± 0.4 
LC -1 to 0 6.8 ± 0.3 
Values are mean ± SEM.  Values for NAc, SN, VTA, DRN, and LC represent pooled 
weights of both sides of the structure.  Coordinates from Pax and Watson (2005). 
 
2.4 Rotating Disk Electrode Voltammetry (RDEV) 
RDEV is an electrochemical technique that measures the uptake of DA, NE, and 5-HT by 
the monoamine transporters (Hagan et al., 2010; Burnette et al., 1996; Earles et al., 1998).  
The experimental setup consists of a rotating glassy carbon electrode (Pine Instruments, 
special order AFMDO3GC, Pennsylvania) that is lowered into a sample chamber 
containing an auxiliary platinum electrode and a Ag/AgCl reference electrode (Figure 
2.1).  The rotating electrode keeps samples in the chamber homogenous and creates a 
diffusion layer around the submerged electrode.  Monoamines in this layer are oxidised at 
the electrode and release 1 or 2 electrons which produces a measureable current.  Because 
the contents of the chamber is constantly mixed, new species continuously replace those 
already in the diffusion layer, so that old oxidation products are removed and new 
monoamines are available at the electrode.  As monoamines are taken up by tissue there is 
a reduction in free monoamines, and a decrease in the current produced by oxidation 
products.  This decrease can then be used to calculate the rate of monoamine uptake by 
the monoamine transporters. 
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Figure 2.1:  RDEV experimental setup.  The rotating glassy carbon electrode is lowered 
into a sample chamber containing an auxiliary platinum electrode and Ag/AgCl reference 
electrode.  The glassy carbon electrode is rotated at 2000 rpm and +450 mV potential was 
applied relative to the Ag/AgCl electrode.  This causes monoamines (MA) to oxidize and 
release electrons, which are measured as a current by eDAQ ecorder and recorded in chart 
software.  In the presence of tissue, monoamines are taken up by the monoamine 
transporters, resulting in a decreased current.  The rate of uptake can be measured from 
the slope of the line on chart software. 
 
2.4.1 Standard Curve 
Prior to each experiment a standard concentration-response curve was produced by 
adding increasing amounts of DA (0.5-2 µM; Tocris) or 5-HT (0.1-1.5 µM; Tocris) to 
KREBS buffer (130 mM NaCl, 1.3 mM KCl, 2.2 mM CaCl2, 1.2 mM MgSO4.6H20, 1.2 
mM KH2PO4, 10 mM HEPES, 10 mM D-glucose, pH 7.4) (Appendix 1).  The increase in 
the current with each monoamine addition was used to calculate a linear regression that 
allowed nA readings from these experiments to be converted into µM concentrations.  
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2.4.2 Sample Preparation 
Frozen tissue samples were used in all RDEV experiments.  In a recent paper, Volz et al. 
(2009) established that frozen tissue samples could be used for RDEV experiments.  This 
was confirmed in our laboratory by Dr. Bridget Simonson who showed that SERT 
function in frozen tissue was measurable with no significant difference to fresh tissue 
following up to one week of frozen storage (unpublished data).  Thus, for these 
experiments tissue was frozen for up to one week, and each data set was generated from 
tissue that had been frozen for the same number of days.  Tissue samples frozen dry at -
80°C were thawed at room temperature for 20 min.  Following this, they were minced in 
300 µL of ice-cold KREBS buffer on a glass petri dish for 30 sec with ice-cold razor 
blades.  Samples were then collected in a microcentrifuge tube and allowed to settle to the 
bottom of the tube before the supernatant was removed and replaced with 37°C KREBS 
aerated with carbogen gas (95% O2, 5% CO2).  This was repeated 8 times to wash the 
tissue thoroughly before removing it in 296 µL of aerated KREBS to add to the RDEV 
chamber (kindly donated by J. B. Justice Jnr.).   
 
2.4.3 Experimental Procedure 
The rotating glassy carbon electrode was rotated at 2000 rpm by an MSR rotator (Pine 
Instruments), and a +450 mV potential was applied relative to the Ag/AgCl reference 
electrode by an eDAQ potentiostat EA161 (eDAQ, NSW, Australia).  Chart software 
(eDAQ, NSW, Australia) was used to save the current produced, which was recorded by 
an eDAQ ecorder 201 (eDAQ, NSW, Australia).    
2.4.3.1 DA uptake 
For most experiments the low to infinite trans model was employed, consisting of 
multiple DA additions (0.5-4 µM) to a single sample in increasing concentrations.  This 
has been shown to give comparable results to the zero trans model, which consists of a 
single addition to each tissue sample.  The low to infinite trans model was used in this 
case to reduce the number of animals required for each experiment.  Upon 
commencement of the experiment the current (nA) was allowed to reach a stable baseline 
before the first DA addition.  The nA was left to reach this same baseline value before 
each subsequent addition.  When a single DA (2µM) addition was used, the nA was 
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allowed to reach baseline, DA was added, and nA measurement was continued for 30 s.  
Because NET is responsible for a large portion of DA uptake in the PFC (Dichiara et al., 
1992), 1µMdesipramine-HCl (Sigma) was used as a NET inhibitor in all experiments on 
DAT function in PFC tissue samples, as previously described by Zhu et al. (2009).  The 
desipramine-HCl was added after baseline and incubated for 5 min prior to the first DA 
addition.  Dopamine uptake by NET in the NAc and striatum is minimal (Moron et al., 
2002) and NET has not been blocked in DA uptake experiments in these brain regions in 
previous experiments (Hart and Ksir 1996; Middleton et al., 2007a).  For these reasons, 
desipramine-HCl was not used in DA uptake experiments in the NAc and striatum.  The 
DAT inhibitor GBR12909 (1 µM, Tocris) was used as described above in place of 
desipramine to measure DA uptake by NET in the PFC.  1 µM GBR12909 was chosen 
because it has previously been shown to completely block DA uptake by DAT in the PFC 
(Drew and Werling, 2003).  Serotonin transporter inhibitors were not used in DA uptake 
experiments due to the low affinity of SERT for DA (Moron et al., 2002).  For in vitro 
experiments 2 µM nicotine, TPM (containing 2 µM nicotine), or vehicle were added to 
the chamber following baseline for 5 min prior to first DA addition.  Upon completion of 
each data set the tissue was removed from the chamber and homogenised in 300 µL RIPA 
buffer (10 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1% Triton-X-100, 0.1% SDS, 1% 
sodium deoxycholate, pH 7.5, (Appendix 1)) containing 10 µL/mL protease inhibitor 
(Sigma) with a small plastic pestle for use in Western blotting experiments.  The rotating 
electrode was cleaned between each set of DA additions with milliQ water on a 
BuechlerMicrocloth (Pine Instruments) by rotating it on the cloth at 2000 rpm for 30 s.  
The electrode was cleaned more thoroughly after each set of experiments with 0.05 
micron aluminium slurry on BuechlerMicrocloth by hand.  This was followed by cleaning 
with milliQ water as described above.   
2.4.3.2 5-HT uptake 
Measurement of 5-HT uptake was conducted using a protocol recently established in our 
laboratory by Dr. Bridget Simonson (unpublished data).  Experiments were performed as 
described for DA uptake with the following changes; 5-HT concentrations ranged from 
0.25-3 µM, and the DAT inhibitor GBR12909 (1 µM) was used in all experiments as 
DAT is found in the striatum and impedes measurement of SERT function.  Recently, 
Hagan et al. (2011) found that 5-HT uptake in whole brain mouse synaptosomes was 
partially non-SERT mediated and that transporters with a low affinity for 5-HT may 
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contribute to 5-HT clearance in this system.  To confirm that the 5-HT uptake we 
measured was SERT specific control experiments were run with the low affinity 
transporter inhibitor 1’-diethyl-2,2’-cyanine iodide (D-22, 10 µM, Sigma) as outlined by 
Hagan et al. (2011).  D-22 was suspended in a 1% 1:1 dimethylformamide and methanol 
solution.  Tissue samples were allowed to baseline and D-22 was added to the RDEV 
chamber for 5 min prior to the first 5-HT addition.  The NET inhibitor desipramine-HCl 
(1 µM, Sigma) was also used as a control to evaluate whether 5-HT uptake occurred via 
NET.  Desipramine, or PBS vehicle, was added to the RDEV chamber following baseline 
and incubated for 5 min prior to the first 5-HT addition as described above.   
 
2.4.4 Data Analysis 
Monoamine uptake was measured 1 s following either DA or 5-HT addition.  This was 
done by taking 10 s of nA data (chart software) and plotting a linear regression (Microsoft 
Office Excel) to find the change in current per 1 s (Figure 2.2).  The R
2
 value of each 
regression was calculated and anything less than 0.95 was not used in the final data.  The 
concentration curve plotted for each experiment was then used to convert the nA value 
into µM, and this value was normalised to the weight of the tissue used.  The final 
measurement is expressed as uptake in pmol/s/g.  Values were then entered into 
GraphPad 5 software (GraphPad Software Inc, La Jolla, CA, USA), and for low to infinite 
trans model data a Michaelis-Menten curve was fitted.  The Vmax and Km of each 
individual repeat was calculated and the average and SEM of these was computed.  
Student’s unpaired t-tests were performed for each treatment group on Vmax and Km 
values, or on uptake values for single addition experiments, to determine whether 
significant differences were attained.  Significance was defined as p<0.05.   
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Figure 2.2:  RDEV data analysis.  Following DA addition 10 s of uptake data is 
collected from chart software (A) and plotted in Microsoft excel (B).  Initial uptake of 
monoamines is linear, and the slope of this line is used to calculate the rate of uptake of 
monoamines.     
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2.5 SDS Polyacrylamide Gel Electrophoresis and Western Blotting 
2.5.1 Sample Preparation 
Following RDEV experiments, minced tissue from the PFC, striatum and NAc, were 
homogenised in RIPA buffer containing 10 µL/mL protease inhibitors.  Samples from 
midbrain regions (VTA, SN, LC and DRN) that had previously been frozen at -80°C were 
allowed to thaw at room temperature for 20 min before being homogenized in 300 µL 
RIPA buffer (containing 10 µL/mL protease inhibitor, Sigma) with a small plastic pestle.  
Samples were then centrifuged at 12,000 g for 10 min at 4°C to allow pelleting of DNA 
and large cellular components. The supernatant was transferred to a fresh tube and an 
aliquot taken to measure protein concentration using the bicinchoninic acid (BCA) assay 
(Pierce).  Absorbance was measured at 562 nm using an automated multi-well plate 
reader (Versamax, Molecular Devices, Sunnyvale, CA).  A 20 µL aliquot of each sample 
was incubated with 5 µL 5x reducing buffer (62.5 mM Tris-HCl, pH 6.8, 2% SDS, 20% 
glycerol, 1% bromophenol blue (Appendix 1)) containing 10% β-mercaptoethanol 
(Sigma)  at room temperature for 5 min prior to loading into the gel. 
 
2.5.2 SDS-PAGE and Membrane Transfer 
15 well SDS-PAGE gels (10% separating gel, 4 % stacking gel) (Appendix I) were made 
the day prior to experiment and refrigerated in paper towels soaked with distilled water 
overnight.  20 µL of sample containing 30 µg protein was loaded into each well along 
side 1 µL of Precision Plus Protein
TM
 Dual Colour standard (Bio-Rad).  Gels were run at 
120 V for 90 min in 1x running buffer (3.5 mM SDS, 25 mM Tris base, 190 mM glycine 
(Appendix I)) and transferred onto an Immobilon-FL polyvinylidinedifluoride (PVDF) 
membrane (0.2 μM pore size, Millipore Corporation, MA) that was pre-soaked in 
methanol for 5 min, prior to soaking in transfer buffer (190 mM glycine, 25 mM Tris, 
20% methanol) (Appendix 1).  The transfer was run in transfer buffer at 20V, 4°C, for 18 
hr.    
 
2.5.3 Western Blotting 
Following transfer, membranes were removed and placed briefly into 1x Tris buffered 
saline (TBS, 50 mMTris base, 150 mMNaCl, pH 7.5) (Appendix I) to remove excess 
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transfer buffer.  They were then blocked with 5% donkey serum (Millipore) in TBS 
containing 0.1% Tween-20 (T-TBS) for 1 hr at room temperature, followed by incubation 
with primary antibodies (see Table 2.2 for antibodies and concentrations) in T-TBS 
containing 5% donkey serum overnight (approximately 18 h).  The following day 
membranes were washed in T-TBS 3x for 5 min, and were incubated with an anti-goat 
DyLiteTM 649 conjugated secondary antibody (Jackson Immunoresearch) in the dark for 1 
hr at room temperature.  This was followed by 3x 5 min washes in TBS and the 
membranes were visualised using a Fuji film laser scanner (Fujifilm FLA-5100, Tokyo, 
Japan) with a 635 nm laser and DBR1 filter.  The membranes were stripped in stripping 
buffer (Appendix I) for 40 min and washed 3 x for 20 min each with T-TBS before being 
probed for α-tubulin.  This was done as described above except membranes were blocked 
with 10% milk powder in T-TBS, and incubation with the primary antibody was for 1 hr 
only (see Table 2.2).  Representative full blots for the antibodies used in this study are in 
Appendix II. 
 
2.5.4 Data Analysis 
Western blots were analysed using Image J software to obtain the density of bands.  The 
densities for bands corresponding to DAT, NET and SERT were normalised to α-tubulin 
expression in each sample.  This relative expression was then expressed as a percentage 
relative to control within membrane, and plotted using GraphPad Prism software as mean 
± SEM.  The SEM for controls was obtained from raw data values for all samples and 
adjusted for an average of 100%.  One-way ANOVA with Bonferroni post-hoc analysis 
was performed to measure significance which was defined as p<0.05. 
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Table 2.2:  Primary and Secondary Antibodies used for Western Blotting. 
Epitope Primary or 
Secondary 
Host, Isotype, 
Clonality 
Manufacturer Blocking 
Solution 
Dilution 
Factor 
Incubation 
time 
DAT (C-20) Primary Goat, IgG, Polyclonal Santa Cruz 
Biotechnology 
5% Donkey 
Serum (Millipore) 
1:300 Overnight 
NET (K-15) Primary Goat, IgG, Polyclonal Santa Cruz 
Biotechnology 
5% Donkey 
Serum (Millipore) 
1:200 Overnight 
SERT (C-
20) 
Primary Goat, IgG, Polyclonal Santa Cruz 
Biotechnology 
5% Donkey 
Serum (Millipore) 
1:300 Overnight 
alpha-
tubulin 
Primary Rabbit, IgG, 
Polyclonal 
Abcam 10% milk powder 1:5,000 1 hr 
Goat IgG Secondary 
(DyLiteTM 649 
conjugated) 
Donkey, IgG, 
Polyclonal 
Jackson 
Immunoresearch 
Laboratories Inc. 
N/A 1:5,000 1 hr 
Rabbit IgG Secondary (ECL 
Plex CY5 
conjugated) 
Goat, IgG, Polyclonal Amersham N/A 1:5,000 1 hr 
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2.6 Quantitative PCR 
2.6.1 Sample preparation and RNA Extraction 
Tissue samples were immediately homogenised in 300 µL TRIzol
®
 LS Reagent 
(Invitrogen) and frozen at -80°C until required.  Samples were thawed on ice and 
centrifuged at 12,000 g for 10 min at 4°C to pellet excess cellular debris, and the 
supernatant was removed to a clean tube.  200 µL of chloroform was added per mL of 
Trizol™ reagent and samples were vigorously shaken, incubated at room temperature for 
3 min, and centrifuged at 12,000g for 15 min (4°C).  The upper aqueous layer was 
removed to a fresh microcentrifuge tube containing an equal volume of 70% molecular 
grade ethanol and the sample was thoroughly mixed.  This was then transferred to a High 
Pure Filter tube and purified using a High Pure RNA Isolation Kit (Roche) according to 
manufacturer’s protocol.  The final product was collected in 50 µL elution buffer and the 
yield was measured using a ND-1000 Spectrophotometer (Nanodrop, Wilmington, DE) 
by measuring sample absorbance at 260 nm.  The 260/280 nm absorbance ratio was also 
measured as an indication of sample purity, and samples with a reading of 1.8-2.0 were 
considered sufficiently pure for use.      
 
2.6.2 Reverse Transcription 
500 ng of RNA per reaction was reverse transcribed in the presence of RNAseOUT 
(Invitrogen) using SuperScript™ III Reverse Transcriptase (Invitrogen).  The reaction 
was carried out at 50°C using oligo(dT)18 (2.5 µM) for specific reverse transcription of 
mRNA to cDNA. 
 
2.6.3 Real time PCR with SYBR Green Chemistry 
Real time PCR was conducted using Platinum® SYBR® Green qPCRSuperMix-UDG 
(Invitrogen) and either an iQ4 real-time PCR detection system based on an iCycler 
platform (Bio-Rad, Hercules, CA) (for all acute experiments), or a Rotor-Gene
TM
 6000 
(Corbett Life Sciences) (for all chronic experiments).  1 µL of cDNA was used in each 
reaction with a total reaction volume of 25 µL.  Specific primers for one of DAT, NET, 
SERT or cyclophilin A (cyc A) (Invitrogen) were used in each reaction to a final 
concentration of 200 nM.  Fluorescein (20 nM) (Invitrogen) was also added to the 
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reaction to allow collection of background well-factors, which allows for the correction of 
non-uniformity in fluorescence.  Negative control reactions containing RNA or H2O were 
included in every experiment.  Cycling conditions consisted of: an initial step of 50°C for 
2 min, denaturation at 95°C for 3 min, and amplification over 35 cycles of 95 °C, 15 s; 55 
°C, 30 s; 72 °C, 30 s.  The initial step was included to eliminate any contaminating PCR 
products.  Platinum® SYBR® Green qPCRSuperMix-UDG contains uracil DNA 
glycolase (UDG) and dUTP instead of dTTP, therefore any PCR product from previous 
PCR amplifications will contain uracil which will be digested by UDG.   
 
Melt curve analysis was also conducted at the end of each cycle to analyse the purity of 
PCR products.  This consisted of increasing the temperature of the reaction from 72°C – 
94.5°C in 0.5°C increments every 10 s.  As the temperature of the reaction rises, double 
stranded DNA will melt apart at a specific temperature depending on the sequence, which 
results in a reduction in fluorescent signal from intercalated SYBR green.  A graph is then 
plotted of the first derivative of relative fluorescence units over temperature versus 
temperature of the reaction mixture (dRFU/dTvs. T), and specific PCR products will 
produce a distinct peak in the graph.  Therefore if a single product is expected a single 
distinct peak should be seen, whereas a diffuse peak in the lower temperature range 
indicates the presence of primer dimer.  Melt curve analysis was also carried out on 
negative controls to ensure that there was no contamination.  
 
Table 2.3:  Primers used for quantitative PCR. 
Primer 
Target 
Primer Sequence 5’ – 3’  
 Forward Reverse 
cyc A GGG GAG AAA GGA TTT GGC TA ACA TGC TTG CCA TCC ACC CTG 
DAT CATGCTGCTCACTCTGGGTA AGCACGCCAAAGAGGATAGA 
NET TCATCTCCTGCCAGAAAACC CCCTCTCTGCCTTCTCAATG 
SERT GGCGGTTTCCTTACATA  TCCTGGGCGAAGTAGTTGGT 
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2.6.4 Data Analysis 
All samples were run in duplicate and the average Ct value was used in analysis.  Any 
duplicates with Ct values differing by more than 0.5 were not used in the final data.  The 
Ct value of the housekeeper gene cyc A was subtracted from the Ct value for the gene of 
interest in each sample to calculate the ΔCt value.  Cyc A was chosen as a housekeeper 
gene as it is commonly used and has previously been shown to not be affected by nicotine 
(Weisinger et al., 1999).  Furthermore, mean cyc A Ct values did not differ across 
treatment groups (Appendix III).  Delta Ct values were plotted in GraphPad Prism 
software and a one-way ANOVA with Bonferroni post-hoc analysis was performed for 
each group.  A difference of 1 Ct value represents a doubling or halving in expression, 
with an increase in Ct representing a decrease in mRNA expression and vice versus.  
Estimations of relative mRNA expression were calculated from the ΔΔCt (ΔCt treatment 
– ΔCt control group) and expressed as a percentage. 
 
2.6.5 Agarose Gel Electrophoresis 
PCR product was visualised on 2% agarose gels to ensure that a single product of the 
expected size was present. Gels were prepared by microwaving 1 g of agarose 
(Invitrogen) with 50 mL of 1x Tris-acetate EDTA buffer (TAE) (Appendix I) and were 
then placed in an electrophoresis tank containing 1x TAE buffer.  Samples were prepared 
by mixing 18 µL neat PCR product with 2 µL of BlueJuice
TM
 (Invitrogen).  The entire 
sample was loaded into the gel and electrophoresis was conducted at 100 V for 40 min.  
Gels were then stained with 2 µg/mL ethidium bromide (Invitrogen) in 1x Tris EDTA 
(TE) buffer for 30 min, followed by 15 min de-staining in dH2O.  Gels were visualised 
using the KODAK Gel Logic 100 system (Kodak). 
 
2.6.6 Primer Efficiency Testing 
Primer efficiency is important for sensitivity in real time PCR reactions.  Primer 
efficiencies were calculated for all primers used in this study.  PCR products purified by 
agarose gel electrophoresis were used as template.  Following electrophoresis bands were 
excised and homogenised in 500 µL of 1x TE buffer, followed by heating at 60°C for 1 
hr.  Template was then serially diluted from 10
1
-10
4
, the equivalent to 3.3 Ct values 
between each dilution, and a quantitative PCR reaction was conducted as described 
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above.  Dilutions were run in triplicate and the average Ct value was plotted against the 
log of the fold dilution.  Primer efficiency was then calculated using the equation: 
Primer Efficiency = (10(1/slope))-1 (Modified from Peters et al., (2004))  
Ideally primer efficiencies should be approximately 100%; efficiencies less than 100% 
indicate the presence of primer dimer, while those greater than 100% indicate the 
presence of non-specific products.   
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Chapter 3:  The chronic effects of nicotine and 
TPM on DA and 5-HT uptake and monoamine 
transporter expression 
3.1 Control RDEV and real time PCR experiments 
3.1.1 Non-SERT mediated 5-HT uptake in the striatum 
Recently Hagan et al. (2011) showed that 5-HT uptake in whole mouse brain 
synaptosomes was partially mediated by non-SERT uptake (Hagan et al. 2011).  To 
confirm that 5-HT uptake observed in rat striatum in this study was SERT-mediated,  we 
conducted control experiments with D-22, an inhibitor of low affinity 5-HT transporters 
including the organic cation transporters, plasma membrane monoamine transporter, and 
extraneuronal monoamine transporter.  The NET inhibitor desipramine-HCl was also 
used in control experiments.  Minced striatal tissue from drug naive animals was treated 
with D-22 (10 µM) or desipramine-HCl (1 µM) 5 min prior to first 5-HT addition and 
uptake was measured.  The dopamine transporter inhibitor GBR12909 (1 µM) was 
incubated with the tissue concurrently with the other inhibitors.  Neither D-22 nor 
desipramine had any significant effect on 5-HT uptake (Figure 3.1) in these preparations.  
There appears to be slight decrease in Vmax values with both treatments; however, this 
was accompanied by a slight decrease in Km and statistical analysis showed no significant 
change in Vmax (Student’s t-test, vehicle vs. desipramine p=0.3936, vehicle vs. D-22 
p=0.4938) (Figure 3.1).  It was, therefore, concluded that 5-HT uptake in our system was 
entirely SERT-mediated.    
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Figure 3.1:  D-22 and desipramine have no significant effect on 5-HT uptake in the 
striatum of drug naive rats.  Minced striatal tissue from drug naive rats was pre-
incubated with D-22 (10 µM) (A), desipramine (1 µM) (B), or respective vehicles for 5 
min prior to the first 5-HT addition.  1 µM GBR2909 was also pre-incubated with each 
tissue sample for 5 min.  Neither D-22 nor desipramine caused a significant change in 5-
HT uptake.  Data points are mean ± SEM (n= 4-5).    
 
Table 3.1:  5-HT uptake kinetics with D-22 and desipramine treatment in rat 
striatum.  
Treatment Vmax (pmol/s/g) Km (µM)  
Vehicle (A) 367 ± 33 0.68 ± 0.11 
D-22 328 ± 44 0.62 ± 0.08 
Vehicle (B) 413 ± 28 0.73 ± 0.10 
Desipramine 354 ± 53 0.67 ± 0.13 
Values are mean ± SEM. 
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3.1.2 Real-time RT-PCR Control Experiments 
3.1.2.1 Primer Efficiencies 
Primer efficiencies were calculated for all primer sets used in this study.  Purified PCR 
product was serially diluted and amplified in triplicate, and the average Ct value was 
plotted against the log dilution (Figure 3.2).  Primer efficiencies were calculated from the 
slope of the line and are; DAT, 97.7%; NET, 98.4%; SERT, 102.5 %; and cyc A, 98.9%.  
Ideally primer efficiencies should be 100% for optimal results; all primer pairs used in 
this study have efficiencies close to 100%. 
 
 
Figure 3.2:  Efficiencies of primers used in this study.  Purified PCR product dilutions 
were amplified in triplicate and the average Ct value was plotted against the log of the 
dilution.  R
2
 values show the fit of the trend line to data, and the slope of this trend line 
was used to calculate efficiencies displayed on the graphs.   
 
  
56 
 
3.1.2.2 Agarose gel electrophoresis and melt curve analysis  
PCR product was separated on a 2% agarose gel to confirm the presence of a single band 
of product at the correct size.  All products showed a distinct single band that 
corresponded to the predicted size of the product (DAT, 228 bp; NET, 106 bp; SERT, 340 
bp; cyc A, 287 bp) (Figure 3.3A).  Melt-curve analysis was also conducted following 
amplification to confirm the presence of specific products.  Rate of change of 
fluorescence is plotted against temperature and a single product is represented by a single 
peak in the graph.  Figure 3.3B-D shows representative trace images of data generated 
through real time PCR with the corresponding melt-curve for primer sets used.  Distinct 
single peaks were seen for DAT (86°C), NET (80°C), SERT (86°C) and cyc A (83°C).  
Low levels of non-specific product was seen at 73-85°C most likely corresponding to 
some primer dimer formation.  Negative control samples containing H2O or equimolar 
RNA in place of template were run with each experiment and melt-curve profile analysis 
showed no specific products for these samples (Figure 3.3E).    
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Figure 3.3:  Representative data from real-time PCR experiments.   
(A)  Representative agarose gels of PCR products showing a single band in each lane 
corresponding to the expected product size (DAT, 228 bp; NET, 106 bp; SERT, 340 bp; 
cyc A, 287 bp).  (B-D)  Representative trace images and melt curve profiles for DAT (B), 
NET (C), SERT (D) and cyc A (B-D).  All samples were run in duplicate, and duplicates 
of RNA and H2O negative controls (samples that stay below the threshold line in the trace 
image) were run with each experiment.  Cyc A amplification was run concurrently with 
every sample analysis for use as a housekeeper gene.  The melt curve profile analysis 
shows distinct peaks for DAT (86°C), NET (80°C), SERT (86°C) and cyc A (83°C) PCR 
products, with low levels of product at 73 - 85°C for all primer pairs.  (E)  Representative 
melt curve profile analysis for negative controls shows no specific PCR product.   
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3.2 The effects of chronic nicotine and TPM on DAT function and 
expression  
3.2.1 Changes in DAT function and protein expression in the NAc, striatum, and PFC 
Animals were treated with nicotine (0.35 or 3 mg/kg), TPM (matched to 0.35 mg/kg 
nicotine dose), or control for 10 days and euthanized 14-16 hrs after the final treatment.  
Brain regions of interest were dissected to assess DAT function, protein expression, and 
mRNA expression using RDEV, Western blotting, and real time PCR respectively.  The 
kinetic parameters Vmax and Km were determined for DA uptake in all RDEV experiments 
(Table 3.2).  There was no significant change in DAT function seen in the NAc following 
any treatment (Figure 3.4A); however, there was a significant increase in protein 
expression seen in response to 0.35 mg/kg nicotine and TPM (p<0.05, one-way ANOVA 
with Bonferroni post-hoc analysis) (Figure 3.4B).  A trend towards an increase with 3 
mg/kg nicotine was also observed that did not reach significance.  No change in function 
or protein expression was observed in the striatum (Figure 3.5) or PFC (Figure 3.5).   
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Figure 3.4:  The effects of chronic nicotine and TPM on DAT function and protein 
expression in the NAc.  (A)  DAT function was measured ex vivo in minced NAc tissue 
from rats treated in vivo for 10 days with nicotine, TPM or control.  No significant change 
was found between treatment groups.  Data points show mean ± SEM (n= 5-7).  (B)  
Graph demonstrating DAT protein expression accompanied by representative Western 
blot (C, control; N, nicotine (0.35 mg.kg); X, nicotine (3 mg/kg); T, TPM).  Chronic 
nicotine (0.35 mg/kg) and TPM (containing 0.35 mg/kg nicotine) treatment significantly 
increased DAT protein expression in the NAc compared to control.  Bars represent mean 
± SEM.  *p<0.05, one-way ANOVA with Bonferroni post-hoc analysis (n= 8-9). 
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Figure 3.5:  DAT function and protein expression in the striatum following chronic 
nicotine and TPM treatment.  Chronic nicotine (0.35 and 3 mg/kg) and TPM 
(containing 0.35 mg/kg nicotine) treatment had no significant effect on DAT function (A) 
or protein expression (B) in minced striatal tissue from rats treated in vivo for 10 days (C, 
control; N, nicotine (0.35 mg/kg); X, nicotine (3 mg/kg); T, TPM).  Data points and bars 
represent mean ± SEM (n= 5-7).   
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Figure 3.6:  DAT function and protein expression in the PFC following chronic 
nicotine and TPM treatment.  Ten days treatment with nicotine (0.35 or 3 mg/kg) and 
TPM (containing 0.35 mg/kg nicotine) had no effect on DAT function (A) or protein 
expression (B) in the PFC (C, control; N, nicotine (0.35 mg/kg); X, nicotine (3 mg/kg); T, 
TPM) following 10 days of in vivo treatment.  Data points and bars represent mean ± 
SEM (n= 4-6).   
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Table 3.2:  DAT kinetic data for chronic nicotine and TPM treatment. 
 Treatment Vmax (pmol/s/g) Km (µM) 
 Control 429 ± 69 1.20 ± 0.34 
NAc Nicotine (0.35 mg/kg) 381 ± 44 1.33 ± 0.21 
 Nicotine (3 mg/kg) 447 ± 43 1.52 ± 0.23 
 TPM (0.35 mg/kg nicotine) 443 ± 84 1.35 ± 0.28 
 Control 480 ± 44 1.72 ± 0.27 
Striatum Nicotine (0.35 mg/kg) 461 ± 27 1.30 ± 0.17 
 Nicotine (3 mg/kg) 457 ± 34 1.31 ± 0.22 
 TPM (0.35 mg/kg nicotine) 512 ± 54 1.33 ± 0.18 
 Control 497 ± 87 1.30 ± 0.37 
PFC Nicotine (0.35 mg/kg) 502 ± 54 1.73 ± 0.28 
 Nicotine (3 mg/kg) 671 ± 102 2.10 ± 0.49 
 TPM (0.35 mg/kg nicotine) 518 ± 47 1.90 ± 0.22 
Values are mean ± SEM. 
 
3.2.2 Changes in DAT mRNA and protein expression in the VTA and SN 
DAT mRNA and protein expression was measured in VTA and SN tissue from 
chronically treated animals using real time PCR and Western blotting.  Both nicotine 
doses (0.35 and 3 mg/kg) and TPM (containing 0.35 mg/kg nicotine) caused a significant 
decrease in DAT protein expression in the SN (27-36%; p<0.05, one-way ANOVA with 
Bonferroni post-hoc analysis); however, there was no significant change in the VTA 
(Figure 3.7B).  The observed decrease in protein expression in the SN was not due to 
changes in mRNA expression (Figure 3.7A) as there was no significant difference 
between ΔCt values for control and treatment groups (Table 3.3).  
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Figure 3.7:  DAT mRNA and protein expression in the VTA and SN following 
chronic nicotine and TPM treatment.  Nicotine (0.35 and 3 mg/kg) and TPM 
(containing 0.35 mg/kg) caused no significant change in DAT mRNA expression in the 
VTA and SN following 10 days treatment (A); however, there was a significant decrease 
in DAT protein expression in the SN but not the VTA (B).  Representative blots for the 
VTA (C) and SN (D) are shown below the graphs.  Bars represent mean ± SEM *p<0.05, 
one-way ANOVA with Bonferroni post-hoc analysis (n= 6-9).  C, control; N, nicotine 
(0.35 mg/kg); X, nicotine (3 mg/kg); T, TPM.   
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Table 3.3:  ΔCt values for DAT mRNA expression in the SN and VTA following 
chronic nicotine and TPM treatment. 
Treatment  ΔCT value SN ΔCT value VTA 
Control 13.7 ± 0.6 11.1 ± 1.4 
Nicotine (0.35 mg/kg) 11.4 ± 1.4
 
13.3 ± 0.6 
Nicotine (3 mg/kg) 12.5 ± 0.8 13.3 ± 0.5 
TPM (0.35 mg/kg nicotine) 12.2± 0.8 12.6 ± 0.3 
Values are mean ± SEM. 
 
3.3 The effects of chronic nicotine and TPM on NET function and 
expression  
3.3.1 Chronic nicotine (3 mg/kg) causes a significant increase in DA uptake by NET 
in the PFC  
RDEV and Western blotting were used to measure DA uptake by NET and NET protein 
expression in the PFC following 10 days nicotine (0.35 and 3 mg/kg) and TPM 
(containing 0.35 mg/kg nicotine) treatment.  Nicotine at a dose of 3 mg/kg, but not 0.35 
mg/kg or TPM (containing 0.35 mg/kg nicotine), caused an increase in DA uptake by 
NET (Figure 3.8).  The Vmax and Km values for the nicotine (3 mg/kg) treatment groups 
were both significantly increased compared to the control group (Table 3.4) at 76% 
(p<0.05) and 69% (p<0.01) (Student’s t-test).  An increase in Km denotes a decrease in 
binding of the neurotransmitter to the transporter and thus often a decrease in uptake; 
however, in this case the increase in Vmax was large enough counteract any binding effects 
and an overall increase in uptake was seen.  This change in uptake was not accompanied 
by any change in protein expression for the 3 mg/kg,   0.35 mg/kg nicotine, or TPM 
containing 0.35 mg/kg nicotine (Figure 3.8B). 
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Figure 3.8:  Chronic nicotine (3 mg/kg) treatment increases DA uptake by NET in 
the PFC but has no significant effect on NET protein expression.  (A) Ten days 3 
mg/kg nicotine treatment, but not 0.35 mg/kg nicotine or TPM (containing 0.35 mg/kg 
nicotine) treatment, increases DA uptake by NET in the PFC.  (B) Chronic nicotine and 
TPM have no significant effect on NET protein expression in the PFC (C, control; N, 
nicotine (0.35 mg/kg); X, nicotine (3 mg/kg); T, TPM).  Data points and bars represent 
mean ± SEM (n= 4-8).  
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Table 3.4: NET kinetics in the PFC following chronic nicotine and TPM treatment. 
Treatment  Vmax (pmol/s/g) Km (µM)  
Control 797 ± 83 2.37 ± 0.24 
Nicotine (0.35 mg/kg) 885 ± 44
 
3.03 ± 0.14 
Nicotine (3 mg/kg) 1406 ± 162* 4.01 ± 0.25** 
TPM (0.35 mg/kg nicotine) 988 ± 122 3.60 ± 0.68 
Values are mean ± SEM.  *p<0.05 compared to control, **p<0.01 compared to control, 
Student’s t-test.   
 
3.3.2 TPM but not nicotine causes a decrease in NET mRNA expression in the LC 
Real time PCR experiments on LC tissue from chronically treated animals (0.35 or 3 
mg/kg/day nicotine or TPM containing 0.35 mg/kg/day nicotine for 10 days) showed that 
TPM but not nicotine caused a significant decrease in NET mRNA expression (p<0.05, 
one-way ANOVA with Bonferroni post-hoc analysis) (Figure 3.9A).  The difference in 
ΔCt value between control and TPM was 4.5 Ct values (Table 3.5), which corresponds to 
a 95.5% decrease in mRNA.  This change in mRNA expression was not accompanied by 
a change in protein expression for TPM treated animals or the nicotine treated groups 
(Figure 3.9B).   
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Figure 3.9:  The chronic effects of nicotine and TPM on NET mRNA and protein 
expression in the LC.  (A) TPM (containing 0.35 mg/kg nicotine) significantly decreased 
NET mRNA expression in the LC (represented as an increase in ΔCt), whereas nicotine 
(0.35 and 3 mg/kg) had no significant effect.  (B) Nicotine and TPM had no significant 
effect on NET protein expression in the LC (C, control; N, nicotine (0.35 mg/kg); X, 
nicotine (3 mg/kg); T, TPM).  Bars represent mean ± SEM (n= 6-9).  *p<0.05 compared 
to control, one-way ANOVA with Bonferroni post-hoc analysis.   
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Table 3.5:  ΔCt values for NET mRNA expression in the LC following chronic 
nicotine and TPM treatment. 
Treatment  ΔCT value 
Control 6.5 ± 0.6 
Nicotine (0.35 mg/kg) 8.4 ± 0.6
 
Nicotine (3 mg/kg) 7.0 ± 0.4 
TPM (0.35 mg/kg nicotine) 11.0 ± 1.5* 
Values are mean ± SEM.  *p <0.05 compared to control, one-way ANOVA with 
Bonferroni post-hoc analysis. 
 
3.4 The effects of chronic nicotine and TPM on SERT function and 
expression  
3.4.1 Chronic nicotine and TPM treatment has no significant effect on SERT function 
or protein expression in the striatum 
Animals were treated with 0.35 or 3 mg/kg nicotine or TPM containing 0.35 mg/kg 
nicotine for 10 days prior to sacrifice.  Striatal tissue from chronically treated animals was 
used in RDEV and Western blotting experiments to assess the function and protein 
expression of SERT.  No significant changes were found in either function or protein 
expression (Figure 3.10).  Table 3.6 shows the Vmax and Km values for SERT function in 
this experiment.   
Table 3.6:  SERT kinetics in the striatum following chronic nicotine and TPM 
treatment.   
Treatment  Vmax (pmol/s/g) Km (µM)  
Control 269 ± 16 1.12 ± 0.30 
Nicotine (0.35 mg/kg)  274 ± 38 0.80 ± 0.13 
Nicotine (3 mg/kg) 248 ± 39 0.86 ± 0.21 
TPM (0.35 mg/kg nicotine) 326 ± 62 0.81 ± 0.21 
Values are mean ± SEM. 
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Figure 3.10:  Chronic nicotine and TPM treatment has no effect on SERT function 
(A) or protein expression (B) in the rat striatum.  Animals were sacrificed following 
10 days nicotine (0.35 and 3 mg/kg) and TPM (containing 0.35 mg/kg nicotine) 
treatment.  Data points and bars represent mean ± SEM (C, control; N, nicotine (0.35 
mg/kg); X, nicotine (3 mg/kg); T, TPM) (n= 4-6).   
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3.4.2 SERT mRNA and protein expression in the DRN following chronic nicotine and 
TPM treatment 
Nicotine and TPM treatment caused no significant changes in SERT mRNA and protein 
expression compared to control in the DRN (Figure 3.11).  Interestingly, TPM 
(containing 0.35 mg/kg nicotine) did cause a significant decrease in SERT mRNA 
expression (2.3 Ct values) compared to the 0.35 mg/kg nicotine dose (p<0.05, one-way 
ANOVA with Bonferroni post-hoc analysis) (Table 3.7).  This difference corresponds to a 
91% decrease in mRNA in the TPM treatment group compared to the 0.35 mg/kg nicotine 
group; however, no corresponding decrease in protein expression was observed (Figure 
3.11B).   
 
Table 3.7:  ΔCT values for SERT mRNA expression in the DRN following chronic 
nicotine and TPM treatment. 
Treatment  ΔCT value 
Control 10.7 ± 0.8 
Nicotine (0.35 mg/kg) 9.5 ± 0.5
 
Nicotine (3 mg/kg) 12.6 ± 0.9 
TPM (0.35 mg/kg nicotine) 13.0 ± 0.9* 
Values are mean ± SEM.  *p<0.05 compared to nicotine (0.35 mg/kg), one-way ANOVA 
with Bonferroni post-hoc analysis. 
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Figure 3.11:  SERT mRNA and protein expression in the DRN following chronic 
nicotine and TPM treatment.  (A) Nicotine and TPM have no significant effect on 
SERT mRNA expression compared to control; however, TPM (containing 0.35 mg/kg 
nicotine) causes a significant decrease in SERT mRNA expression compared to 0.35 
mg/kg nicotine.  (B) Nicotine and TPM have no significant effect on SERT protein 
expression in the DRN.  Bars represent mean ± SEM, *p<0.05 one-way ANOVA with 
Bonferroni post-hoc analysis (n= 5-6). 
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Chapter 4:  The acute effects of nicotine and TPM 
on DA and 5-HT uptake and monoamine 
transporter expression 
4.1 The in vitro effects of nicotine and TPM on monoamine uptake 
4.1.1 DA uptake in the NAc, striatum, and PFC 
The in vitro effects of nicotine and TPM on DA uptake were assessed using tissue from 
drug naive animals.  Nicotine (2 µM) or TPM (containing 2 µM nicotine) were incubated 
with minced tissue for 5 min prior to the first DA addition.  Neither nicotine nor TPM 
caused any significant change in DA uptake by DAT in the NAc, striatum or PFC, or DA 
uptake by NET (Figure 4.1) using RDEV.  Nicotine did cause a significant increase in Km 
compared to control in the NAc (Table 4.1); however, this was accompanied by a non-
significant increase in Vmax that resulted in no change in uptake overall.   
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Table 4.1:  DAT and NET kinetics for DA uptake from in vitro nicotine and TPM 
treatment. 
 Treatment Vmax(pmol/s/g) Km (µM) 
 Control 400 ± 51 0.92 ± 0.23 
DAT NAc Nicotine (0.35 mg/kg) 442 ± 40 1.66 ± 0.25* 
 TPM (0.35 mg/kg nicotine) 358 ± 56 0.68 ± 0.09 
 Control 390 ± 41 0.91 ± 0.09 
DAT Striatum Nicotine (0.35 mg/kg) 408 ± 53 0.92 ± 0.13 
 TPM (0.35 mg/kg nicotine) 448 ± 51 1.16 ± 0.12 
 Control 419 ± 62 0.90 ± 0.13 
DAT PFC Nicotine (0.35 mg/kg) 409 ± 41 1.09 ± 0.18 
 TPM (0.35 mg/kg nicotine) 384 ± 74 0.81 ± 0.17 
 Control 516 ± 75 1.45 ± 0.15 
NET PFC Nicotine (0.35 mg/kg) 494 ± 40 1.58 ± 0.15 
 TPM (0.35 mg/kg nicotine) 509 ± 48 1.83 ± 0.53 
Values are mean ± SEM.  *p<0.05 compared to control, Student’s t-test. 
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Figure 4.1:  In vitro nicotine and TPM treatment has no significant effect on DA 
uptake in isolated tissue.  Tissue from drug naive rats was treated with control, nicotine 
(2 µM), or TPM (containing 2 µM nicotine) 5 min prior to the first DA addition.  It had 
no significant effect on DAT mediated DA uptake in the NAc (A) (n= 7-9), striatum (B) 
(n= 6), or PFC (C) (n= 6-7); or on NET mediated DA uptake in the PFC (D) (n= 4-5).  
Data points represent mean ± SEM.   
  
75 
 
4.1.2 5-HT uptake in the striatum 
Striatal tissue from drug naive animals was incubated with PBS or the non-selective, non-
competitive nicotinic acetylcholine receptor antagonist mecamylamine (1 µM) for 5 min, 
followed by treatment with control, nicotine (2 µM), or TPM (containing 2 µM nicotine) 
for 5 min prior to the first 5-HT addition.  TPM, but not nicotine, significantly decreased 
SERT function compared to control (Figure 4.2).  This decrease was characterised by a 
decrease in 31.5% decrease in Vmax for the PBS/TPM treatment group compared to 
PBS/control (p<0.05, Student’s test), with no significant change in Km (Table 4.2).  Pre-
treatment with mecamylamine had no effect on control, and did not completely 
antagonise the effects of TPM.  The mecamylamine/TPM treatment group had a Vmax 
25.8% lower than PBS/control.  This is a slightly higher uptake than the PBS/TPM group, 
but this difference is not significant.  Furthermore, the mecamylamine/TPM group had a 
higher Km value than PBS/TPM.  This increase in both Vmax and Km resulted in no 
significant overall difference in 5-HT uptake between the PBS/TPM and 
mecamylamine/TPM treatment groups. 
 
Table 4.2:  Kinetic data for 5-HT uptake in the striatum following in vitro nicotine 
and TPM treatment. 
Treatment Vmax (pmol/s/g) Km (µM)  
PBS/Control 460 ± 52 0.94 ± 0.13 
PBS/Nicotine (2 µM)  413 ± 36 0.66 ± 0.12 
PBS/TPM (2 µM nicotine) 315 ± 33* 0.67 ± 0.10 
Mec/Control 429 ± 37 0.85 ± 0.11 
Mec/TPM (2 µM nicotine) 346 ± 67 1.05 ± 0.28 
Values are mean ± SEM.  *p<0.05 compared to PBS/Control, Student’s t-test.  PBS, 
phosphate buffered saline; Mec, mecamylamine.   
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Figure 4.2: In vitro TPM treatment significantly decreases 5-HT uptake by SERT in 
the striatum.  TPM (containing 2 µM nicotine) significantly decreased 5-HT uptake in 
drug naive rat striatal tissue.  Nicotine (2 µM) had no significant effect on uptake.  
Mecamylamine (1 µM) pre-treatment did not affect uptake in control treated tissue and 
did not completely antagonise TPM-induced decreases in 5-HT uptake.  Data points 
represent mean ± SEM (n=4-8) (PBS, phosphate buffered saline; TPM, tobacco 
particulate matter; mec, mecamylamine). 
 
4.2 The effects of acute in vivo nicotine and TPM treatment on the 
monoamine transporters 
Animals were treated in vivo with control, nicotine (0.35 mg/kg) or TPM (containing 0.35 
mg/kg nicotine) and sacrificed 15 min, 30 min, or 1 hr after treatment.  DAT, NET and 
SERT function were assessed ex vivo using RDEV and, additionally, monoamine 
transporter protein and mRNA expression were measured at the 1 hr time-point. 
4.2.1 The effects of nicotine and TPM on monoamine transporter function at 15 min 
Nicotine and TPM treatment had no significant effect on DAT, NET or SERT function in 
any brain region (Figure 4.3).  In the NAc TPM did significantly increase the Km by 54% 
compared to control (p<0.05, Student’s t-test) (Table 4.3); however, this was 
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accompanied by a modest, non-significant increase in Vmax and resulted in no overall 
change in uptake (Figure 4.3A).  Similarly, the Km of SERT function in the striatum was 
significantly increased (88%) with nicotine treatment (Table 4.3).  This was also 
accompanied by an increase in Vmax and resulted in no overall change in 5-HT uptake 
(Figure 4.3E).   
 
Table 4.3:  Kinetic data for DA and 5-HT uptake at 15 min following nicotine and 
TPM treatment. 
 Treatment Vmax(pmol/s/g) Km (µM) 
 Control 580 ± 61 1.09 ± 0.15 
DAT NAc Nicotine (0.35 mg/kg) 619 ± 58 1.64 ± 0.35 
 TPM (0.35 mg/kg nicotine) 628 ± 62 1.69 ± 0.22* 
 Control 359 ± 46 0.78 ± 0.13 
DAT Striatum Nicotine (0.35 mg/kg) 345± 37 1.01 ± 0.18 
 TPM (0.35 mg/kg nicotine) 325± 51 1.02 ± 0.29 
 Control 517 ± 73 1.55 ± 0.26 
DAT PFC Nicotine (0.35 mg/kg) 614 ± 84 1.94 ± 0.42 
 TPM (0.35 mg/kg nicotine) 648 ± 79 2.11 ± 0.26 
 Control 586 ± 19 1.60 ± 0.52 
NET PFC Nicotine (0.35 mg/kg) 661 ± 54 1.74 ± 0.06 
 TPM (0.35 mg/kg nicotine) 626 ± 78 1.71 ± 0.31 
 Control 417 ± 54 0.60 ± 0.08 
SERT Striatum Nicotine (0.35 mg/kg) 510 ± 42 1.13 ± 0.20* 
 TPM (0.35 mg/kg nicotine) 481 ± 49 0.88 ± 0.16 
Values are mean ± SEM. *p<0.05 compared to control, Student’s t-test.   
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Figure 4.3:  Nicotine and TPM cause no significant changes in monoamine uptake at 
15 min.  Rats were treated with control, nicotine (0.35 mg/kg), or TPM (containing 0.35 
mg/kg nicotine) 15 min prior to sacrifice, and monoamine transporter function was 
assessed ex vivo using RDEV.  Drug treatments had no significant effect on DA uptake by 
DAT in the NAc (n=6) (A), striatum (n=6-8) (B) or PFC (n=8-9) (C).  There were also no 
changes in DA uptake by NET in the PFC (n=4) (D), or 5-HT uptake by SERT in the 
striatum (n=5-6) (E).  Data points represent mean ± SEM.   
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4.2.2 The effects of nicotine and TPM on monoamine transporter function at 30 min 
4.2.2.1 Nicotine and TPM decrease DAT function in the NAc at 30 min in a nicotinic 
receptor-  α4 subunit- dependent manner 
Nicotine (0.35 mg/kg) and TPM (containing 0.35 mg/kg nicotine) treatment caused a 
decrease in DAT function in the NAc in animals sacrificed 30 min following treatment 
(Figure 4.4A).  This change was not facilitated by a decrease in protein expression 
(Figure 4.4D).  Kinetic data showed that for both nicotine and TPM there was a decrease 
in Vmax (30.6% and 17.9% respectively; p<0.05, Student’s t-test), with no change in Km 
(Table 4.4).  To test whether this decrease was nicotinic receptor-dependant, the non-
specific nicotinic antagonist mecamylamine (1.5 mg/kg i.p.) or PBS vehicle was used to 
pre-treat animals 20 min prior to nicotine (0.35 mg/kg), TPM (containing 0.35 mg/kg 
nicotine), or control injection.  Mecamylamine treatment inhibited the observed decrease 
in DAT function (Figure 4.4B-C) and completely attenuated the decrease in Vmax seen for 
the PBS/TPM and PBS/Nicotine treatment groups (Table 4.4).   
 
To investigate specific nicotinic receptors that could be mediating the effects of nicotine 
and TPM, the α4 and α7 receptor subtype specific antagonists DHβE (8 mg/kg salt 
weight) and MLA (10 mg/kg salt weight), respectively, were used.  Animals were pre-
treated with the antagonists or PBS vehicle 20 min prior to control, nicotine (0.35 mg/kg) 
or TPM (containing 0.35 mg/kg nicotine) treatment as described above.  Tissue was then 
subjected to a single 2 µM DA addition to measure uptake.  The 2 µM DA concentration 
was chosen as this is close to the Km value obtained in kinetic data above (Table 4.4).  
Single additions of DA showed a decrease in DA uptake with PBS/nicotine (19.4%) 
(p<0.05, Student’s t-test) and PBS/TPM (26.8%) compared to control.  This decrease was 
attenuated by pre-treatment with DHβE (β2 antagonist; 8 mg/kg) (p<0.05, Student’s t-
test) but not MLA (α7 antagonist; 10 mg/kg) for both nicotine and TPM treatments 
(Figure 4.5).     
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Figure 4.4:  Nicotine and TPM significantly decrease DAT function in the NAc at 30 
min in a mecamylamine-sensitive manner.  Animals were treated with mecamylamine 
(1.5 mg/kg) or PBS vehicle 20 min prior to nicotine (0.35 mg/kg), TPM (0.35 mg/kg 
nicotine) or control treatment, and sacrificed 30 min later.  Both PBS/Nicotine and 
PBS/TPM significantly decreased DAT function (A) and had no effect on DAT protein 
expression in the NAc (E) (n=7-9).  The decrease in DAT function produced by nicotine 
(B) and TPM (C) was attenuated by pre-treatment with the nicotinic antagonist 
mecamylamine (n=4-6).  Vmax values for all treatment groups are represented in (D) C, 
control; N, nicotine; T, TPM.  Values and bars represent mean ± SEM.  *p<0.05 
compared to control, #p<0.05 comparing drug to drug + mec, Student’s t-test. 
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Table 4.4:  Kinetic data for DAT function in the NAc at 30 min.   
Treatment Vmax (pmol/s/g) Km (µM)  
PBS/Control 723 ± 39 2.51 ± 0.22 
PBS/Nicotine (0.35 mg/kg) 502 ± 49** 2.15 ± 0.50 
PBS/TPM (0.35 mg/kg nicotine) 594 ± 34* 2.57 ± 0.54 
Mec/Control 687 ± 148 1.98 ± 0.56 
Mec/Nicotine (0.35 mg/kg) 704 ± 78
#
 1.86 ± 0.27 
Mec/TPM (0.35 mg/kg nicotine) 822 ± 91
#
 2.17 ± 0.35 
Values are mean ± SEM.  *p<0.05, **p<0.01 compared to PBS/Control, 
#
p<0.05 
compared to corresponding treatment pre-treated with PBS, Student’s t-test.  PBS, 
phosphate buffered saline; Mec, mecamylamine.   
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Figure 4.5:  The effects of α4 and α7 nicotinic receptor antagonism on nicotine- and 
TPM-induced decreases in DAT function.  Animals were pretreated with PBS, the β2 
subunit inhibitor DHβE (8 mg/kg), or α7 subunit inhibitor MLA (10 mg/kg) followed by 
control, nicotine (0.35 mg/kg), or TPM (containing 0.35 mg/kg nicotine) 20 min later.  A 
single DA addition (2 µM) was then added to the tissue and uptake measured.  DHβE 
completely attenuated the decrease in uptake caused by nicotine and TPM; MLA had no 
significant effect (n=3-4).  The difference between PBS/TPM and PBS/DHβE is not 
significant but is trending towards significance (p=0.089).  *p<0.05 compared to 
PBS/Control, 
#
p<0.05 comparing drug to drug + mec, Student’s t-test. 
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4.2.2.2 Nicotine and TPM have no effect on DA uptake in the striatum or PFC, or 5-HT 
uptake in the striatum at 30 min 
Nicotine (0.35 mg/kg) and TPM (containing 0.35 mg/kg nicotine) had no effect on DA 
uptake by DAT in striatal or PFC tissue from animals sacrificed 30 min following 
treatment (Figure 4.6).  DA uptake by NET and 5-HT uptake by SERT were also 
unaffected by drug treatments (Figure 4.6).  There was no significant effect on the Km or 
Vmax of DAT, NET or SERT in any of these brain regions (Table 4.5). 
 
 
Figure 4.6:  The effects of nicotine and TPM on monoamine uptake in the striatum 
and PFC.  Animals were treated with control, nicotine (0.35 mg/kg) or TPM (containing 
0.35 mg/kg nicotine) and sacrificed 30 min following treatment.  Ex vivo uptake studies 
showed no change in DA uptake by DAT in the striatum (n=4) (A); DA uptake by DAT 
in the PFC (n=6-7) (B); DA uptake by NET in the PFC (n=3-4) (C); or 5-HT uptake by 
SERT in the striatum (n=4) (D).  Data points are mean ± SEM. 
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Table 4.5:  Kinetic data for DA and 5-HT uptake at 30 min 
 Treatment Vmax(pmol/s/g) Km (µM) 
 Control 365 ± 38 0.90 ± 0.098 
DAT Striatum Nicotine (0.35 mg/kg) 397 ± 12 1.34 ± 0.15 
 TPM (0.35 mg/kg nicotine) 378 ± 28 1.31 ± 0.15 
 Control 559 ± 103 1.54 ± 0.28 
DAT PFC Nicotine (0.35 mg/kg) 572 ± 67 1.69 ± 0.37 
 TPM (0.35 mg/kg nicotine) 537 ± 90 1.40 ± 0.21 
 Control 740 ± 32 2.04 ± 0.27 
NET PFC Nicotine (0.35 mg/kg) 748 ± 36 2.27 ± 0.40 
 TPM (0.35 mg/kg nicotine) 730 ± 71 2.14 ± 0.18 
 Control 300 ± 22 0.60 ± 0.11 
SERT Striatum Nicotine (0.35 mg/kg) 313 ± 27 0.59 ± 0.12 
 TPM (0.35 mg/kg nicotine) 339 ± 23 0.60 ± 0.09 
Values are mean ± SEM. 
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4.3 The effects of nicotine and TPM on monoamine transporter 
function and expression at 1 hr 
4.3.1 DAT function and protein expression in the NAc, striatum, and PFC  
Rats were sacrificed 1 hr after treatment with control, nicotine (0.35 mg/kg), or TPM 
(containing 0.35 mg/kg nicotine), and ex vivo function and protein expression were 
measured using RDEV and Western blotting respectively.  In the NAc no significant 
change in either function or protein expression was seen (Figure 4.7), including no 
significant changes in the Vmax or Km of DA uptake (Table 4.6).   
 
Table 4.6:  Kinetic data for DA uptake in the NAc at 1 hr. 
Treatment Vmax (pmol/s/g) Km (µM)  
Control 390± 52 1.30± 0.43 
Nicotine (0.35 mg/kg) 353± 46 0.89± 0.13 
TPM (0.35 mg/kg nicotine) 339± 40 0.91± 0.15 
Values are mean ± SEM. 
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Figure 4.7:  Nicotine and TPM have no effect on DAT function and expression in the 
NAc at 1 hr.    Tissue from animals treated with nicotine (0.35 mg/kg) or TPM 
(containing 0.35 mg/kg nicotine) showed no significant difference in DA uptake (A) or 
DAT protein expression (B) compared to control (n= 5-8).  Data points and bars represent 
mean ± SEM.  C, control; N, nicotine; T, TPM.  
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For striatal samples, animals were pre-treated with PBS vehicle or mecamylamine (1.5 
mg/kg) 20 min prior to control, nicotine (0.35 mg/kg) or TPM (containing 0.35 mg/kg) 
treatment.  An increase in DAT function was seen in the PBS/TPM group compared to 
PBS/Control (Figure 4.8A) that was not accompanied by an increase in protein expression 
(Figure 4.8B).  The Mecamylamine/Control group did not significantly differ from 
PBS/Control, and mecamylamine pre-treatment did not completely attenuate the increase 
in uptake observed in the PBS/TPM group (Figure 4.8A).  Kinetic data showed a 
significant increase in Vmax for the PBS/TPM group (40.5%; p<0.05, Student’s t-test), 
with a slight non-significant increase in Km (28.1%) (Table 4.7).  This increase in Vmax 
was not completely attenuated with mecamylamine pre-treatment; the 
Mecamylamine/TPM group had a 33.3% increase in  Vmax.  
 
Table 4.7:  Kinetic values for DAT function in the striatum at 1 hr.   
Treatment Vmax (pmol/s/g) Km (µM)  
PBS/Control 342 ± 50 1.09 ± 0.10 
PBS/Nicotine (0.35 mg/kg) 369 ± 38 1.09 ± 0.13 
PBS/TPM (0.35 mg/kg nicotine) 481 ± 37* 1.39 ± 0.15 
Mec/Control 363 ± 48 0.91 ± 0.20 
Mec/TPM 456 ± 34 1.3 ± 0.47 
Values are mean ± SEM.  *p<0.05 compared to PBS/Control, Student’s t-test. 
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Figure 4.8:  TPM, but not nicotine, increased DAT function in the striatum at 1 hr.  
Animals were pre-treated with PBS vehicle or mecamylamine (1.5 mg/kg) followed by 
control, nicotine (0.35 mg/kg), or TPM (containing 0.35 mg/kg nicotine) 20 min later.  
There was a significant increase in DAT function with PBS/TPM compared to 
PBS/control that was not completely attenuated by mecamylamine pre-treatment (n=4-9) 
(A).  There was no change in DAT protein expression with any treatment (n=7-8) (B).  
Data points and bars represent mean ± SEM.  C, control; N, nicotine; T, TPM.   
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DA uptake by DAT in the PFC was not affected by treatment with nicotine (0.35 mg/kg) 
or TPM (containing 0.35 mg/kg nicotine) (Figure 4.9A); and no change in Vmax or Km 
was observed compared to control (Table 4.8).  DAT protein expression in this brain 
region was also unaffected by nicotine and TPM treatment (Figure 4.9B).   
 
Table 4.8:  Vmax and Km values for DA uptake in the PFC 1 hr after drug treatment. 
Treatment Vmax(pmol/s/g) Km (µM)  
Control 540 ± 38 1.74 ± 0.19 
Nicotine (0.35 mg/kg) 550 ± 57 1.69 ± 0.27 
TPM (0.35 mg/kg nicotine) 517 ± 72 1.56 ± 0.17 
Values are mean ± SEM. 
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Figure 4.9:  Nicotine and TPM have no effect on DA uptake by DAT in the PFC.  
Tissue from animals sacrificed 1 hr following control, nicotine (0.35 mg/kg), or TPM 
(containing 0.35 mg/kg) treatment showed no difference in DA uptake (A) or DAT 
protein expression (B) compared to control in the PFC (n=6-8).  Bars and data points 
represent mean ± SEM.  C, control; N, nicotine; T, TPM. 
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4.3.2 DAT protein and mRNA expression in the VTA and SN 
The VTA and SN were dissected from animals that had been sacrificed 1 hr following 
control, nicotine (0.35 mg/kg), or TPM (containing 0.35 mg/kg nicotine) treatment.  
Protein expression and mRNA were measured using Western blotting and real time PCR.  
Nicotine (p<0.05) and TPM (p<0.05, one-way ANOVA with Bonferroni post-hoc 
analysis) significantly decreased DAT mRNA expression in the VTA, but not the SN 
(Figure 4.10A).  The ΔCt values for nicotine and TPM were 4.78 and 3.89 Ct values 
greater than control respectively, corresponding to a 96.4% and 93.3% reduction in 
mRNA expression (Table 4.9).  This decrease in DAT mRNA expression did not translate 
to a decrease in protein expression in the VTA and, similarly, there was no change in 
protein expression in the SN (Figure 4.10B).     
 
Table 4.9:  ΔCt values for DAT mRNA expression in the VTA and SN. 
Treatment  ΔCt value VTA ΔCt value SN 
Control 10.6 ± 0.7 6.7 ± 0.9 
Nicotine (0.35 mg/kg)  15.4 ± 0.7**
 
7.7 ± 0.9 
TPM (0.35 mg/kg nicotine) 14.5 ± 1.0* 8.0 ± 0.8 
Values are mean ± SEM.  *p<0.05, **p<0.01 one-way ANOVA with Bonferroni post-hoc 
analysis.  
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Figure 4.10:  DAT mRNA and protein expression in the VTA and SN 1 hr after 
nicotine or TPM treatment.  Animals were treated with control, nicotine (0.35 mg/kg) 
or TPM (containing 0.35 mg/kg nicotine) and sacrificed 1 hr later.  (A) Nicotine and TPM 
caused a significant decrease in DAT mRNA expression in the VTA but not the SN.  (B) 
There were no significant changes in DAT protein expression in either brain region.  
Representative blots for the VTA (C) and SN (D) are shown.  Bars represent mean ± 
SEM (n=5-7).  C, control; N, nicotine; T, TPM.  *p<0.05, **p<0.01, one-way ANOVA 
with Bonferroni post-hoc analysis.   
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4.3.3 NET function and expression 
Animals were sacrificed 1 hr after control, nicotine (0.35 mg/kg), or TPM (containing 
0.35 mg/kg nicotine) treatment and DA uptake by NET and NET protein expression were 
assessed in the PFC using RDEV and Western blotting.  No significant changes in NET 
function or protein expression were found in the PFC in response to either nicotine or 
TPM (Figure 4.11), including no change in Km or Vmax values (Table 4.10).  In addition, 
NET protein and mRNA expression were measured in the LC using Western blotting and 
real time PCR.  No change in protein expression was found in this brain region, and there 
was no significant change in mRNA expression with nicotine or TPM treatment 
compared to control (Figure 4.12).  There was, however, a significant difference in 
mRNA expression between nicotine and TPM treatments.  The ΔCt value for nicotine 
treated animals was 1.28 Ct values greater than that for TPM (Table 4.11).  This 
corresponds to 59% reduction in mRNA expression in the TPM group compared to the 
0.35 mg/kg nicotine group.   
 
Table 4.10:  Kinetic data for DA uptake by NET in the PFC 1 hr after drug 
treatment. 
Treatment Vmax (pmol/s/g) Km (µM)  
Control 586 ± 66 2.39 ± 0.46 
Nicotine (0.35 mg/kg) 547 ± 83 1.54 ± 0.13 
TPM (0.35 mg/kg nicotine) 590 ± 58 2.07 ± 0.47 
Values are mean ± SEM. 
 
Table 4.11:  ΔCt values for mRNA expression in the LC at 1 hr. 
Treatment  ΔCT value 
Control 7.1 ± 0.5 
Nicotine (0.35 mg/kg) 6.1 ± 0.2
 
TPM (0.35 mg/kg nicotine) 7.3 ± 0.4* 
*p<0.05 compared to nicotine, Student’s t-test. 
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Figure 4.11:  DA uptake by NET and NET protein expression in the PFC 1 hr after 
drug treatment.  Nicotine (0.35 mg/kg) and TPM (containing 0.35 mg/kg) had no 
significant effect on DA uptake by NET in the PFC 1 hr after treatment compared to 
control (n=4-5) (A).  There was no change in NET protein expression in the PFC with 
nicotine or TPM at this time point (n=6-8) (B).  Data points and bars represent mean ± 
SEM.  C, control; N, nicotine; T, TPM. 
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Figure 4.12:  NET mRNA and protein expression in the LC 1 hr after drug 
treatment.  Animals were treated with 0.35 mg/kg nicotine or TPM containing 0.35 
mg/kg nicotine and sacrificed 1 hr later.  (A) NET mRNA expression in the LC was 
measured using real time PCR.  Nicotine and TPM had no significant effect on mRNA 
expression compared to control; however, the difference in expression between nicotine 
and TPM was significant (n= 6-7).  (B) There were no significant changes in NET protein 
expression in the LC compared to control as measured by Western blotting (n= 8-10).  
Bars represent mean ± SEM.  C, control; N, nicotine; T, TPM. 
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4.3.4 SERT expression and function 
SERT function, mRNA expression and protein expression in rats were measured ex vivo 1 
hr after control, nicotine (0.35 mg/kg), or TPM (containing 0.35 mg/kg nicotine) 
treatment.  No change in function or protein expression was found in the striatum (Figure 
4.13), including no change in the Vmax or Km of 5-HT uptake (Table 4.12).  Similarly, in 
the DRN, no significant changes in SERT mRNA or protein expression were found 
(Figure 4.14).  ΔCt values for mRNA expression are shown in Table 4.13. 
 
Table 4.12:  Vmax and Km values for 5-HT uptake by SERT in the striatum 1 hr after 
nicotine or TPM treatment. 
Treatment Vmax (pmol/s/g) Km (µM)  
Control 449± 37  1.08± 0.33 
Nicotine (0.35 mg/kg) 444± 35 1.18± 0.12 
TPM (0.35 mg/kg nicotine) 438± 50 1.05 ± 0.22 
Values are mean ± SEM. 
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Figure 4.13:  SERT function and expression in the striatum at 1 hr.  No significant 
changes were found in SERT function (n=5) (A) or protein expression (n=7-9) (B) 1 hr 
following control, nicotine (0.35 mg/kg), or TPM (containing 0.35 mg/kg nicotine) 
treatment.  Data points and bars represent mean ± SEM.  C, control; N, nicotine; T, TPM.  
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Figure 4.14:  SERT mRNA and protein expression in the DRN at 1 hr.  Rats were 
treated with control, nicotine (0.35 mg/kg), or TPM (containing 0.35 mg/kg nicotine) and 
sacrificed 1 hr after treatment.  No change in mRNA (A) or protein expression (B) was 
seen with any treatment.  Bars represent mean ± SEM (n=6-7).  C, control; N, nicotine; T, 
TPM.   
Table 4.13:  ΔCt values for SERT mRNA expression in the DRN at 1 hr. 
Treatment  ΔCt Value 
Control 6.2 ± 0.7 
Nicotine (0.35 mg/kg) 6.1 ± 0.7
 
TPM (0.35 mg/kg nicotine) 6.0 ± 0.6 
Values are mean ± SEM.  
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Chapter 5:  Discussion 
 
5.1 Significance 
Cigarette smoking is the leading cause of preventable death worldwide, and accounts for 
almost 6 million deaths every year (WHO, 2011).  Current smoking cessation therapies 
have limited success (Jorenby et al., 2006; Balfour et al., 2000a), which is partially due to 
an inadequate understanding of the molecular biology of smoking addiction.  Nicotine has 
been shown to act on monoaminergic reward pathways in the brain (Seth et al., 2002; 
Balfour et al., 2000b) and cause the release of DA, 5-HT, and NE (Singer et al., 2004; 
Dichiara and Imperato, 1988; Nisell et al., 1996; Ma et al., 2005; Yu and Wecker, 1994; 
Rossi et al., 2005; Scholze et al., 2007).  Uptake of monoamines by the monoamine 
transporters is the primary mechanism for monoamine clearance from the synapse, and 
this makes the monoamine transporters integral to the regulation of reward mechanisms in 
the brain (Howell and Kimmel, 2008).  It has previously been reported that nicotine 
affects the function and expression of the monoamine transporters; however, there is 
some discrepancy in the literature and our understanding of these effects is incomplete 
(see Danielson et al., 2011).  Emerging evidence suggests that non-nicotinic components 
of cigarette smoke may also contribute to the development and maintenance of smoking 
addiction.  There is currently very little information in the literature on the effects of non-
nicotinic components of cigarette smoke on the monoamine transporters.  The aim of this 
study was to assess the effects of nicotine and a tobacco extract, TPM, on the function 
and expression of the monoamine transporters DAT, NET, and SERT in the rat brain.  
This will improve our understanding of the molecular biology of smoking addiction, and 
could in future lead to the development of more successful smoking cessation therapies. 
 
5.2 TPM as a model for smoking addiction 
5.2.1 TPM and reward-related neuroadaptations 
Emerging evidence indicates that non-nicotinic components of tobacco smoke may 
contribute to smoking addiction, and some recent studies have indicated that tobacco 
extracts have a different pharmacological profile to that of nicotine alone.  Firstly, a 
tobacco extract produced stronger inhibition of dorsal raphe serotonergic neurons when 
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compared to a matched dose of nicotine (Touiki et al., 2007).  Serotonin has a critical role 
in reinforcement processes, and this effect could determine reinforcing properties. 
Secondly, TPM exposure increased nAChR expression in cell cultures to a greater extent 
than nicotine alone (Ambrose et al., 2007).  The functional significance of these findings 
is unclear; however, it is known that blocking nAChRs inhibits both nicotine self-
administration (O'Connor et al., 2010, Stairs et al., 2010, Toll et al., 2012) and nicotine 
enhanced brain stimulation reward (Spiller et al., 2009).  Furthermore, baseline 
expression levels of α4β2 receptors can also predict motivation to self-administer in 
animals (Le Foll et al., 2009).  The monoamine transporters are an integral part of reward 
circuitry in the brain and nicotine has previously been shown to alter monoamine 
transporter function and expression (reviewed in Danielson et al., 2011).  However, 
information on the effects of non-nicotinic components of cigarette smoke on monoamine 
transporter is very limited.  This is the first study to describe the effects of a tobacco 
extract on monoamine transporter function and expression. 
 
5.2.2 Animal models of tobacco dependence 
The majority of research in pre-clinical models of smoking addiction has focused on 
nicotine alone, despite the fact that human smokers expose themselves to over 4000 
different chemicals.  Nicotine is the principal addictive agent in cigarette smoke but 
increasing evidence suggests that non-nicotinic components of tobacco smoke may also 
contribute to neuroadaptations related to smoking and the development of smoking 
addiction.  Accordingly, inhalative smoke exposure in animals has been used as a model 
to examine smoking related neuroadaptations (Harris et al., 2010, Small et al., 2010).  
This model suffers from several methodological issues, and these limit its usefulness as a 
smoking dependence model.  Firstly, whole body immersion smoke exposure is aversive 
for animals, and animals must be exposed for at least 4 hrs per day to produce serum and 
brain nicotine levels that are comparable to human smokers (Harris et al., 2010).  Nose-
only smoke exposure is also a considerable stressor as it requires restraint of the animal.  
Stress is known to lead to alterations in monoaminergic system function and should be 
limited to avoid production of behavioural effects and neuroadaptations that do not relate 
specifically to drug exposure.  Secondly, animals are non-contingently exposed to smoke 
in inhalative models and it has been demonstrated that the effect of contingency can 
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determine drug-produced neuroadaptations (Dworkin et al., 1995, Stefanski et al., 1999, 
Jacobs et al., 2003). 
 
The present study utilised i.p. injection as the mode of administration for TPM and 
nicotine.  This mode of administration is much less aversive for animals compared with 
long periods of exposure to cigarette smoke, and allows for greater precision and control 
of the quantities of smoke constituents being delivered.  Additionally, this method did not 
involve expensive equipment (i.e. smoking chambers) or surgical procedures. Relative 
ease of producing the animal model allowed for reasonably large sample sizes, and 
different dosing regimens and time points to be examined.  Since this was the first attempt 
to assess the effects of TPM on monoamine transporter status, the ability to vary several 
of the parameters was critical. 
 
 
The main disadvantages of administering TPM in this manner is that infusions are non-
contingent and the smoke components will go through first pass metabolism in the liver 
before reaching the brain.  First pass metabolism could result in the relative 
concentrations of some components being decreased.  Given these limitations, an 
alternative model of tobacco dependence that addresses both of these issues has recently 
been created by Dr Katie Brennan: intravenous TPM self-administration (School of 
Psychology VUW, unpublished results).  There have been no previous reports of animals 
voluntarily self-administering tobacco smoke/extracts, thus this new model represents an 
exciting new advancement in the study of tobacco dependence.  Preliminary results 
indicate that rats respond more for TPM than a matched dose of nicotine, and that TPM 
self-administration is more resistant to mecamylamine-produced decreases in responding 
observed in nicotine animals (Katie Brennan, personal communication).  Further work is 
required to interpret these data; however, these results suggest behavioural differences 
exist between TPM and nicotine, and that there is a potential role for non-nicotinic smoke 
components in reward. 
  
5.2.3 TPM composition 
The TPM used in this study is an extract that contains tobacco combustion products that a 
human smoker would typically inhale.  TPM is extracted in ethanol and represents the 
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ethanol soluble fraction of compounds present in cigarette smoke.  The use of a tobacco 
extract such as this is preferable to testing individual components of cigarette smoke as 
components may have additive or synergistic effects on cellular processes.  The exact 
composition of TPM is currently unknown, including the ratio of the (+) nicotine and (-) 
nicotine isomers.  We can assume that the majority of nicotine found in TPM is the (-) 
isomer as it has been previously shown that (-) nicotine makes up 90% of the nicotine 
content in tobacco smoke (Matta et al., 2007).  The (-) nicotine isomer is more 
pharmacologically active than (+) nicotine and more potent in behavioural studies in 
animals (Matta et al., 2007).  It is for this reason that (-) nicotine was used for the nicotine 
treatment groups.  The slightly larger Vmax value for TPM compared to nicotine in the 30 
min NAc experiment could, therefore, be due to the isomer composition in TPM (Figure 
4.4, p77).   
 
The presence of the psychoactive β-carboline alkaloids harman and norharman in TPM 
has been confirmed (Dr Penelope Truman, personal communication).  Harman and 
norharman exhibit strong MAO inhibitor activity (Rommelspacher et al., 1994; 
Rommelspacher et al., 2002; Herraiz and Chaparro, 2005) and are present in relatively 
large amounts in tobacco smoke (Herraiz, 2004).  Furthermore, MAO inhibitor drug pre-
treatment has been shown to enhance the rewarding effects of nicotine (Guillem et al., 
2005; Guillem et al., 2006; Villegier et al., 2006; Villegier et al., 2007), and MAO 
inhibitors accumulate in the rat brain following systemic nicotine injections (Pawlik et al., 
1990, Fekkes and Bode, 1993).  Harman and norharman present in TPM could, therefore, 
alter monoaminergic systems through their MAO inhibitory activity and indirectly affect 
the function of monoamine transporters.   
 
No other specific compounds have been measured in TPM; however, we can assume that 
ethanol-soluble compounds are present.  Candidate compounds known to have 
pharmacological and behavioural effects in drug addiction models include the minor 
tobacco alkaloids and acetaldehyde.  Rats will respond more for a cocktail of nicotine 
plus the minor tobacco alkaloids than nicotine alone (Clemens et al., 2009), and the minor 
tobacco alkaloid nornicotine has been shown to decrease DA uptake in the striatum of rats 
(Middleton et al., 2007b).  Acetaldehyde has long been implicated in the reinforcing 
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effects of alcohol (Quertemont et al., 2005), and has more recently been shown to 
increase acquisition of nicotine self-administration in adolescent rats (Belluzzi et al., 
2005).  The effects of acetaldehyde on monoamine transporter function have not been 
extensively examined, although one study reported no change in DAT function in 
Xenopus oocytes in response to acetaldehyde (Mascia et al., 2001).     
 
5.2.4 Ethanol content in nicotine and TPM treatments 
Nicotine and TPM treatments used in this study were delivered in a vehicle that contained 
8% ethanol in PBS.  This was due to the ethanol content of the TPM originally acquired 
for experiments.  The ethanol content of treatments used in this study should be taken into 
account when interpreting results for several reasons.  Ethanol is known to act on the 
mesolimbic DA system and cause increases in DA in reward related regions of the brain 
(Hurley et al., 2012).  Furthermore, it has been shown that co-administration of nicotine 
and alcohol has an additive effect on DA release in the NAc (Tizabi et al., 2007), and the 
two drugs possibly have synergistic effects on the reward system (Hurley et al., 2012).  
Cross-potentiation of rewarding effects with nicotine and ethanol has also been reported 
in human studies.  Rose et al. (2004) found that self-reported pleasure from cigarette 
smoking was increased by alcohol consumption (Rose et al., 2004).  It has also been 
reported that alcohol consumption increased with the smoking of regular cigarettes 
compared to denicotinised cigarettes (Barrett et al., 2006).  Secondly, there is evidence 
that ethanol affects monoamine transporter function and expression.  Data on the effects 
of ethanol on DAT are conflicting and there have been reports of increases and decreases 
in function as well as no change (reviewed in Zhu and Reith, 2008).  There is very limited 
information available on the effects of ethanol on SERT and NET expression and 
function.  SERT expression has been shown to be up-regulated in response to ethanol in 
dendritic cells (Babu et al., 2009).  In addition, Hwang et al. (2000) reported that NET 
expression is higher in the LC of rats selectively bred for alcohol preference compared to 
low alcohol drinking and non-preferring rats (Hwang et al., 2000).  Finally, acetaldehyde 
is a metabolic product of ethanol; therefore, the concentration of acetaldehyde that the 
animals are exposed to will be greater than the actual amount present in TPM.  Since 
acetaldehyde has previously been shown to affect nicotine self-administration in 
adolescent rats (Beluzzi et al., 2005), and to have reinforcing properties on its own (Amit 
and Smith, 1985), this increased dose could affect nicotine-derived neuroadaptations.   
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The ethanol content of nicotine and TPM treatments used in this study was controlled for 
with an 8% ethanol solution in PBS.  This should have controlled for the majority of 
effects possibly produced by ethanol, so that the observed effects were due to nicotine 
and TPM.  However it is possible that there could be synergistic effects of ethanol and 
nicotine, or ethanol and compounds present in TPM.  Furthermore, changes produced by 
ethanol could have masked some effects that would otherwise be observed with nicotine 
and TPM.  There is a high co-morbidity rate of alcohol consumption and tobacco use in 
humans (Hurley et al., 2012).  In light of this, the present study is still relevant but results 
need to be interpreted in context as they may be due to the combined effects of ethanol 
and nicotine.  Future studies could be conducted on lower ethanol content models where 
possible, and repeats of nicotine and control treatments without ethanol could also be 
performed to confirm that reported findings with nicotine were due to nicotine alone.  In 
the newly established TPM self-administration model ethanol content has been reduced to 
1%, which should reduce some of the problems discussed in this section.   
 
5.3 Chronic effects of nicotine and TPM on monoamine transporter 
function and expression  
 
This is the first study to examine the effects of TPM on monoamine transporter function, 
and because of this it is highly relevant in contributing to our understanding of the effects 
of tobacco smoke on this system.  In order to study the chronic effects of nicotine and 
TPM on the monoamine transporters, we used a 10 day dosing regimen where rats 
received a daily total of 0.35 or 3 mg/kg nicotine, or TPM containing 0.35 mg/kg 
nicotine.  Since human smokers dose themselves chronically with cigarette smoke, it is 
important to investigate the effects of chronic nicotine and tobacco extracts in animal 
models.  A 10 day treatment regimen was chosen as previous studies have used this 
treatment period (Awtry and Werling, 2003; Drew and Werling, 2003), and it is within 
the median time point used previously in chronic nicotine models.  In this model 
treatments were split across four injections 2 hrs apart to better mimic the rise and fall in 
nicotine brain and plasma levels that human smokers are exposed to.  Animals were 
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sacrificed the morning after their final treatment (14-16 hrs later), and thus the effects 
observed are those of animals in withdrawal.  It is important to understand the effects of 
nicotine and TPM withdrawal as this has considerable implications for the development 
of smoking cessation aids.  Human smokers suffer withdrawal and it is the unpleasant 
experience of this that often leads to relapse (De Biasi and Dani, 2011).  With a greater 
understanding of the molecular biology of nicotine and TPM withdrawal, it may be 
possible to develop more effective cessation therapies targeting specific neuroadaptations 
related to smoking withdrawal.  In this study, monoamine transporter function and 
expression were measured using RDEV, Western blotting, and real time PCR.  A 
summary of the results found are in Table 5.1. 
 
5.2.1 DAT function and expression following chronic nicotine and TPM treatment 
There is conflicting data in the literature on the effects of chronic nicotine treatment on 
DAT.  Chronic nicotine treatment has been shown to cause no change in [
3
H]DA uptake 
in chopped rat NAc or striatal tissue (Izenwasser et al., 1992), rat PFC synaptosomes 
(Drew and Werling, 2003), or rat striatal and NAc synaptosomes (Carr et al., 1989).  
However, increases in DAT function in mouse striatal synaptosomes (Hadjiconstantinou 
et al., 2011), and in the NAc of nicotine self-administering rats (Rahman et al., 2004) 
have been reported.  No changes in DAT function in the NAc (Figure 3.4, p56), striatum 
(Figure 3.5, p57), or PFC (Figure 3.6, p58) were observed following chronic nicotine 
(0.35 or 3 mg/kg) or TPM (containing 0.35 mg/kg nicotine) treatment in this study.     
 
An important difference in methodology between these studies is the time between final 
nicotine treatment and sacrifice.  Both Izenwasser and Cox (1992) and Carr et al. (1989) 
utilised osmotic minipumps (s.c.) for delivery of nicotine, and so nicotine treatment 
would have been continuous up until sacrifice.  However, Hadjiconstantinou et al. (2011) 
and Rahman et al. (2004) found increases in DAT function in animals sacrificed 12-24 
hrs after the last nicotine treatment.  This means that the effects of nicotine withdrawal on 
monoamine transporter function were being measured in these studies.  In our study, we 
chose to sacrifice animals at between 14 and 16 hrs after their last nicotine treatment, and 
thus monoamine transporter function was measured in nicotine withdrawal.  It is 
interesting, therefore, that the increases in DAT function in the striatum and NAc shown 
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by Hadjiconstantinou et al. (2011) and Rahman et al. (2004) were not observed in our 
study.  This could be due to several factors in the current study, including the dose 
chosen, the length of treatment, and the co-administration of alcohol.  The two previous 
studies that showed changes in DAT function in response to chronic nicotine treated 
animals for 14 and 25 days.  This is longer than other studies that have only treated 
animals for 7-10 days for chronic models.  In the current study, animals were treated for 
10 days, which may not have been long enough to produce the effects previously shown 
by Rahman et al. (2004) and Hadjiconstantinou et al. (2011).  It would be interesting in 
future to study the chronic effects of nicotine on DAT function over an extended time 
period.  Furthermore, time-effects could be examined by studying different groups of 
animals that had been treated for different periods of time.  Particularly, it would be of 
interest to look at the 10-14 day period to see if there is a change evident somewhere 
during this time.   
 
In this study, rats received 0.35 or 3 mg/kg/day nicotine or TPM containing 0.35 
mg/kg/day nicotine.  This is a comparatively low dose of nicotine compared to other 
chronic studies that used 0.6-6 mg/kg/day nicotine in chronic treatments for rats.  When 
choosing nicotine doses for study many factors need to be considered including: what an 
animal will self-administer in a day; what plasma and brain levels of nicotine it is likely 
to produce; how this compares to human nicotine consumption.  The doses chosen in this 
study fall roughly within the range of what an animal will self-administer in a day 
(Corrigall and Coen 1989; Boulles et al., 2010), and should produce plasma nicotine 
levels similar to that seen in human smokers (Matta et al., 2007); however, plasma levels 
were not actually measured in this study.  The 0.35 mg/kg dose would be expected to 
produce only moderate plasma and brain nicotine levels (Matta et al., 2007), and was 
chosen in part because a higher nicotine concentration would require a higher ethanol 
concentration in the TPM group.  Using this dose is still relevant for comparison to 
human smoking behaviour as it would be comparable to the nicotine consumption of a 
light smoker.  Furthermore, many nicotine studies look at the effect of a single large 
nicotine dose, or continuous administration through s.c. osmotic minipumps, both of 
which differ greatly to human smoking behaviour.  In this model, a moderate nicotine 
dose is administered across 4 daily injections so that several rises and falls in nicotine 
plasma and brain levels are produced throughout the day.  This better mimics the 
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exposure to nicotine that humans experience.  The 3 mg/kg nicotine dose administered in 
chronic experiments in this study was used to examine dose effects of nicotine, and to 
ensure that the 0.35 mg/kg dose was not too low to produce effects.  Since the 3 mg/kg 
dose also produced no changes in DA uptake with chronic treatment, it can be concluded 
that in this model nicotine does not affect DAT function.  Future research could examine 
the effects of a wider range of nicotine doses on DAT function, and a lower ethanol 
concentration in TPM could allow for higher doses to be used. 
 
A substantial number of studies that have previously examined monoamine uptake in 
response to nicotine have been conducted using radioactive uptake assays and 
synaptosomal preparations (Carr et al., 1989; Drew and Werling, 2003; Awtry and 
Werling, 2003; Middleton et al., 2007a; Zhu et al., 2009).  This differs considerably from 
the methodology employed in the current study, where uptake was measured in chopped 
tissue using RDEV.  Firstly, there is a greater diffusion barrier for drugs and monoamines 
to cross in chopped tissue compared to synaptosomes, necessitating larger concentrations 
of these agents to be applied to the chopped tissue (Near et al., 1988).  Secondly, RDEV 
differs from radioactive uptake assays in several respects:  measurement of monoamine 
uptake is immediate with no delay produced by wash steps that are necessary in 
radioactive uptake; the uptake is measured in real time; and measurement of uptake is 
continuous and does not rely on discrete data points (Earles et al., 1998).  For these 
reasons RDEV is arguably the more favourable methodology for the measurement of 
monoamine uptake.  Furthermore, the differences between these two methodologies are 
great enough to warrant consideration when comparing results from this study to previous 
studies that utilize radioactive uptake techniques.    
 
Although there was no change in DAT function observed with chronic nicotine and TPM 
treatment in this study, there was a change in total DAT protein expression.  In the NAc, 
an increase of 39.1% for nicotine (0.35 mg/kg), and 42.8% for TPM (containing 0.35 
mg/kg nicotine) was found (Figure 3.4, p56).  Furthermore, there was a trend towards an 
increase of 32.4% for the 3 mg/kg nicotine group.  No previous studies have shown an 
increase in DAT protein expression in the NAc, or a decrease in DAT protein expression 
in the SN of rats.  A decrease in [
99m
Tc] TRODAT-1 binding has been reported in the 
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striatum of human smokers compared to non-smokers (Krause et al., 2002; Newberg et 
al., 2007; Yang et al., 2008).  However, this may be due to decreased binding affinity of 
[
99m
Tc] TRODAT-1 to DAT rather than a decrease in the amount of DAT present.  DAT 
protein expression in this study was measured using Western blotting with a DAT-
specific antibody. This method measures the total DAT present on both the cell surface 
and in the interior of the cell.  The observed increase in DAT protein in the NAc may, 
therefore, not indicate an increase in functional DAT on the cell surface, but an increase 
in DAT protein in the intracellular pool.  Since there was no increase in DA uptake in the 
NAc, this is more likely.   
 
In addition to the increase in DAT protein found in the NAc, there was a decrease in DAT 
protein expression found in the SN with 0.35 mg/kg nicotine (27.5%), 3 mg/kg nicotine 
(33%) and TPM (containing 0.35 mg/kg nicotine) (36.1%) (Figure 3.7, p60).  In contrast 
to this, Miller et al. (2007) reported a 52% increase in [
3
H]GBR12935 binding to DAT in 
crude membrane preparations from the midbrain of guinea pigs exposed chronically to 
cigarette smoke.  This preparation would have included several brain nuclei in addition to 
the SN.  The discrepancy between our findings and the findings by Miller et al. (2007) 
could also be due to a combination of species and/or treatment differences.  The cause for 
this decrease in DAT expression in the SN is not clear.  Since nicotine has been reported 
to have a neuroprotective role in the SN by several studies (Takeuchi et al. 2009; Quik et 
al., 2007; Park et al., 2007), it is unlikely that this decrease in DAT protein is due to 
toxicity or cell death.  No change in DAT mRNA expression was found in the SN in this 
study (Figure 3.7, p60), indicating that the decrease in DAT protein expression was not 
due to a decrease in gene expression.  However, quantifying mRNA only measures 
changes in gene transcription and the possibility of a reduction in mRNA translation 
cannot be ruled out. 
 
Chronic nicotine and cigarette smoke treatment have previously been shown to increase 
DAT mRNA expression in the VTA and SN of rats (Li et al., 2004c; Hadjiconstantinou et 
al., 2011).  Interestingly, Li et al. (2004c) found a greater increase in DAT mRNA 
expression in animals that had been chronically exposed to passively inhaled cigarette 
smoke than animals that had received chronic oral nicotine.  In contrast, no change in 
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DAT mRNA expression in the SN or VTA was found in our study in response to nicotine 
or TPM.  This indicates that changes in protein expression observed in this study are not 
regulated through gene expression.  As mentioned above, discrepancies between this 
study and previous ones could be explained by factors such as dose and length of 
treatment.  In the study by Li et al. (2004c) rats received 12 mg/kg/day oral nicotine for 4 
weeks.  This is both a significantly longer time period and larger dose than what we used 
in the present study (0.35 or 3 mg/kg/day nicotine).  Similarly, Hadjiconstantinou et al. 
(2011) treated mice for 14 days to a total of 8 mg/kg/day.    
 
5.2.2 NET function and expression 
There have been no previous studies that examined the effects of chronic nicotine 
administration on DA uptake by NET.   [
3
H]NE uptake by NET has been measured in 
cultured bovine adrenal medullary cells and Itoh et al. (2010) found a 61% increase in 
uptake in response to 5 days nicotine treatment (Itoh et al., 2010).  In our study, the 
effects of chronic nicotine and TPM treatment on DA uptake by NET in the PFC were 
measured.  The chronic treatment regime consisted of a total of 0.35 or 3 mg/kg/day 
nicotine or 0.35 mg/kg/day TPM over 10 days.  An increase in DA uptake by NET (76% 
increase in Vmax) was observed in the PFC following 3 mg/kg nicotine, but not following 
0.35 mg/kg nicotine or TPM (containing 0.35 mg/kg nicotine) (Figure 3.8, p62).  This 
increase in uptake appears to be a dose effect of nicotine as both 0.35 mg/kg nicotine and 
TPM containing 0.35 mg/kg nicotine had no effect on NET function.  Furthermore, this 
change is consistent with the increase in NET function shown by Itoh et al. (2010), and 
suggests that nicotine may up-regulate NET function in a manner that is not 
discriminatory between DA and NE uptake.  It is especially interesting that an increase in 
DA uptake by NET was observed in this study where there was no increase in DA uptake 
by DAT in the same brain region and treatment group (Figure 3.6, p58).  This difference 
highlights the specific regulation of the monoamine transporters by nicotine.  NET is 
known to be responsible for a considerable portion of DA uptake in the PFC and this 
increased uptake could have significant effects on dopaminergic tone (Dichiara et al., 
1992).  It has previously been shown that, although DA output is decreased in the NAc 
during nicotine withdrawal, it is increased in the PFC at this stage (De Biasi and Salas, 
2008).  This increase in DA output is believed to mediate some of the aversive effects of 
nicotine withdrawal such as anxiety.  The increased uptake of DA by NET observed here 
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could be a feedback mechanism that partially tempers the increase DA output in this brain 
region during withdrawal.  The mechanism for this change is not currently known.  Since 
there are very little data on the effects of nicotine on NET, future studies examining this 
would be useful. 
 
The increase in NET function found in this study was not accompanied by an increase in 
NET protein expression in the PFC (Figure 3.8, p62) or LC (Figure 3.9, p64).  Previous 
studies have found no significant change in NET density in the LC of human post mortem 
brains of smokers compared to non-smokers (Klimek et al., 2001).  Similarly, Andreasen 
et al. (2009) found no change in NET density in hippocampal and cortical membrane 
preparations from mice treated chronically with nicotine.  This indicates that nicotine 
does not affect NET protein expression, and that the increase in DA uptake observed here 
occurred through some other mechanism.  An increase in Vmax indicates that the change is 
due to increased cell surface expression of the transporter, or increased catalytic activity 
of the transporters present on the cell surface.  It should be noted that nicotine also 
affected the binding properties of DA to NET, as indicated by the increase in Km.   
However, the increase in Vmax compensated for the increase in Km and an overall increase 
in DA uptake was observed in Figure 3.8 (p62).  
  
Although we found no significant difference in protein expression of NET with any 
treatment, a significant decrease in NET mRNA expression was observed with TPM 
treatment (fig 3.9, p64).  This change equated to a 95.5% reduction in mRNA in the TPM 
group compared to the control group, and was not seen with either 0.35 or 3 mg/kg 
nicotine treatment.  It is interesting that TPM caused a change in mRNA expression 
where the dose matched nicotine did not.  This suggests that some component in TPM 
other than nicotine caused the change; however, the molecular relevance of this finding is 
questionable due to the lack of an accompanying change in protein.  It should also be 
noted that the standard error (SEM) of the TPM group was 1.5 Ct values which equates to 
approximately 34% error in the value.  Since no change in protein expression was 
observed, the reported difference in mRNA between the two groups is most likely 
inflated.  The SEM of the mRNA values was reasonably considerable in this study, and 
this most likely stems from error in tissue dissections.  The four brain regions examined 
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for monoamine transporter mRNA expression (LC, DRN, VTA, and SN) are all small and 
not very clearly defined in the rat.  Dissections were performed using a standard protocol 
routinely used (Heffner et al., 1980; Corcoran et al., 2012) and all samples were weighed 
in attempt to limit variation (Table 2.1, p38).  However, in future it would be beneficial to 
use laser capture microdissection for more accurate dissection of these regions.  At the 
time of this study, this option was not available to us.   
 
5.2.3 SERT function and expression 
Chronic nicotine treatment has been previously shown to increase [
3
H]5-HT uptake by 
SERT in PFC and hippocampal synaptosomes (Awtry and Werling, 2003); however, this 
is the first study to examine 5-HT uptake in response to nicotine in the striatum.  No 
change was observed in SERT function or protein expression in the striatum (Figure 3.10, 
p66), suggesting that the effects of nicotine on SERT are brain region specific. SERT 
protein and mRNA expression were also examined in the DRN and no difference was 
found compared to control.  However, a significant difference in SERT mRNA was 
observed between 0.35 mg/kg nicotine and TPM (containing 0.35 mg/kg nicotine) in the 
DRN (Figure 3.11, p68).  This difference equated to a 91% reduction in mRNA 
expression in the TPM group compared to the nicotine group.  As stated in the previous 
section, this statistic may be misleadingly large and should be interpreted with caution.  It 
is interesting that for SERT TPM produced a decrease in mRNA expression compared to 
nicotine.  This suggests that TPM may cause some subtle changes in gene expression.  
Although in this case no significant change compared to control and no change in SERT 
protein expression occurred, this difference is still worth some consideration.  If TPM has 
subtle effects on the gene expression of multiple components of the 5-HT system it could 
result in a change in the overall 5-HT tone.  Western blotting experiments may not show 
very small changes (<10%) in protein expression, and while a change in protein 
expression of this size may not be significant when considering a single system, it could 
cause a significant change in overall 5-HT tone in combination with other subtle changes 
within the reward circuitry of the brain.  Furthermore, it should be noted that the 
specificity of SERT antibodies has been brought into question.  There is some debate in 
the literature as to how reliable they are, and what product size they should recognise.  
The antibody used in this study has been previously published and recognises a single 
distinct band at 70-75 kDA (Appendix) that we believe to be SERT.  However, in future it 
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would be beneficial to confirm that this band represents SERT using MALDI-TOF or 
protein sequencing techniques.        
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Table 5.1:  Summary of results from this study. 
Time point  Uptake Protein expression mRNA expression 
 DAT No change in NAc, 
striatum, or PFC. 
39-43% inc in NAc 
with nic (0.35 
mg/kg) and TPM. 
No change in 
striatum, PFC or 
VTA.  Dec in SN 
with all treatments 
(27-36%). 
No change in VTA or SN. 
Chronic NET 76% inc in Vmax with nic (3 
mg/kg).  
No change in PFC 
or LC. 
95.5% Dec in LC with 
TPM  
 SERT No change in striatum. No change in 
striatum or DRN. 
No change compared to 
con in DRN.  91% dec 
with TPM compared to nic 
(0.35 mg/kg).  
 DAT No change in NAc or PFC.  
Inc in Vmax (40.5%) with 
TPM in striatum not 
completely attenuated by 
mec.   
No change in NAc, 
striatum, PFC, 
VTA, or SN. 
Dec in VTA with nic (0.35 
mg/kg) (96.4%) and TPM 
(93.3%) compared to con, 
no change in SN. 
1 hr NET No change in PFC. No change in PFC 
or LC. 
No change compared to 
con in PFC, TPM dec 
compared to nic (0.35 
mg/kg) (59%). 
 SERT No change in striatum. No change in 
striatum or DRN. 
No change in DRN. 
 
 
 
 
30 min 
DAT Dec in NAc with nic (0.35 
mg/kg) (30.6%) and TPM 
(17.9%), attenuated by mec 
and DHβE but not MLA. 
No change in striatum or 
PFC.   
No change in 
protein expression 
in the NAc. 
 
 NET No change in PFC.   
 SERT No change in striatum.   
 
15 min 
DAT No change in NAc, 
striatum, or PFC. 
  
 NET No change in PFC.   
 SERT No change in striatum.   
 DAT No change in NAc, 
striatum, or PFC. 
  
In vitro 
treatment 
NET No change in PFC.   
 SERT Dec with TPM (Vmax 
24.8%) in striatum, not 
attenuated with mec. 
  
inc, increase; dec, decrease; NAc, Nucleus Accumbens; PFC, Prefrontal Cortex; DRN, dorsal raphe nuclei; 
SN, substantia nigra; VTA, ventral tegmental area; con, control; nic, nicotine; TPM, tobacco particulate 
matter; mec, mecamylamine 
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Acute effects of nicotine and TPM on monoamine transporter 
function and expression 
The acute effects of nicotine (0.35 mg/kg) and dose-matched TPM were examined in this 
study using RDEV, Western blotting, and real time PCR.  Previous literature has reported 
changes in monoamine transporter function and expression at a range of different time 
points.  For this reason we chose 3 time points for acute treatments: 15 min, 30 min, and 1 
hr.  Function of the transporters was measured at all 3 time points, and transporter protein 
and mRNA expression were also measured at 1 hr as a representative time point for acute 
treatment.  No previous studies have examined the effects of a tobacco extract on 
monoamine transporter function or expression, and reports on the effects of nicotine on 
monoamine transporters are often contradictory.  Therefore, it is important to further 
clarify the effect of nicotine on the transporters with acute treatment, and to elucidate 
what the comparative effects of TPM are.  This could lead to a better understanding of 
initial neuroadaptations in response to smoking, and how this can lead to smoking 
addiction in humans. 
 
5.3.1 DA uptake and DAT protein expression in the NAc 
Few studies have examined the acute effects of nicotine on DAT function in the NAc, 
which is surprising considering the status of this brain region as the brain’s major reward 
centre (Balfour et al., 2000b).  Studies that have examined the effects of nicotine on DAT 
function in the NAc have found conflicting results.  Hart and Ksir (1996) reported an 
increase in DAT function in the NAc following a single 0.4 mg/kg s.c. dose of nicotine 
using in vivo voltammetry.  This effect was almost immediate and persistent through to 1 
hr.  In contrast, Carr et al. (1989) found no change in [
3
H]DA uptake in NAc 
synaptosomes from rats that had been treated with 0.1 mg/kg nicotine for 15 min, or with 
in vitro nicotine treatment (0.1-10 µM) of drug naive synaptosomes.  Consistent with Carr 
et al. (1989), our study found no changes in DA uptake in the NAc with in vitro nicotine 
(2 µM) or TPM (containing 2 µM nicotine) treatment (Figure 4.1, p71).  There was also 
no change in DA uptake observed at 15 min (Figure 4.3, p75) or 1 hr (Figure 4.7, p83) 
following in vivo nicotine (0.35 mg/kg) or TPM (containing 0.35 mg/kg nicotine) 
treatment, and no change in DAT protein expression was found at the 1 hr time point 
(Figure 4.7, p83).   
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In this study, a decrease in DA uptake in the NAc was found at 30 min post nicotine (0.35 
mg/kg) and TPM (containing 0.35 mg/kg nicotine) treatment (Figure 4.4, p77).  Kinetic 
analysis showed a significant decrease in Vmax for both nicotine (30.6%) and TPM 
(17.9%) with no change in Km.  This change in uptake is similar in magnitude to 
previously reported changes in DAT function, which have ranged from 25-87%.  As there 
was no change observed in DAT protein expression, this indicates that the decrease in 
uptake may be due to either a decrease in DAT cell surface expression or a decrease in 
DAT catalytic function at the cell surface.  The lack of a corresponding change in DAT 
protein expression at this time point is not surprising.  In general, acute monoamine 
transporter regulation is dependent on transporter redistribution in the cell and post-
translational modifications such as phosphorylation and glycosylation (reviewed in 
Kristensen et al., 2011).  Changes in monoamine transporter number and density is more 
commonly reported following chronic drug exposures (Miller et al., 2007; Krause et al., 
2002; Yang et al., 2008).   
 
The decrease in DA uptake we observed is the opposite effect to that found by Hart and 
Ksir (1996), which saw an increase in DA uptake in the NAc.  There are several 
differences in methodology used between the Hart and Ksir (1996) study and our study 
that could account for this discrepancy.  As mentioned previously, the ethanol content of 
the injections used in this study could affect DAT function.  Furthermore, Hart and Ksir 
(1996) measured in vivo DA uptake in live animals under urethane anaesthesia, which 
could also possibly affect monoamine transporter function.  It has been shown that 
urethane potentiates nAChR function (Hara and Harris, 2002), and the effects of nicotine 
on monoamine transporter function have consistently been shown to be nAChR- 
dependent.  It is possible that because of this, urethane could have an indirect effect on 
monoamine transporter function.  This is worthy of consideration when examining 
findings from studies using animals under anaesthesia.   
 
To test whether the decrease in DAT function observed in this study was nAChR-
dependent, animals were pre-treated with the non-specific, non-competitive nAChR 
antagonist mecamylamine (1.5 mg/kg) 20 min before nicotine or TPM treatment.  This 
pre-treatment completely attenuated the effects of both nicotine and TPM, indicating that 
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the observed decrease in DAT function is mediated entirely through nAChR activation 
(Figure 4.4, p77).  The involvement of specific nAChR subtypes was then investigated 
using the β2 subunit antagonist DHβE (8 mg/kg salt weight), and the α7 subunit specific 
antagonist MLA (10 mg/kg salt weight).  The doses selected were based on a previous 
study by Zhu et al. (2009).  Zhu et al. (2009) showed that both drugs attenuate nicotine-
induced increases in DAT function.   In this study we show that DHβE, but not MLA, 
attenuates the decrease in DAT function produced by both nicotine and TPM (Figure 4.5, 
p79).  This suggests that receptors containing the β2, but not the α7 subunit, mediate this 
effect.  Furthermore, DHβE is a moderately selective α4 subunit antagonist, so the α4β2 
nAChRs are likely to be involved in this effect.  This receptor subtype is the most 
abundant subtype in the rat brain and blocking this receptor has previously been shown to 
attenuate nicotine self-administration in rats (O’Conner et al., 2010).  Furthermore, 
previous studies on the effects of nicotine on DAT function have also shown that DHβE 
attenuates nicotine induced increases in DAT function (Zhu et al., 2009; Drew et al., 
2000).   
 
Uptake of DA by DAT is the primary mechanism for clearance of this neurotransmitter 
from the synapse.  With a decrease in DAT function observed here, it can be assumed that 
there is an excess of DA left in the synapse, although this was not directly measured in 
this study.  Nicotine is known to increase extracellular DA in the NAc (Dichiara and 
Imperato, 1988), and this study further reports that synaptic DA may be increased via a 
decrease in uptake.  The NAc is the brain’s major reward centre and part of the 
mesolimbic DA system, which all drugs of abuse act on either directly or indirectly.  An 
increase in synaptic DA in the NAc incurs reward and reinforcement and is implicated in 
the development of drug dependence.  This decrease in DAT function observed with 
nicotine and TPM treatment may, therefore, be one of the mechanisms partially 
responsible for initiation of smoking dependence.  Drugs of abuse such as cocaine and 
amphetamines have previously been shown to interact with DAT to exert their addictive 
properties by increasing extracellular DA concentrations.  However, nicotine appears to 
affect DAT function through an indirect mechanism, particularly through β2-containing 
nAChRs.  How this effect occurs is not currently known and future studies into the 
mechanism of nAChR modulation of DAT function would be beneficial.   
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5.3.2 DA uptake and DAT protein expression in the striatum 
The effects of nicotine on DAT function in the striatum are not currently clear.  An 
increase in DAT function has previously been shown to occur in the rat striatum at 10 and 
40 min post-treatment (Middleton et al., 2007a); however, Zhu et al. (2009) have also 
reported no change in [
3
H]DA uptake in striatal synaptosomes at 30 min.  Similarly Carr 
et al. (1989) found no change in DAT function in the striatum of rats with in vitro or 15 
min in vivo nicotine treatment.  This indicates that the effects of nicotine on striatal DAT 
function are both time-dependent and require intact brain circuitry.  In the current study 
the effects of nicotine and TPM were examined with in vitro treatment as well as in vivo 
treatment at 15 and 30 min, and 1 hr.  No change in DA uptake in the striatum was 
observed with in vitro nicotine (2 µM) or TPM (containing 2 µM nicotine) treatment 
(Figure 4.1, p71), consistent with the study by Carr et al. (1989).  There was also no 
change found with in vivo nicotine (0.35 mg/kg) or TPM (containing 0.35 mg/kg 
nicotine) treatment at 15 (Figure 4.3, p75) or 30 min (Figure 4.6, p80).   
 
Interestingly, treatment with TPM (containing 0.35 mg/kg nicotine), but not nicotine 
(0.35 mg/kg), induced an increase in DAT function in the striatum at 1 hr that was not 
accompanied by a change in DAT protein expression (Figure 4.8, p85).  The Vmax of the 
TPM group was increased by 40.5% with no change in Km, indicating that the change was 
due to an increase in DAT cell surface expression or catalytic activity.  To determine 
whether the increase in DAT function in response to TPM was nAChR-dependent the 
non-specific nAChR antagonist mecamylamine was used.  Animals were pre-treated with 
mecamylamine (1.5 mg/kg) 20 min prior to TPM treatment and function was measured.  
It was found that the increase in DAT function was not completely attenuated by 
mecamylamine, with a Vmax value 33% greater than control for the mecamylamine/TPM 
group compared to 40.5% for the PBS/TPM group (p<0.05, Studen’t t-test).  This 
difference is marginal and most probably represents no real change between the two 
groups.  Furthermore, because the nicotine group did not differ significantly from control, 
it can be assumed that the increase in DAT function in response to TPM is due to one or 
several non-nicotinic components of TPM.  This is highly relevant to the molecular 
biology of smoking addiction, especially because the majority of work conducted on 
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smoking addiction has examined nicotine alone.  In particular, there have been no 
previous studies on the effects of a tobacco extract on monoamine transporter function.   
 
Human smokers are exposed to a mixture of compounds more closely resembling an 
extract such as TPM than nicotine alone.  Differences between the two treatment groups 
are, therefore, significant for the understanding of how human smoking addiction 
develops.  The specific content of TPM used in this study is not currently known.  This 
makes it difficult to speculate on what components in TPM may be responsible for the 
observed change.  As mentioned previously, the MAO inhibitors harman and norharman 
are known to be present in TPM.  Furthermore, the presence of other pharmacologically 
active compounds such as acetaldehyde and the minor tobacco alkaloids are a probability.  
Cigarette smoke contains a cocktail of over 4000 different compounds, and it can be 
assumed that TPM should contain a great number of these.  It is possible that a 
combination of these compounds act additively or synergistically to produce 
neuroadaptations such as the increase in DAT function observed here.  This specific 
change could be the result of various interactions between TPM constituents and cellular 
processes in neuronal tissue leading to an indirect effect on DAT.  In contrast it is also 
possible that one or more particular compounds are interacting more directly with DAT; 
however, this is unlikely given that in vitro TPM treatment had no effect on DAT 
function in striatal tissue.  Future research should address specific compounds and 
combinations of compounds within TPM that could be responsible for the change 
observed here.  
 
The mechanism responsible for the observed increase in DAT function in response to 
TPM is not yet known.  It is not nAChR-dependent and could be produced in response to 
a number of different compounds present in TPM.  One possibility is that it could be the 
result of an increase in DA release induced by TPM.  The D2 DA receptors are known to 
interact with DAT and modulate its function (Bolan et al., 2007), and excess DA in the 
synapse could stimulate D2 receptors and thereby cause an increase in DAT function.  
Dopamine output produced by nicotine and TPM was not measured in this study, and so 
this theory would need to be confirmed in future experiments.   
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5.3.3 DA uptake by DAT and DAT protein expression in the PFC 
Increases in DA uptake by DAT in the PFC have previously been found in response to 
nicotine (Middleton et al., 2004; Zhu et al., 2009).  In this study, nicotine (0.35 mg/kg) 
and TPM (containing 0.35 mg/kg) had no significant effect on DA uptake by DAT in the 
PFC at any acute time point.  Furthermore, DAT protein expression in the PFC was not 
affected by nicotine or TPM at the 1 hr time point (Figure 4.9, p87).  This is inconsistent 
with previous reports and could be accounted for by methodological differences including 
nicotine dose, and time points examined in the different studies.  Using in vivo 
voltammetry techniques, Middleton et al. (2004) found increases in DA uptake from 10 
min following a single 0.14 mg/kg (free base) nicotine injection, with a maximal increase 
in uptake at 30 min post injection.  Interestingly, this effect was also dose-dependent and 
no significant changes in DAT function were found at any other dose ranging from 0.03-
0.3 mg/kg.  Zhu et al. (2009) found an increase in DAT function in PFC synaptosome at 
15 and 30 min with 0.8 mg/kg nicotine, but not 0.3 mg/kg nicotine.  This suggests that the 
effects of nicotine on DAT in the PFC are heavily dose- and time-dependent.  No 
previous studies have examined the effects of TPM on DAT function in the PFC; 
therefore, it would be useful to investigate more nicotine doses and treatment time-points 
in future studies. 
    
5.3.4 DAT protein and mRNA expression in the VTA and SN 
The protein and mRNA expression of DAT was measured in the VTA and SN after 1 hr 
nicotine (0.35 mg/kg) and TPM (containing 0.35 mg/kg) treatment.  It was found that 
DAT mRNA expression was decreased with both nicotine (4.78 Ct values) and TPM 
(3.89 Ct values) treatment in the VTA 1 hr after treatment (Figure 4.10, p89).  This 
corresponds to a decrease in DAT mRNA expression of 96.4% for nicotine and 93.3% for 
TPM.  This decrease in DAT mRNA expression is inconsistent with an earlier study by 
Ferrari et al. (2002) who found no change in DAT mRNA levels in the VTA or SN of 
rats.  However, this study measured mRNA 24 hrs after a single nicotine injection, and so 
any earlier effects of the injection may have disappeared by this point.  As mentioned 
earlier, the large decreases in mRNA expression found in this study should be interpreted 
with caution as they may be inflated due to large error in real time PCR experiments.  
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There was no corresponding change in DAT protein expression in the SN at this time 
point, which further questions the molecular relevance of the observed change.  It is 
possible; however, that the 1 hr time point was not long enough to observe changes in 
protein expression.  As mentioned previously, acute changes in monoamine transporter 
function are commonly reported to be due to cellular redistribution rather than alterations 
in overall protein expression.  In this study, nicotine and TPM did induce a decrease in 
DAT protein expression in the SN following chronic treatment.  This suggests that an 
earlier decrease in mRNA expression may have only been measurable at the protein level 
at a later time point.  Although there was no change in mRNA expression at the chronic 
time point, the decrease in protein expression at this time could in part be due to a latent 
effect of earlier mRNA depletion.  Further examination into the persistence of the acute 
depletion of mRNA, as well as investigation of DAT protein expression at more sub-
chronic time points would be required to validate this speculation.   
 
5.3.5 NET function and expression in the PFC and LC 
There is a severe lack of information in the literature on the effects of nicotine on NET 
function and expression.  NET is responsible for a considerable portion of DA uptake in 
the PFC, and for this reason DA uptake by NET was measured in the PFC in this study.  
Zhu et al. (2009) have previously reported finding no change in DA uptake by NET in 
PFC synaptosomes 30 min following 0.8 mg/kg nicotine.  We examined DA uptake by 
NET at 15 min, 30 min, and 1 hr following in vivo nicotine and TPM treatment and found 
no significant change in uptake at any time point.  Furthermore, no change in NET 
protein expression in the PFC or LC, or NET mRNA expression in the LC compared to 
control, was found at the 1 hr time point (Figure 4.11, p91; Figure 4.12, p92).  It is 
interesting that no difference in NET function was found at the acute time points when an 
increase in function was seen with chronic nicotine treatment.  This suggests that the 
increase in NET function observed with chronic treatment is time-dependent and occurs 
only in response to long-term nicotine exposure.   
As previously reported for SERT mRNA expression in the DRN following chronic 
treatment, there was a significant difference in mRNA expression between nicotine (0.35 
mg/kg) and TPM (containing 0.35 mg/kg nicotine) treatment groups (Figure 4.12, p92).  
This was a difference of 1.28 Ct values, corresponding to a 59% decrease in mRNA 
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content in the TPM compared to the nicotine group.  This suggests that non-nicotinic 
components of TPM may have some subtle effects on gene expression in both the DRN 
and LC.  This difference between nicotine and TPM may have no significant effect on 
mRNA or protein expression compared to control, but, in combination with other subtle 
changes in gene expression, it could cause a significant change in overall NE tone.   
 
5.3.6 SERT function and expression in the striatum and DRN 
There has been only one study on the effects of acute nicotine on SERT function to date.  
Awtry and Werling (2003) found significant increases in SERT Vmax following in vitro 
nicotine treatment of PFC and hippocampal synaptosomes.  In addition, a single 0.7 
mg/kg nicotine injection produced increases in 5-HT uptake in synaptosomes of the PFC 
and hippocampus.  The current study is the first that has examined the acute effects of 
nicotine and TPM on SERT function in the striatum.  In vitro TPM (containing 2 µM 
nicotine), but not nicotine (2 µM), treatment decreased SERT function in the striatum 
(Figure 4.2, p73).  This effect was shown to not be attenuated by mecamylamine, 
indicating that some component other than nicotine in the TPM was responsible for the 
change.  Furthermore, because this change occurred with in vitro treatment it is possible 
that a component of TPM is interacting more directly with SERT.  However, this was not 
tested in this study, and it is also possible that a component of TPM is acting on SERT in 
an indirect manner.   
 
This change with in vitro treatment was not seen with any of the in vivo nicotine or TPM 
treatment groups, where no change in 5-HT uptake was seen.  Due to this, the molecular 
relevance of the TPM induced decrease in SERT function with in vitro treatment is 
questionable.  The lack of any change in SERT function with in vivo nicotine treatment 
found in this study contrasts to the increases in SERT Vmax described by Awtry and 
Werling (2003) in PFC and hippocampal synaptosomes in response to nicotine.  
However, this could be attributed to brain region-specific effects of nicotine in affecting 
SERT function.  No change in SERT protein expression in the striatum or DRN was 
found, and no change in SERT mRNA expression in the DRN was observed in this study 
(Figure 4.13, p94; Figure 4.14, p95).  This is in agreement with the findings of Semba and 
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Wakuta (2008) who found no difference in SERT mRNA expression compared to control 
following a single 0.5 mg/kg nicotine injection 2 hrs before sacrifice.   
 
Key Findings 
Nicotine and TPM alter DAT function and expression in the NAc 
The NAc is the brain’s major reward centre and all drugs of abuse cause increases in 
extracellular DA in this region (Vokow et al., 2008).  In this study we found a significant 
decrease in DAT function in the NAc at 30 min post in vivo nicotine (0.35 mg/kg) and 
TPM (containing 0.35 mg/kg nicotine) treatment (Figure 4.4, p77).  No previous studies 
have shown a decrease in DAT function in the NAc in response to nicotine treatment; 
therefore, this presents a novel mechanism through which nicotine may produce 
rewarding effects.  This decrease would result in a decrease in DA uptake and likely an 
increase in the reward and reinforcement produced by nicotine.  The effect was 
mecamylamine and DHβE sensitive, indicating that it is mediated by nAChRs containing 
the β2 subunit (Figure 4.5, p79).  DHβE has been shown to attenuate nicotine self-
administration in rats (Watkins et al., 1999) and baseline expression of α4β2 receptors can 
predict motivation to self-administer in animals (Le Foll et al., 2009).  Decreasing DAT 
function in the NAc, and thus increasing DA availability in the synapse, may be one 
mechanism through which α4β2 stimulation produces reward.   
 
It is interesting that with chronic nicotine and TPM treatment there was no change in DA 
uptake in the NAc, but there was an increase in protein expression (Figure 3.4, p56).  It is 
possible that the initial decrease in DAT function is due to a decrease in catalytic activity 
of the transporter.  Following this, an increase in DAT protein expression with chronic 
nicotine treatment could be a compensatory mechanism for the loss of functional DAT.  
This could result in more DAT being expressed on the cell surface to compensate for less 
functional DAT.  Alternatively, the intracellular pool of DAT could be increased and 
higher turnover of cell surface DAT could occur, ultimately resulting in a return to 
normal levels of uptake.  This would in part explain the initial reinforcing effects of 
nicotine and the later reinforcement being attributed more to sensory cues such as the 
taste of tobacco smoke.  Cell surface expression of DAT and DA output following 
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nicotine and TPM treatment has not been measured in this study.  Future studies should 
examine this to determine whether the above speculation is valid.  
 
TPM causes changes in monoamine transporter function independent of nicotine 
This is the first study to examine the effects of TPM on monoamine transporter function 
and expression.  To do this, we measured the effects of nicotine (0.35 mg/kg) and dose-
matched TPM in both acute and chronic models.  Interestingly, there were some 
differences in effect between nicotine and TPM.  In the striatum, in vivo TPM treatment 
increased DAT function at 1 hr where nicotine did not, and this effect was not completely 
attenuated by mecamylamine pre-treatment (Figure 4.8, p85).  This strongly indicates that 
the effect was independent of the nicotine content in TPM, and must instead be due to one 
or more non-nicotinic components of TPM.  In addition, TPM produced a significant 
decrease in 5-HT uptake with in vitro nicotine treatment in the striatum that was also not 
attenuated by mecamylamine pre-treatment (Figure 4.2, p73).  It is interesting that both of 
these differences were found in the striatum, albeit in different neurotransmitter systems.  
The dorsal striatum is important in habit response learning, an important process in the 
development of drug addiction (Everitt and Robins, 2005).  As mentioned previously, 
preliminary work in the School of Psychology by Dr Katie Brennan has shown that rats 
respond more for TPM than nicotine alone (personal communication).  This could 
theoretically be due to neuroadaptations in response to TPM in this region, and future 
studies on the effects of contingent TPM treatment on striatal DAT and SERT would be a 
promising direction.  
  
Studying the effects of a tobacco extract such as TPM is preferable to studying nicotine 
alone in relation to human smoking addiction.  Human smokers are exposed to over 4000 
components in tobacco smoke (Burns et al., 1991) and recent studies have shown that 
some of these non-nicotinic constituents may have rewarding properties.  In particular, 
the MAO inhibitors, minor tobacco alkaloids, and acetaldehyde have all been shown to be 
pharmacologically active (Herraiz and Chaparro, 2005; Middleton et al., 2007a; Foddai et 
al., 2004) and the minor tobacco alkaloids and acetaldehyde have effects on self-
administration in rats (Clemens et al., 2009; Belluzzi et al., 2005).  There is also evidence 
that tobacco smoke is more rewarding than nicotine in humans (Barrett, 2010; Rose et al., 
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2010).  Smokers will choose de-nicotinised tobacco smoke over i.v. nicotine (Rose et al., 
2010), and de-nicotinised tobacco smoke decreases cigarette craving more than nicotine 
inhalers (Barrett, 2010).  This makes the use of tobacco extracts for the study on smoking 
addiction highly relevant, and this is the first study to show that TPM has different effects 
on monoamine transporter function compared to nicotine alone.  Further research on the 
mechanisms responsible for these effects and elucidation of the wider effects of TPM on 
monoaminergic systems would be an exciting future avenue in smoking research.   
   
Future Directions 
 
This study has identified several novel brain regions and time points where nicotine 
and/or TPM affect monoamine transporter function.  However it has not examined the 
mechanisms responsible for the observed changes, and future studies should be directed 
towards elucidating these mechanisms.  The majority of the alterations in monoamine 
transporter function observed in this study have occurred due to changes in the Vmax of 
monoamine uptake with no change in Km.  Increases or decreases in Vmax with no change 
in Km indicate that the change is due to a change in cell surface expression or catalytic 
activity of the transporter.  To determine whether or not the observed changes were due to 
a change in cell surface expression, experiments such as synaptosomal biotinylations 
could be used.  This is an established technique, and previous work by Zhu et al. (2009) 
has shown an increase in DAT function in PFC synaptosomes at 30 min post nicotine 
treatment to be due to an increase in cell surface expression using synaptosomal 
biotinylation techniques.  In contrast Middleton et al. (2007a) reported that nicotine 
induced increases in DA uptake in striatal synaptosomes were not trafficking-dependent.  
The changes we have reported in this thesis with in vivo treatment were: a decrease in 
DAT function in the NAc in response to nicotine and TPM; an increase in DAT function 
in the striatum in response to TPM only; and an increase in DA uptake by NET in the 
PFC in response to 3 mg/kg nicotine.  These changes have not been previously been 
shown; therefore, it is not known whether or not they are trafficking-dependent.  Once it 
has been established whether or not the changes in monoamine transporter function are 
due to trafficking, investigation into the cell signalling systems responsible for this can be 
examined.  PKC is the most thoroughly studied kinase known to phosphorylate the 
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monoamine transporters.  It has been shown to down-regulate DAT function through 
trafficking dependent (Boudanova et al., 2008) and independent mechanisms (Foster et 
al., 2008), and is one pathway that could be explored.    
 
The decrease in DAT function in the NAc at 30 min with both nicotine and TPM (in vivo 
treatment) was mecamylamine- and DHβE-sensitive, indicating that the changes are 
dependent on β2 subunit containing nicotinic receptors.  The mechanism by which 
nAChRs modulate monoamine transporter function is currently unclear, and future 
studies should be directed accordingly.  We have shown that changes in transporter 
function are not consistent between in vivo and in vitro nicotine and TPM treatment.  This 
indicates that whole brain circuitry is required for the effects to be seen.  Therefore, it is 
unlikely that changes are due to a direct interaction between the nAChRs and monoamine 
transporters.  Instead, signalling pathways involved in this effect could be investigated.  
Previous research by Awtry et al. (2006) has shown that the PKA inhibitor Rp-cAMP 
blocked 5-HT uptake following nicotine treatment.  Investigation into the role of PKA 
and other kinases in nAChR modulation of monoamine transporters would be a 
worthwhile endeavour.   
 
Another possible mechanism for changes observed in DA uptake is interaction of the D2 
DA receptor with DAT.  D2 DA receptors have previously been shown to interact with 
DAT (Bolan et al., 2007), and D2/D3 receptor agonists increase DA clearance in the 
striatum (Meiergerd et al., 1993).  Tobacco particulate matter, but not nicotine, increased 
DA uptake by DAT in striatum at 1 hr in this study.  A possible mechanism for this effect 
would be that TPM caused a greater outflow of DA than nicotine alone, stimulating the 
D2 DA receptors, and resulting in increased DAT function.  No previous studies have 
investigated the effects of a tobacco extract on DA concentrations in discrete brain 
regions.  This could be examined using high-performance liquid chromatography or 
microdialysis studies to establish whether or not there is increased DA outflow in 
response to TPM compared to nicotine.  Furthermore, pre-treatment with a D2 DA 
receptor antagonist prior to TPM treatment could be used to determine the role of D2 DA 
receptors in the observed increase in DA uptake in response to TPM.   
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This study has found some changes in monoamine transporter function in response to 
TPM but not nicotine treatment; however, the exact composition of the TPM utilised is 
not known.  It would be beneficial to ascertain what compounds are present in TPM so 
that directed studies could examine the effects of individual compounds, and 
combinations of compounds, on the monoamine transporters.  In addition, other 
components of reward-related pathways in the brain could be examined.  The levels of 
specific compounds that are known to be pharmacologically active and likely to be 
present in TPM could be tested for, including acetaldehyde and the minor tobacco 
alkaloids.  The changes observed with TPM but not nicotine treatment in this study were 
not completely attenuated by mecamylamine pre-treatment.  This strongly indicates that 
the effects were due to non-nicotinic components of TPM.  To further confirm this, a de-
nicotinised TPM solution could be used to determine whether results are comparable to 
the nicotinised TPM solution.   
 
As well as changes in monoamine transporter function in response to TPM, there were 
some changes in transporter mRNA expression observed in this study.  Chronic TPM, but 
not nicotine, treatment significantly decreased NET mRNA expression in the LC 
compared to control.  Furthermore, chronic TPM treatment significantly decreased SERT 
mRNA expression compared to dose matched nicotine, and 1 hr TPM treatment 
decreased NET mRNA in the LC compared to control.  None of these changes resulted in 
a change in protein expression; however, Western blotting may not detect small changes 
(<10%) in total protein.  This indicates that TPM could have subtle effects on gene 
expression that differ from nicotine alone.  While these individual effects appear to have 
no significant outcome, multiple subtle changes in gene expression with TPM could result 
in a significant change in overall monoaminergic tone compared to nicotine alone.  Gene 
expression profiles have previously been conducted for nicotine in cell (Konu et al., 
2004) and animal models (Li et al., 2004d).  Similar profiles could be repeated with TPM 
and compared to nicotine to establish whether TPM causes any significant or profound 
changes in gene activation.  This could lead to the discovery of new molecular targets for 
study in smoking addiction, and for the development of smoking cessation therapies.  
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As mentioned previously, contingent TPM administration in rats has been established, 
and preliminary results show that animals respond for TPM more than nicotine alone 
(Katie Brennan, personal communication).  Contingency has previously been shown to 
affect drug produced neuroadaptations (Dworkin et al., 1995; Stefanski et al., 1999; 
Jacobs et al., 2003); therefore, comparisons of molecular data from animals that have self-
administered TPM to the findings from non-contingent animals used in this study would 
be of interest.  Furthermore, examination of other reward-related cellular mechanisms in 
contingent animals could be conducted.  This could include assessment of monoamine 
oxidase activity, nAChR expression, monoamine receptor expression, and studies on 
other neural circuitry such and GABA and glutamatergic systems.     
 
It is well established that there are differences in response to drugs of abuse between adult 
and adolescent subjects in animal models of addiction (Schramm-Sapyta et al., 2009).  In 
humans, adolescence is associated with high rates of initiation in drug taking, and 
increased risk of developing drug dependence (Laviola et al., 1999).  This is true for 
smoking, with approximately 75% of adult smokers reporting that they first began 
smoking between 11 and 17 years of age (Eissenberg and Balster, 2000).  It has been 
previously shown that acetaldehyde, which is present in the combustion products of 
tobacco, increases nicotine self-administration in adolescent, but not adult rats.  
Investigating the effects of TPM compared to nicotine alone in an adolescent animal 
model would be highly significant.  This would include both the self-administering 
behaviour of adolescent animals compared to adults, and the molecular changes resultant 
from exposure to TPM.  Findings from this could aid in the development of smoking 
cessation agents or preventative measures tailored specifically towards adolescents. 
 
Finally, there is currently a lack of information in the literature on the effects of nicotine 
on NET, despite the fact that bupropion works in part by blocking NET (Dwoskin et al, 
2006).  This study has shown that nicotine (3 mg/kg) increases DA uptake by NET in the 
PFC following chronic treatment.  It would be beneficial to study the effects of NE uptake 
by NET in the PFC and other areas of the brain.  Several anti-depressants that affect the 
function of NET are currently being trialled as smoking cessation therapies.  These 
therapies could be better targeted to find the most effective treatment with a greater 
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understanding of the effects of nicotine and tobacco smoke on cellular components such 
as NET.   
 
Overall Significance 
Cigarette smoking is the single largest cause of preventable mortality worldwide (WHO, 
2011).  Despite this, smoking addiction at the molecular level is still poorly understood, 
and current smoking cessation aids are only marginally effective (Jorenby, 2006; Balfour 
et al., 2000a).  The majority of smoking research to date has been conducted on nicotine 
alone; however, there are over 4000 chemicals present in tobacco smoke.  Some of these 
chemicals have been shown to be pharmacologically active and to be self-administered in 
animal models.  Previous studies on the effects of nicotine on monoamine transporters 
have shown that nicotine does, in some cases, modulate their function, and that this effect 
is dependent on nAChRs.  However, the current literature is often contradictory and more 
research is needed to develop a better understanding of how nicotine affects the 
monoamine transporters.  This thesis has examined the effects of nicotine and dose-
matched TPM on the monoamine transporters.  It is the first study to investigate the 
effects of a tobacco extract on monoamine transporters, and has found some differences 
between the effects of TPM and nicotine alone.  This is highly important because human 
smokers are exposed to tobacco smoke, not nicotine alone, and these findings contribute 
to a growing body of evidence that non-nicotinic components of cigarette smoke may 
contribute to tobacco addiction.  This is also the first study to report a nicotine-induced 
decrease in DAT function in the NAc, which could contribute to the initial rewarding 
effects of cigarette smoking.  Findings from this study have contributed to the 
understanding of the molecular biology of smoking addiction, which could in future lead 
to the development of more effective smoking cessation therapies. Furthermore, these 
findings have highlighted the use of TPM as an exciting new avenue for studying 
smoking addiction.   
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Appendices 
Appendix I:  Solutions 
 
10 x Phosphate Buffered Saline (PBS) pH 7.4 
Concentration  g/L  
NaCl   1.4 M    80  
KCl   26.8 mM  2.0  
Na2HPO4  81.0 mM  26.8  
KH2PO4  14.7 mM  2.4  
 
KREBS Buffer pH 7.4 
Concentration  g/L  
NaCl   130 mM  7.6  
KCl   1.3 mM  0.10  
CaCl2   2.2 mM  0.24  
MgSO4.6H2O   1.2 mM  0.27  
KH2PO4  1.2 mM  0.16  
HEPES   10 mM  2.6  
D-Glucose   10 mM  1.8  
 
RIPA buffer pH 7.5 
Concentration  g/L  
Tris-HCl  10 mM  1.2  
NaCl   150 mM  8.766  
EDTA   1 mM   0.37  
Triton-X-100   1%    10 mL  
SDS    0.1%    1.0  
Sodium deoxycholate 1%    10  
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5 x Reducing buffer  
Concentration  
Tris-HCl, pH 6.8  62.5 mM 
SDS    2%  
Glycerol   20%  
Bromophenol Blue  1% 
 
Gels  
Enough for 2 gels  
10% Separating Gel  
dH2O       8 mL  
1.5 M Tris pH 8.8      5 mL  
10% SDS       200 μL 
Acrylamide (30% acrylamide/Bis solution)  6.66 mL  
10% APS       100 μL 
TEMED       10 μL 
The gel was layered with 100% isopropanol while setting, which was then poured off 
prior to addition of the stacking gel. 
4% Stacking Gel  
dH2O       6.1 mL  
0.5 M Tris pH 6.8      2.5 mL  
10% SDS       100 μL 
Acrylamide       1.33 mL  
10% APS       50 μL 
TEMED       10 μL 
 
10 x Running buffer  
Concentration  g/L  
SDS   35 mM  10  
Tris-HCl 250 mM  30.3  
Glycine  1.9 M    144.1  
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Western Transfer Buffer  
Concentration  g/L  
Glycine  190 mM  14.4  
Tris-HCl 25 mM  3.03  
Methanol  20%    200 mL 
 
10 x TBS pH 7.5  
Concentration  g/L  
TrisHCl 500 mM  60.5  
NaCl  1.5 M    87.6  
 
T-TBS  
1 x TBS containing 0.1% Tween-20 
 
Stripping buffer  
SDS     69 mM, 20 g/L 
0.05 M TrisHCl, pH 6.8  992.5 mL  
β-mercaptoethanol  7.5 mL 
 
50 x TAE  
TrisHCl   242 g/L 
0.5 M Na2EDTA (pH8.0) 100 mL 
Glacial acetic acid  57.1 mL 
 
1 x TE 
1 M Tris (pH8.0)  10 mL 
0.5 M Na2EDTA (pH8.0) 2 mL 
dH2O    88 mL  
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Appendix II:  Representative Western blots 
 
Western blots were performed to measure the total protein present in brain tissue lysates 
using specific antibodies for DAT, NET, SERT, and the housekeeper protein α-tubulin.  
Distinct bands were found with the use of each antibody that corresponded to an expected 
size for the proteins (Figure A2.1).  Non-specific binding in other parts of the membrane 
was minimal.  A control blot of samples with secondary antibody only was also 
performed to check for non-specific binding (Figure A2.1 E).  This showed minimal non-
specific binding of the secondary antibody to protein in the membrane. 
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Figure A2.1:  Representative Western blots for antibodies used in this study.  
Antibodies used for DAT (75-80 kDa) (A), NET (75 kDa) (B), SERT (70-75 kDa) (C) 
and tubulin (50 kDa) (D) all showed distinct bands corresponding to expected protein 
sizes;  (E) shows a membrane probed with secondary antibody only. 
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Appendix III:  Cyclophilin A mRNA expression across treatment 
groups 
 
The mean Ct value for cyc A was compared across treatment groups for each real time 
PCR experiment to ensure that there was no significant difference between treatment 
groups.  Statistical analysis showed no significant change (one-way ANOVA with 
Bonferroni post-hoc analysis).  From this we concluded that nicotine and TPM did not 
affect cyc A mRNA expression.  This validated the use of cyc A as a housekeeper gene 
for real time PCR experiments.  Mean Ct values for cyc A in chronic and acute treatments 
are shown in Table A3.1 and Table A3.2 respectively.    
 
Table A3.1:  Mean cyc A Ct values for chronic nicotine and TPM treatments. 
 Control Nicotine 
(0.35 mg/kg) 
Nicotine 
(3 mg/kg) 
TPM (containing 
0.35 mg/kg nicotine) 
VTA 13.6 ± 0.5 13.2 ± 0.3 14.0 ± 0.3 13.7 ± 0.4 
SN 13.3 ± 0.7 13.2 ± 0.5 13.3 ± 0.7 14.0 ± 0.5 
LC 13.8 ± 0.5 13.8 ± 0.5 14.1 ± 0.3 13.3 ± 0.4 
DRN 15.2 ± 1.2 14.6 ± 1.2 14.9 ± 0.3 14.4 ± 1.0 
Values represent mean ± SEM.   
 
Table A3.2:  Mean cyc A Ct values for acute nicotine and TPM treatments. 
 Control Nicotine (0.35 mg/kg) TPM  
(containing 0.35 mg/kg nicotine) 
VTA 19.5 ± 0.9 18.9 ± 1.6 19.1 ± 0.9 
SN 18.1 ± 0.8 17.8 ± 0.8 17.7 ± 0.6 
LC 16.7 ± 0.3 17.3 ± 0.5 16.9 ± 0.3 
DRN 17.6 ± 0.3 18.4 ± 1.5 17.4 ± 1.1 
Values represent mean ± SEM. 
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